|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
|
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475 2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/20 ¤U¤È 03:34:00²Ä 5608 ½g¦^À³
|
Lebrikizumab 52¶gªºªvÀø®ÄªG 1¡AAD1. 52¶gQ4W//Q2W IGA ¡G74%(EASI50)x74%//76% =55//56% Vs 16¶gÀø®Ä 43%¡A¸g18¡ã52¶gªvÀø«á¦ôp´£¤ÉIGA 12//13% EASI75: 74%(EASI50)x79%//79%% =58% Vs 16¶gÀø®Ä 59%¡A¸g18¡ã52¶gªvÀø«á¦ôpEASI75,Ë°h1%¡C 2.AD2 IGA ¡G66%(EASI50)x81%//65% =53%//43% Vs 16¶gÀø®Ä 33%¸g18¡ã52¶gªvÀø«á¦ôp´£¤ÉIGA 23%//10% EASI75: 66%¡]EASI50)x85%//77% =56//51% Vs 16¶gÀø®Ä 51%¸g18¡ã52¶gªvÀø«á¦ôp´£¤ÉEASI75 5%//0% µ²½×¡G©µªø52¶g§MÀø¹ïIGA´£¤É®ÄªG顕µÛ¡A¦ý¹ïEASI75¤§´£¤É®ÄªG¤£¤j¡C ¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@ Lebrikizumab Week 52 Results 1¡PADvocate 1(¦ôp¦b²Ä16¶g¦³74%¹FEASI50¡A¦b¤T´Áµ²ªG¤¤§ä¤£¨ìEASI750¼Æ¾Ú¡^ Lebrikizumab 250 mg Q4W//Q2W IGA (0,1) 74 %//76 % EASI¤@75 79%//79% Pruritis (Itch) NRS 80 %//81 % 2¡PADvocate2¡]¦ôp¦³66%¹FEASI50¡A¦b¤T´Áµ²ªG¤¤§ä¤£¨ìEASI50ªº¼Æ¾Ú¡^ Q4W//Q2W IGA (0,1) 81 %//65 % EASI-75 85 %//77 % Pruritis (Itch) NRS 88 %//90 % Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) ¤T´ÁÁ{§Éµ²ªG clinicaltrials.gov/ct2/show/results/NCT04146363 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2) clinicaltrials.gov/ct2/show/results/NCT04178967?term=ADvocate2+lebrikizumab&draw=2&rank=1 ¤@.Lebrikizumab(16¶g)¡A¤T´Á ¹êÅç²Õvs¹ï·Ó²Õ In ADvocate 1, (IGA) 43%-13%=30%...A EASI75 59%-16%=43%...B In ADvocate 2, (IGA) 33%-11%=22%...C EASI75 51%-18%=33%...D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/20 ¤U¤È 03:02:52²Ä 5607 ½g¦^À³
|
§¨Ó¤½¥q¦b9¤ë¦bEADVªº¤fÀY³ø§i ¿ï¨ú16¶gLebrikizumabªvÀø¤¤-«AD«áÀø®Ä¹FªºEASI50¥H¤WªÌÄ~ÄòªvÀø18¡ã52¶gªº¤T´Áµ²ªG³ø§i ⋯⋯ Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly¡¦s Phase 3 Monotherapy Atopic Dermatitis Trials ¦b§¨Ó¤½¥qªº 3 ´Á³æÃĪvÀø¯SÀ³©Ê¥Öª¢¸ÕÅ礤¡A¨C¥|©Pµ¹ÃĤ@¦¸ªº Lebrikizumab ¥i«O«ù«ù¤[ªº¥Ö½§²M°£ finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html September 8, 2022¡P These data were featured in a late-breaking, oral presentation at the 31st European Academy of Dermatology and Venerology (EADV) Congress. New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity Results suggest less frequent, every four week dosing of lebrikizumab provided similar improvements to every two week dosing Regulatory submissions for U.S. and EU planned for this year ³Ì·sªº³Ì·s¼Æ¾ÚÅã¥Ü¡Alebrikizumab À³µªªÌ¡]16¶gEASI¶W¹L50%,¦ôp74%¡þAD1¡ã66%/AD2) ¦bªvÀø¤@¦~«á ³ø§i¤F¦b¥Ö½§²M°£¡Bæ±Äo©M¯e¯fµ{«×©MÄY«µ{«×§ïµ½¤è±ªºªø´Áµ²ªG µ²ªGªí©ú¡Alebrikizumab ¨C 4 ¶gµ¹ÃÄÀW²v¸û§C¡A»P¨C 2 ¶gµ¹ÃĦ³¬Û¦üªº§ïµ½ p¹º©ó¤µ¦~¦V¬ü°ê©M¼Ú·ù´£¥æºÊºÞ¤å¥ó Lebrikizumab Week 52 Results 1¡PADvocate 1(¦ôp¦b²Ä16¶g¦³74%¹FEASI50¡A¦b¤T´Áµ²ªG¤¤§ä¤£¨ìEASI750¼Æ¾Ú¡^ Lebrikizumab 250 mg Q4W//Q2W IGA (0,1) 74 %//76 % EASI¤@75 79%//79% Pruritis (Itch) NRS 80 %//81 % 2¡PADvocate2¡]¦ôp¦³66%¹FEASI50¡A¦b¤T´Áµ²ªG¤¤§ä¤£¨ìEASI50ªº¼Æ¾Ú¡^ Q4W//Q2W IGA (0,1) 81 %//65 % EASI-75 85 %//77 % Pruritis (Itch) NRS 88 %//90 % Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) ¤T´ÁÁ{§Éµ²ªG clinicaltrials.gov/ct2/show/results/NCT04146363 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2) clinicaltrials.gov/ct2/show/results/NCT04178967?term=ADvocate2+lebrikizumab&draw=2&rank=1 ¤@.Lebrikizumab(16¶g)¡A¤T´Á ¹êÅç²Õvs¹ï·Ó²Õ In ADvocate 1, (IGA) 43%-13%=30%...A EASI75 59%-16%=43%...B In ADvocate 2, (IGA) 33%-11%=22%...C EASI75 51%-18%=33%...D |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/20 ¤W¤È 08:46:00²Ä 5606 ½g¦^À³
|
To:ª©¥D ·Ð½Ð¥[¤J¥H¤U³sµ²¦Ü¼ÐÃD¡A·PÁÂ~ 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/9/19 ¤U¤È 08:38:40²Ä 5605 ½g¦^À³
|
ASLAN004¥þ²y¤GbÁ{§É¸ÕÅç¥Ø«e¶}³]65Ó©Û¶Ò¤¤¤ß¡A¬ü°ê¦b18Ó¦{¶}¤F39Ó¡A¦L«×8Ó¡A¿D¬w6Ó¡A¯Ã¦èÄõ1Ó¡A·s¥[©Y4Ó¡Aªñ´Á¦b¤S¦b¥[®³¤j¶}¤F7Ó©Û¶Ò¤¤¤ß¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/19 ¤U¤È 07:55:31²Ä 5604 ½g¦^À³
|
¥|.©ú¦~4¤ëASLAN004 2b¸Ñª¼ EASI 75 = 73% (ASLAN004)VS 24%(¹ï·Ó²Õ)-----´Á±æÈ IGA0,1 = 57% (ASLAN004)VS 15%(¹ï·Ó²Õ)-----´Á±æÈ ASLAN004 2b VS Lebrikizumab 2b ---¦©°£¹ï·Ó²Õ¤zÂZ (°²³]°ò½u¦P¬°EASI 25.5) EASI75 49%(73%-24%)-004 /37%(61%-24%)-Leb=132%---(¹ï·Ó²Õ24%) IGA0,1 42%(57%-15%)-004 /30%(45%-15%)-Leb=140%---(¹ï·Ó²Õ15%) Y¯à¦p¥H¤W´Á±æÈ, ¨º±wªÌªº¹ïASLAN004³ß¦n«×(ASLAN004 VS DUPILUMAB) ¥i¯à±q50%©Ô¨ì80%. 100~140»õ¬ü¤¸¾P°â¼ç¤O¤~¦³¥i¯à. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/19 ¤U¤È 07:15:02²Ä 5603 ½g¦^À³
|
§ó¥¿-1 ¤@.P.39 ¥»¶ªº60»õ¬ü¤¸¬O2021¦~Dupilumab¦b¦U°Ïªº¾P°â¹êÁZ. ¨Ã«DASLN ¤½¥q¦Û¦ô¥¼¨Ó¾P°â¼ç¤O¹w´ú. P.39 Commercialization of eblasakimab has potential in different regional markets Eblasakimab(ASLAN004) ¦b¤£¦P»â°ì¨ã¦³¼ç¤O °Ï°ì¥«³õªº°Ó·~¤Æ. 2021¦~Dupilumab ¾P°â¹êÁZ//2019¦~,AD±wªÌ¤H¼Æ US $4,849M //41.4M(226¸U¤H)(¥¼¨ü±±¤¤-««×¥Íª«»s¾¯¤H¤f¬ù¦û5.5%----REGN¸ê®Æ) EU $793M//30.7M JAPAN $322M//5.0M CHINA $35M//535M ¦Xp $5,999M ¤G. P.38 Eblasakimab could be the favoured biologic, despite dermatologists¡¦ long experience with dupilumab Eblasakimab ¥i¯à¬O³Ì¨üÅwªïªº¥Íª«»s¾¯¡A¾¨ºÞ ¥Ö½§¬ìÂå¥Íªø´Á¨Ï¥Î dupilumab ªº¸gÅç 150¤H¥«½Õ ASLAN004 VS DUPILUMAB ³ß¦nµ{«× ¤è®×A Àø®ÄÀu©óDUPILUMAB 8%+4¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g ¤è®×B Àø®ÄÀu©óDUPILUMAB 8%+2¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g ¤è®×C Àø®Äµ¥©óDUPILUMAB +¨C¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g ¤è®×A//¤è®×B//¤è®×C ¤@½u 51%//44%//20% ¤G½u 55%//54%//47% ASLAN004 60»õ¬ü¤¸AD¼ç¦b¦ôºâ¥«³õ: ¥]§t¤@½u&¤G½u¥«³õ. ¤T.¥H¤UÓ¤H¦ôºâASLAN004¾P°â¼ç¤O---- Dupilumab 80»õ¬ü¤¸AD³Ì°ª¾P°â¥«³õ(REGN «Å¥¬Dupilumab 140»õ¬ü¤¸³Ì°ª¾P°â*56% AD/¥þ³¡«¬IIª¢¯g¥¼¨ü±±¬ü°ê¥«³õ)-- 1.AD °²³]DUPILUMAB AD ¤@½u¾P°â¦û2/3,¤G½u¦û1/3 Dupilumab ¨Ï¥Î52¶g«á¦³¤ÏÀ³ªº约50%(9¤ë15¤é CMO³ø§i资®Æ) 80*2/3¡Ñ50%=26.6(¤@½u) + 80*1/3x50%=13.4(¤G½u) =40»õ¬ü¤¸¡C (¥H¤WÓ¤H¨Ì¥«½Õµû¦ô³ß¦nµ{«×¤j¬ù¤ñ²v¦ôp,¥¼¨Ó¨Ì2b¸Ñª¼¼Æ¾Ú¥i¯à·|¦A×¥¿) 2.ASLN004 ¥þ³¡¾P°â¦ô¬ù70»õ¬ü¤¸ 40/56%=¬ù70»õ¬ü¤¸ (¬ùDUPILUMAB 50%) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/19 ¤U¤È 06:03:40²Ä 5602 ½g¦^À³
|
ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 9/15 R&D ¤é¸ê®ÆÀÉ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/19 ¤W¤È 08:25:53²Ä 5601 ½g¦^À³
|
¥»³ø§i«Y Stephen Doyle ---Chief Business Office ©Ò¥X,¥X¦ÛREGN ¤¤°ê Stephen Doyle ¥ý¥Í¬O ASLAN Pharmaceuticals ªºº®u°Ó°È©x¡C ¦b¥[¤J§Ṳ́§«e¡A Stephen ÁÙ´¿¦b¤W®ü¾á¥ôÁɿյ᤽¥q¸~½F¾Ç¡B¦å²G¾Ç©M²¾´Ó·~°È³¡°ÆÁ`µô. ¬ü°ê°Ï°ì¦û80%¬O¥Ø«eDUPILUMAB¾P°â¹êªp. ------------------------------- ASLN ¤½¥q ¦Û¦ôªºASLAN004 AD ¼ç¦b¾P°âª÷ÃB60»õ¬ü¤¸(¤@½u&¤G½u). ¾P°â¼ç¤O//±wªÌ¤H¼Æ(¥¼¨ü±±¤¤-««×¥Íª«»s¾¯¤H¤f¬ù¦û5.5%----REGN¸ê®Æ US $4,849M //41.4M(226¸U¤H) EU $793M//30.7M JAPAN $322M//5.0M CHINA $35M//535M ¦Xp $5,999M ir.aslanpharma.com/events/event-details/aslan-hybrid-rd-day |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/17 ¤U¤È 01:05:01²Ä 5600 ½g¦^À³
|
clinicaltrials.gov/ct2/show/results/NCT03443024 Lebrikizumab 2b AD Á{§É 2¶g¤@°wx16¶g¡AN=75:52¡A°ò½uEASI25¡P5 ¡G27¡P5 ©M¹ï·Ó²ÕÀø®Äpk 1.IGA0¡A1 45%¤@15%=30% 2EASI 75 61%¤@24%=37% ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥¼¨Ó2b ASLAN004Àø®Ä¡A16%°ª©óLebrikizumab ¾÷²v«D±`°ª EASI75 =73%¡K.ASLAN004 2b ´Á±æÈ ¡]°²³]¹ï·Ó²Õ¦PLebrikizumab ªºÀø®Ä24%) 73/61%=116% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/17 ¤U¤È 12:06:59²Ä 5599 ½g¦^À³
|
¤@.Lebrikizumab(16¶g)¡A¤T´Á In ADvocate 1, (IGA) 43%-13%=30%...A EASI75 59%-16%=43%...B In ADvocate 2, (IGA) 33%-11%=22%...C EASI75 51%-18%=33%...D ¤G.Dupilumab ¤T´Á(16¶g) In SOLO 1, (IGA) 38%-10%=28%...E EASI75 51%-15%=36%...F In SOLO2 2, (IGA) 36%-8%=28%...G EASI75 44%-12%=32%...H ¤T¡BLebrikizumab pk Dupilumab ¦©°£¹ï·Ó组 1.(IGA) PK A/E=30%/28%=107%¡K¡K J C/G=22%/28%=79% Lebrikizumab pk Dupilumab 79%-107% MOA¨Ï±oLebrikizumabÀø®Ä¤W¤U30%¥ª¥k¡C ASLAN004 MOA¥i±æ§ïµ½Lebrikizumab °ÝÃD¡A¦pDupilumab¬Û¹ïéwÀø®Ä¡C 2.EASI75 B/F=43%/36%=119%...K D/H=33%/32%=103%...L Lebrikizumab ©úÅãÀuDupilumab 103%-119%¦bEASI75«ü¼Ð ¥|¡B¥Ñ©óASLAN004 §@¥Î¦bIL13¨üÅé¡A§ó±µªñ©óLebrikizumab §@¥Î¦bIL13°tÅé¡C ¦P®É¥h¼vÅTIL4/IL13°T¸¹¶Ç»¼¡C ¥»¦¸ASLN ¤½¥q¡A150¤Hªº¤¤-««×AD±wªÌªº¥«½Õ®×¡C ASLAN004 Àø®Ä8%Àu©óDupilumab ¤§°²³]¨Ì¾Ú¡A Ó¤H²q´ú¨Ó¦Û¤WzLebrikizumab pk Dupilumab IGA ªº¤T´ÁÁ{§É¼Æ¾ÚPK结½×¡C ASLAN004 2b ¸Ñª¼¡A ¼Æ¾ÚÀu¤~ÁÙ·|½Õ¤É预测¡C ´Nµ¥§a¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/17 ¤W¤È 07:56:38²Ä 5598 ½g¦^À³
|
Maintains Piper Sandler: to Overweight 9/16/2022.¥Ø¼Ð»ù4¬ü¤¸(¥Ñ3¬ü¤¸½Õ¤É4¬ü¤¸) Maintains HC Wainwright & Co.: to Buy 8/15/2022¡C¥Ø¼Ð»ù7¬ü¤¸(¥Ñ8¬ü¤¸½Õ°¬°7¬ü¤¸) Maintains Piper Sandler: to Overweight 5/23/2022¡C¥Ø¼Ð»ù3¬ü¤¸(¥Ñ8¬ü¤¸½Õ°¬°3¬ü¤¸) finance.yahoo.com/quote/ASLN/analysis?p=ASLN |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/9/16 ¤U¤È 07:08:03²Ä 5597 ½g¦^À³
|
¤@ª½§Æ±æ¨È·à±d¯à§âªÑ»ù©Ô¨ì1¤¸¥H¤W ¦ýÁÙ¬O¤@ª½¨S¿ìªk ¤½¥q¬£¯u¸Ó¥[¥[ªo¡A1¤¸¥H¤W§ë¸êªÌ¤]·|§ó¦³«H¤ß |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/16 ¤U¤È 05:57:54²Ä 5596 ½g¦^À³
|
ɥθرi¤j±z´£¹Lªº¨Æ¡A¦p¤U : ·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/7/20 ¤W¤È 09:22:08²Ä 5416 ½g¦^À³ ÅÞ¿è«ä¦Ò¡G 3¤ë©³¦]ªÑ»ù§C©ó1¬ü¤¸¡A³Qĵ§i©µ«á6Ó¤ë§ïµ½(§Y9¤ë©³«eªÑ»ùn°ª©ó1¬ü¤¸³sÄò10¤Ñ)¡A ¦Ó9¤ë©³©¡º¡¤]¥u¯à¦A©µ6Ó¤ë¡A§Y112¦~3¤ë©³YªÑ»ù¤´§C©ó1¬ü¤¸¡A«h±N³Qn¨D¤U¥«¡C ¨È·à±dY¦Ò¼{±N¼Ú¬w±wªÌ¦C¤JªvÀø¡AµM«á¨Óµ¥©ú¦~3¤ëªº¸Ñª¼¡C³o¼Ë®É¶¡¤Ó»°¡B·ÀI¤Ó¤j(¸ê®Æ¾ã²z¤£¤Î)¡C ¤@©w·|¦³´Á¤¤³ø§i¡A®É¶¡¸¨©ó111¦~12¤ë¦Ü112¦~2¤ë¤½¥¬´Á¤¤³ø§iªº¾÷·|«Ü¤j(²Å¦XÅÞ¿è)¡C ¥H¤W¥i¯à¤U¥«ªº°T®§¡A½Ð°Ý¦U¦ì¤j¤j¦³¦ó·Qªk? ²¦³º¤µ¤Ñ¬O9/16¡A¨ì9/26¥u¦³10¤Ñ¡C¤£ª¾¹D¤½¥q·|«ç»ò°µ³á ? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/16 ¤W¤È 10:51:00²Ä 5595 ½g¦^À³
|
¸Ø±i¤j¡A ¤@¯ë¬Ò须12-13Ó¤ë¡C ¤½¥q预¦ôªº¦³ÂIÆ[¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K §¨Ó¶}Lebrikizumab (LY3650150) ¶}¤¤-««×AD ¤G½u¥ÎÃÄ(¥ÎDupilumab µL¤ÏÀ³©ÎAE¦ÓµLªk¨Ï¥ÎªÌ) ¤T´ÁÁ{§É 120¤H. Study Design Go to sections Study Type : Interventional (Clinical Trial) Estimated Enrollment : 120 participants Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab Estimated Study Start Date : August 18, 2022 Estimated Primary Completion Date : August 2, 2023 Estimated Study Completion Date : December 6, 2023 clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/9/16 ¤W¤È 10:37:47²Ä 5594 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¤j ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/16 ¤W¤È 05:56:07 ASLSN004 TREK-DX 2´Á AD Á{§É ¤µ¦~²Ä4©u¶}©l©Û¶Ò¡C 预p©Û¶Ò¤H¼Æ75¤H¡AÂùª¼¸ÕÅç¡A¹êÅç组50¤H¡A¹ï·Ó组25¤H 400mg¡Ñ16¶gx¨C¶g¤@°w¡C ¦ôp13Ó¤ë¸Ñª¼¡C -------------------------------------------------------------------------------------------- ASLAN ÁÙ¦b¶i¦æ TREK-AD ¸ÕÅç¡A³o¬O¤@¶µ¥þ²yÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¾¯¶q½d³òªº 2b ´ÁÁ{§É¸ÕÅç¡A¥Hµû¦ô eblasakimab ¹ï±w¦³¤¤«×¦Ü««× AD ªº¦¨¤H±wªÌªºÀø®Ä©M¦w¥þ©Ê¡C¬O¥þ¨ªvÀøªºÔ¿ïªÌ¡C¸Ó¸ÕÅ窺¤@½u¼Æ¾Ú¹wp±N¦b 2023 ¦~¤W¥b¦~µo¥¬¡C ¬O§_×¥¿¬° ¤µ¦~²Ä4©u¶}©l©Û¶Ò¡C 预p©Û¶Ò¤H¼Æ75¤H¡AÂùª¼¸ÕÅç¡A¹êÅç组50¤H¡A¹ï·Ó组25¤H 400mg¡Ñ16¶gx¨C¶g¤@°w¡C ¦ôp112¦~6¤ë«e¸Ñª¼¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/16 ¤W¤È 07:43:57²Ä 5593 ½g¦^À³
|
ASLAN004 ¤¤-««×AD谮¦b¥«¦û¥«Ô·¡A¤@&¤G½u¡A ¤½¥q¦Û¦ô60»õ¬ü¤¸¡C 60/80 (dupilumab AD) ¡Ñ130(dupilumab ³Ì°ª¾P°â)==97.5(¶×²v¬ü¤¸ 1¡G¼Ú¤¸ 1)»õ¬ü¤¸¡C ASLAN004 ¯uªº¦³¦Ê»õ¬ü¤¸ªº¾P°â谮¤O¡C ¤é«á³Q¨ÖÁʮɪº½Í§P°ò¦¡C ASLAN004 欧¬w°ÏAD±ÂÅv°ò¦ ¥i¯à¬°Lebrikizumab(欧°Ï销°â5»õ¬ü¤¸)ªº1.6¿Ã±约ª÷¡C Y§t¨ä¥L¾AÀ³¯g¡A¥i¯à2-3¿¡K¡K¦ô©ú¦~4¤ë±ÂÅv¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/16 ¤W¤È 06:42:13²Ä 5592 ½g¦^À³
|
×¥¿-1 ASLAN004 ¦b¤¤-««×AD ¥þ²y¥«³õ ¦³ªñ60»õ¬ü¤¸¾P°â¼ç¤O(¤@½u¤Î¤G½u AD¥Íª«»s¾¯¥ÎÃÄ), ®Ú¾Ú150¤H ¤¤-««×AD±wªÌ¥«½Õ¤ÀªR¦Ó¨Ó. ¾P°â¼ç¤O//AD©Ò¦³±wªÌ¤H¼Æ(¤¤-««×AD¡A¥¼¨ü±±约¦û¨ä¤¤5%) US $4,849M //41.4M///¥¼¨ü±±AD约2.1M(REGN 资®Æ) EU $793M//30.7M JAPAN $322M//5.0M CHINA $35M//35.6M(§ó¥¿资®Æ) ¦Xp $5,999M//113M(¥þ²y200M ±w-AD) ir.aslanpharma.com/events/event-details/aslan-hybrid-rd-day |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/16 ¤W¤È 06:25:04²Ä 5591 ½g¦^À³
|
ASLAN004 60»õ¬ü¤¸AD¼ç¦b¦ôºâ¥«³õ: ¥]§t¤@½u&¤G½u¥«³õ. Dupilumab 80»õ¬ü¤¸AD³Ì°ª¾P°â¥«³õ Dupilumab ¨Ï¥Î52¶g«á¦³¤ÏÀ³ªº约50%(9¤ë15¤é CMO³ø§i资®Æ) 80¡Ñ50%(¤@½u)+80¡Ñ50%x50%(¤G½u)=60»õ¬ü¤¸¡C (¥H¤WÓ¤H¦ôp) ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K MOA ASLAN004 §@¥Î¦bIL13 ¦¸³æ¦ì¨üÅé(«Ê¦í)¡A°£¥i¦P®Éªý断IL4/IL13Âù¼Ð¹v¡K¡K(¦Pdupilumab)¡C ³Ì·sµo现 ASLAN004¥iª½ªý断·kÄoªº¯«¸g¤¸¡C§Ö³t±±¨î·kÄo¡C 9¤ë©³±N©ó欧¬w¥Ö½§¨ó·|¦~·|µoªí¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/16 ¤W¤È 05:56:07²Ä 5590 ½g¦^À³
|
ASLSN004 TREK-DX 2´Á AD Á{§É ¤µ¦~²Ä4©u¶}©l©Û¶Ò¡C 预p©Û¶Ò¤H¼Æ75¤H¡AÂùª¼¸ÕÅç¡A¹êÅç组50¤H¡A¹ï·Ó组25¤H 400mg¡Ñ16¶gx¨C¶g¤@°w¡C ¦ôp13Ó¤ë¸Ñª¼¡C The TREK-DX trial is expected to enroll 75 patients in a randomized, double-blind, placebo-controlled, multicenter trial in North America to evaluate the efficacy and safety of eblasakimab in patients with moderate-to-severe AD previously treated with dupilumab. The trial will enroll patients who have discontinued dupilumab treatment for any reason, including inadequate control of AD, loss of access or an adverse event |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/15 ¤U¤È 11:50:36²Ä 5589 ½g¦^À³
|
60»õAD¼ç¦b¦ôºâ¥«³õ: ¥]§t¤@½u&¤G½u¥«³õ. 150¤H¥«½Õ ASLAN004 VS DUPILUMAB ³ß¦nµ{«× ¤è®×A Àø®ÄÀu©óDUPILUMAB 8%+4¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµoµ{ ¤è®×B Àø®ÄÀu©óDUPILUMAB 8%+2¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµoµ{ ¤è®×C Àø®Äµ¥©óDUPILUMAB +¨C¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµoµ{ ¤è®×A//¤è®×B//¤è®×C ¤@½u 51%//44%//20% ¤G½u 55%//54%//47% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/15 ¤U¤È 11:29:06²Ä 5588 ½g¦^À³
|
¬ü°ê¤w22¸U¤H¥Î¹LDupilumab,¦ôp35%¬O¹FIGA0,1=0 , ¦ô¥Ø«e22*65%=15¸U¤H ¬°¤G½u¥«³õ¼ç¦b«È¤á. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/15 ¤U¤È 11:23:08²Ä 5587 ½g¦^À³
|
150¤H -¤¤-««× AD±wªÌ ¥«½Õ °²³] 8% Àø®ÄÀu©óDUPILUMAB+ §C°Æ§@¥Î + ¦U2/4¶g¤@°w °Ý±wªÌ³ßÅw (1)ASLAN004(2) DUPILUMAB ±o¥X¤@¤ñ²v*¦U¥«³õ¼ç¤O.=ªñ60»õ¬ü¤¸. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/15 ¤U¤È 11:03:17²Ä 5586 ½g¦^À³
|
9¤ë15¤é R&D DAY ¸ê®Æ: ASLN ¤½¥q¦ôp (2019 BASE) ASLAN004 ¦b¤¤-««×AD ¥þ²y¥«³õ ¦³ªñ60»õ¬ü¤¸¼ç¤O, ®Ú¾Ú150¤H ¤¤-««×AD±wªÌ¥«½Õ¤ÀªR¦Ó¨Ó. ¾P°â¼ç¤O//±wªÌ¤H¼Æ US $4,849M //41.4M EU $793M//30.7M JAPAN $322M//5.0M CHINA $35M//535M ¦Xp $5,999M ir.aslanpharma.com/events/event-details/aslan-hybrid-rd-day |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/15 ¤W¤È 06:56:51²Ä 5585 ½g¦^À³
|
Dupilumab ¼Ð·ÇÀøµ{ 16¶g¡C ²Ä16¶gªºEASI°§C´T¹FEASI50ªÌºÙ¦³¤ÏÀ³¡C«OÀI¤½¥q·|¦P·N17-52¶gªº©µÄòªvÀø¡C Y¦bl6¶g¥¼¹FEASI50ªÌ¡A则«OÀI¤½¥q°±¤î¤ä¥I©¹«áªº¶O¥Î¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K 53¶g¥H«á¥i¯à«OÀI¤½¥q¤£¤ä¥I¡H¡H¡H ¬G¸Ô²ÓŪLebrikizumab ªºDupilumab ¥Î¹L«á(¤G½u) ¤T´ÁAD¤¤-«¯gªºÁ{§É©Û¶Ò±ø¥ó¨Ó¬Ý¡A¥«³õ³W¼Ò½T¹ê¤£¤p¡C Dupilumab ¥é³æ¤¤¡A¦b³Ì«á¤@°w¥´§¹ªº²Ä8¶g¡A¦b¦å²G¤¤ªºÃħt¶q´N°¬°¹s¡C ¬GADªº¯f¯g´N·|¤Ï¼u¾÷·|°ª¡C ¥i±±¨î¦ýÃø®Úªv¡C ®Ú¾Ú½Õ¬d2030¦~ AD ¥Íª«»s¾¯¥«³õ规¼Ò160-240»õ¬ü¤¸¡C Dupilumab ¦û60-80»õ¬ü¤¸¡A¤G½u(§t)¥H«á¡A¦û100-160»õ¬ü¤¸¡A¥u¬OÄvª§ªÌ衆¦h¡A5¦~内n¤W¥«ªÌ约14Ó·sÃÄ¡C clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab 纳¤J标ã¡C ©Ò¦³参ÉOªÌ¤§«e¥²须±µ¨ü过²Å¦X¥H¤U条¥ó¤§¤@ªº§ù¤Ç鲁(dupilumab)单§Üªv疗¡C ¦]ÆÓ¤Ï应¡B³¡¤À¤Ï应¡B¥¢¥h疗®Ä¦Ó°±¤î§ù¤Ç鲁单(dupilumab)§Üªv疗ªº参ÉOªÌ¥²须¤§«e±µ¨ü过§ù¤Ç鲁单§Ü¡]标ª`剂¶q¤ô¥¡^ªv疗¦Ü¤Ö4个¤ë¡C ¦]对药ª«¤£@¨ü©Î发¥Í¤£¨}¨Æ¥ó¡]AEs¡^¦Ó°±¤î§ù¤Ç鲁单§Üªv疗ªº参ÉOªÌ¥i¥H进¤J¬ã¨s¡A¦Ó¤£n¨D¤§«e§ù¤Ç鲁单§Üªv疗ªº时间¡C ¦]费¥Î问题©ÎÆÓªk获±o§ù¤ñ卢单§Ü¡]¦p«O险¡^¦Ó°±¤î§ù¤ñ卢单§Üªv疗ªº参ÉOªÌ¡A¥i¥H¦b没¦³n¨D¤§«e§ù¤ñ卢单§Üªv疗时间ªº±¡úG¤U进¤J¬ã¨s¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 10:15:00²Ä 5584 ½g¦^À³
|
³¯¤j, ¼ÐÃD©MÂI¶i¥h¤º®e¤£¹ï,À³¬OASLN ºôºÞ¤Hûªº»~È. ²Ä¤T½g Eblasakimab, a Monoclonal Antibody Targeting IL‑13R£\1 Reduces Serum Biomarkers Associated with Atopy and Correlated with Disease Severity in Patients With Moderate‑to‑Severe Atopic Dermatitis aslanpharma.com/app/uploads/2022/09/EADV-2022-Biomarker-Poster_P0243_upload.pdf ------------------ aslanpharma.com/news/?cat=publications EDVA ¦³¤T½g,¤Wzºô¶, ¦ý²Ä¤TÓ©M²Ä¤GÓ¼ÐÃD¬Û¦P,ÂI¶i¥h¤º¼ÐÃD¤º®e¬Ò¤£¬Û¦P. ------------------------------ |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/9/14 ¤U¤È 10:10:59²Ä 5583 ½g¦^À³
|
¤Ñ©R¤j ¤½¥q§âìPoster 3 ¸ê®Æ©ñ¤JPoster 2¤º®e¡A©ñ¦b¤@°_嘞 |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/14 ¤U¤È 10:09:24²Ä 5582 ½g¦^À³
|
Á{þH¶¥¬q¥Íª«»sÃÄAslan PharmPharmticals(¯Ç´µ¹F§J¡GASLN)¶g¤Tªí¥Ü¡Ap¹º±Ò°Ê¤@¶µ·sªºÁ{þH¸ÕÅç¡A¨Ï¥Î¨ä³æ§ÜeblasakimabªvÀø¥ý«e±Ä¶°¹L´¶³q¥Ö½§ªº¦¨¦~¤HªºÀã¯lÃĪ«DUPILUMA¡C ASLN¦b¤@¥÷Án©ú¤¤ªí¥Ü¡A¸Ó¤½¥q¹wp¦b2022¦~²Ä¥|©u«×©Û¶Ò²Ä¤@¦W±wªÌ°Ñ¥[¸ÕÅç¡C ¸Ó¸ÕÅç±N¦b¥_¬ü©Û¶Ò75¦W±wªÌ°Ñ¥[¦h¤¤¤ß¸ÕÅç¡C ASLNº®u°õ¦æ©xCarl Firth説¡G¡§§ÚÌ»{¬°¡A³\¦h¥H«e±µ¨üdupilumabªvÀøªº±wªÌ¥i¥H±qeblasakimab¤¤¨ü¯q¡A³o¨Ç¼Æ¾Ú¥i¥H¤ä«ùeblasakimab¦b¥Íª«¥®¸X©M¦³¸gÅ窺±wªÌ羣Å餤¨Ï¥Î¡C ¸Ó¤½¥qªí¥Ü¡A·sªº¸ÕÅç¬O¨ä²{¦³¹BÀçp¹ºªº¤@³¡¤À¡A¹ï¤§«e³ø¹Dªº²{ª÷¶]¹D¨S¦³¼vÅT¡C ASLN¦b¬ü°ê¤W¥«ªºªÑ²¼¦b¦½L¥æ©ö¤¤«ù¥¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/14 ¤U¤È 10:05:38²Ä 5581 ½g¦^À³
|
ASLAN Pharma to Start Trial of Eczema Drug in Patients With a Previous Treatment Aslan Pharma±N±Ò°ÊÀã¯lÃĪ«¦b¬J©¹ªvÀø±wªÌ¤¤ªº¸ÕÅç |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/9/14 ¤U¤È 10:03:49²Ä 5580 ½g¦^À³
|
¤Ñ©R¤j ¤U±´£¨ì²Ä3Ó Poster 3 (Poster #0343) ASLAN PHARMACEUTICALS LIMITED September 7, 2022¡P8 min read In this article: ASLN 0.00% ASLAN PHARMACEUTICALS LIMITED ASLAN PHARMACEUTICALS LIMITED Data presented at EADV for the first time show eblasakimab suppresses downstream inflammatory biomarkers of atopic dermatitis, continuing 4-6 weeks after the last dose Notable improvements in quality-of-sleep measures, with fewer patients reporting sleep disturbance on eblasakimab Eblasakimab significantly reduced P-NRS (itch) scores and improvements continued throughout 8-week course of treatment across all dose cohorts MENLO PARK, Calif. and SINGAPORE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of new eblasakimab data at the 2022 European Academy of Dermatology and Venereology (EADV) annual congress in Milan, Italy. Three posters are being presented as e-posters throughout the duration of the congress from September 7 to 10, 2022. The posters include previously unpublished data on biomarkers and quality-of-life measures, and new, additional analyses of clinical data from the previously reported Phase 1 multiple-ascending dose study of eblasakimab in moderate-to-severe atopic dermatitis (AD). Alex Kaoukhov, Chief Medical Officer, ASLAN Pharmaceuticals, commented, ¡§The newly presented biomarker data provide a robust, objective basis for the clinical efficacy we observed in the Phase 1 trial of eblasakimab and support its potential to offer a clearly differentiated treatment option for AD patients. We observed significant improvements in itch and sleep loss within the 8-week study period, suggesting the potential for a greater magnitude of effect with prolonged treatment and we are investigating this in the ongoing phase 2b study. Collectively, the data being presented at EADV gives us great confidence to continue investigating eblaskaimab¡¦s role in AD and other indications in the future.¡¨ 2022 EADV e-poster details Poster 1 (Poster #0243) Eblasakimab, a monoclonal antibody targeting IL-13R£\1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis Discussion AD is a skin disease with a predominant Type-2-inflammatory signature. Signaling through the Type 2 receptor induces expression of a multitude of marker molecules, correlating with disease severity. Marker molecules such as thymus activation regulated cytokine (TARC/CCL17), immunoglobulin E (IgE), and lactate dehydrogenase (LDH) are elevated in patients with severe disease. The poster shows results of patient samples from the proof-of-concept (PoC) trial of eblasakimab in adults with moderate-to-severe atopic dermatitis. Samples were immunoassayed for serum TARC, IgE and tested for LDH. Results Eblasakimab treatment reduced circulating levels of TARC/CCL17, IgE, and LDH, suggesting eblasakimab¡¦s unique mechanism of action targeting IL-13R£\1 and blocking the signaling of IL-4 and IL-13 through the Type 2 receptor is associated with reduced expression of the biomarker molecules associated with disease severity in AD1. Reductions from baseline were observed as early as the first post-baseline assessment for TARC/CCL17 (day 4), IgE (day 15) and LDH (day 15), with a rapid onset and significant difference at week 8 between 600 mg vs placebo for TARC/CCL17 (mean values of ‑62.23 vs ‑17.83, P<0.001). Serum biomarkers generally remained suppressed in the eblasakimab groups for four to six weeks following the last dose. Poster 2 (Poster #0342) Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study Discussion Chronic itch is a hallmark of AD and occurs in over 80% of patients with the disease2. Itch is the most burdensome symptom reported by patients and is strongly linked to sleep disturbances; in the general population, up to 48% of adults experience sleep disturbances, but in adults with AD this figure is up to 90%3. The poster presents patient reported outcomes from the PoC trial of eblasakimab in adults with moderate-to-severe atopic dermatitis and includes analyses of pruritus numeric rating scale (P-NRS) and Patient Oriented Eczema Measure (POEM) with a single sleep loss component. Results Eblasakimab significantly reduced P-NRS scores across all dose cohorts in the modified Intent to Treat (mITT) population and improvements continued throughout the 8-week course of treatment. At week 8, patients in the 600mg dose group showed a 48% improvement in worst itch, versus a 13% improvement in the placebo group (P=0.05). 56% of patients in the 600mg eblasakimab group demonstrated at least a two point mean improvement in sleep loss, a clinically significant improvement in sleep loss, versus 15% in the placebo group. Poster 3 (Poster #0343) Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study Discussion The poster presents results on assessments of clinical signs of AD from the randomized, placebo controlled, double-blinded Phase 1 PoC trial of eblasakimab in adults with moderate-to-severe AD and highlights improvements in disease measures after treatment with eblasakimab. Efficacy assessments include changes in eczema area and severity index (EASI), Investigators Global Assessment (IGA) and Body Surface Area (BSA) score. Patients in the mITT population received eblasakimab at 200 mg (N=4), 400 mg (N=6), 600 mg (N=16) or placebo (N=13). Results In the mITT population, significant improvements in EASI score were seen early and progressed throughout the trial compared with placebo, with the 400mg and 600mg dose cohorts producing a greater response than the 200mg dose. At week 8, significant improvements were noted in the mean percentage change from baseline in EASI score in the 600mg group versus placebo (65% vs 27%, P=0.014), and 69% of patients achieved EASI-75 in the eblasakimab 600mg dose group versus 15% on placebo (P=0.005). Eblasakimab was well tolerated with notable improvements also seen in IGA versus placebo (44% vs 15%) in the 600mg group at week 8. The posters presented at the conference are available to access here. References Hamilton JD et al (2021) Clin Exp Allergy 51(7):915‑931 Legat (2021) Frontiers in Med 8:644760 Bawany et al (2021) J Allergy Clin Immunol Pract 9(4):1488-1500 About eblasakimab Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, with the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen for atopic dermatitis patients. In September 2021, ASLAN announced positive results from the Phase 1b multiple-ascending-dose study that established proof-of-concept of ASLAN004 and supported its potential as a novel treatment for AD. In January 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 09:58:01²Ä 5579 ½g¦^À³
|
³¯¤j, 1.ASLN ¦bESDR ®i¥Üªº¬OASLAN004 MOA ¤Î IL-13R£\1 «H¸¹¦b¯SÀ³©Ê¥Öª¢¤¤ªºªÅ¶¡©w¦ì©M¥\¯à§@¥Î ----------------------------------------------------- ASLAN Pharmaceuticals «Å§G¦b²Ä 51 ©¡¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¾Ç·|¦~·|¤W±µ¨ü¨â½g³Ì·sªº¹q¤l®ü³ø®i¥ÜºKn ¥[§QºÖ¥§¨È¦{ªù¬¥©¬§J©M·s¥[©Y¡A2022 ¦~ 9 ¤ë 13 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ¬O¤@®aÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡A¸Ó¤½¥q¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¡G 2022 ¦~ 9 ¤ë 28 ¤é¦Ü 10 ¤ë 1 ¤é¦b²üÄõªü©i´µ¯S¤¦Á|¦æªº²Ä 51 ©¡¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¾Ç·| (ESDR) ·|ij¤W¡A¨â¥÷®i¥Ü eblasakimab ·sÂà¤Æ¼Æ¾ÚªººKn³Q±µ¨ü¬°³Ì·sªº¹q¤l®ü³ø¡C ²Ä 51 ©¡¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¾Ç·|¹q¤l®ü³ø¸Ô²Ó«H®§ ®ü³ø 1¡GIL-13R£\1 «H¸¹¦b¯SÀ³©Ê¥Öª¢¤¤ªºªÅ¶¡©w¦ì©M¥\¯à§@¥Î ¡]ºKn½s¸¹¡GLB060¡^ ®ü³ø 2¡G³q¹L¨Ï¥Î¨Ì¥¬©Ô¥q°ò³æ§Ü¹v¦V¥Õ²ÓM¤¶¯À 13 ¨üÅé £\1 (IL-13R£\1) ¨Ó¬}¹î·sªºæ±Äo³~®|©M¦Ûµo¯«¸g¤¸¬¡°Ê ¡]ºKn½s¸¹¡GLB061¡^ ®ü³ø¥i¥Î¤é´Á¡G2022 ¦~ 9 ¤ë 28 ¤é¡A¬P´Á¤T¡C finance.yahoo.com/news/aslan-pharmaceuticals-announces-acceptance-two-110000498.html ¤G.ASLAN004 1b ¤TÓÁ{§É³ø§i,µoªí©ó2022 EVDA(¼Ú¬w¥Ö½§¦~·|)--2022/09/07~10 1.Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study aslanpharma.com/app/uploads/2022/09/EADV-PRO-poster_FINAL.pdf 2.Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study aslanpharma.com/app/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf 3.Eblasakimab, a Monoclonal Antibody Targeting IL‑13R£\1 Reduces Serum Biomarkers Associated with Atopy and Correlated with Disease Severity in Patients With Moderate‑to‑Severe Atopic Dermatitis aslanpharma.com/app/uploads/2022/09/EADV-2022-Biomarker-Poster_P0243_upload.pdf ¥H¤W¤T½g³ø§i¤§¤ÀªR:¬Ò±ÄmITT¤ÀªR 1b ´Á¬ã¨s¤¤ªºÀø®Ä¤ÀªR¨Ï¥Î¤Fקï«áªº·N¦V ªvÀø¡]mITT¡^¤H¸s¡A ¨ä¤¤¨Ó¦Û¤@Ó¦aÂIªº 9 ¦W¬ã¨s±wªÌ ¦b´¦ª¼¤§«e³Q±Æ°£¦b ITT ¤ÀªR¤§¥~¡A ¦]¬°°Ñ»PªÌªº¯e¯f¯S¼x¤£²Å¦X¤¤«×¦Ü««× AD¡C Efficacy analysis in the Phase 1b study used a modified Intent to Treat (mITT) population in which 9 study patients from one site were excluded from the ITT analysis prior to unblinding as the the participants did not have disease characteristics consistent with moderate to severe AD. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 09:48:07²Ä 5578 ½g¦^À³
|
³¯¤j, ¥i§_§iª¾®ø®§¨Ó·½? |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/9/14 ¤U¤È 09:30:56²Ä 5577 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¤j ¨È·à±d°Ñ¥[9¤ë31¤é¼Ú¬w¥Ö½§ÂåÀø·|ij ´£¥X3Ó¹q¤l®ü³ø³ø§i¡A¬°¦ó¥uÀò¥Zµn2Ó¡A³o¤¤¶¡¦³¤°»ò°ÝÃD¶Ü¡A¦n¹³¬O¦³Ãö1b¼Æ¾Ú¤£²z·Q¤§¬ã¨såªR³o³¡¤À¡A |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 09:21:35²Ä 5576 ½g¦^À³
|
¥ß§»¤j, «Ý»ù¦Ó¦ô! |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2022/9/14 ¤U¤È 08:32:47²Ä 5575 ½g¦^À³
|
¤Ñ©R¤j¤j¡F·Pı¤½¥q³o¦¸¯uªº«÷«Ü¤j³á¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 08:18:44²Ä 5574 ½g¦^À³
|
Results from both studies could position eblasakimab as the preferred first-choice biologic for the treatment of moderate-to-severe AD ¨â¶µ(¤@½u¤Î¤G½u)¬ã¨sªºµ²ªG¥i±Neblasakimab(¨Ì¥¬©Ô¦è³æ§Ü)©w¦ì¬°ªvÀø¤¤«×¦Ü««× AD ªºº¿ï¥Íª«»s¾¯ ¥H¤W¤½¥qªº»¡ªk : ¦³¹D²z ¥[¤W¿z¿ï«D¶Ç²ÎAD±wªÌ§ó¦³¾÷·|! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 07:53:29²Ä 5573 ½g¦^À³
|
ASLAN004 ¤]·Ç³Æ·m¶i¤G½uAD ------------------------------------------------- ¥ÎDupilumabµL¤ÏÀ³ªÌ¦b¤T´ÁÁ{§É¬ù35%,¹FEASI75ªÌ¬ù48.5%. §¨Ó¶}Lebrikizumab (LY3650150) ¶}¤¤-««×AD ¤G½u¥ÎÃÄ(¥ÎDupilumab µL¤ÏÀ³©ÎAE¦ÓµLªk¨Ï¥ÎªÌ) ¤T´ÁÁ{§É 120¤H. Study Design Go to sections Study Type : Interventional (Clinical Trial) Estimated Enrollment : 120 participants Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab Estimated Study Start Date : August 18, 2022 Estimated Primary Completion Date : August 2, 2023 Estimated Study Completion Date : December 6, 2023 clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab 纳¤J标ã¡C ©Ò¦³参ÉOªÌ¤§«e¥²须±µ¨ü过²Å¦X¥H¤U条¥ó¤§¤@ªº§ù¤Ç鲁(dupilumab)单§Üªv疗¡C ¦]ÆÓ¤Ï应¡B³¡¤À¤Ï应¡B¥¢¥h疗®Ä¦Ó°±¤î§ù¤Ç鲁单(dupilumab)§Üªv疗ªº参ÉOªÌ¥²须¤§«e±µ¨ü过§ù¤Ç鲁单§Ü¡]标ª`剂¶q¤ô¥¡^ªv疗¦Ü¤Ö4个¤ë¡C ¦]对药ª«¤£@¨ü©Î发¥Í¤£¨}¨Æ¥ó¡]AEs¡^¦Ó°±¤î§ù¤Ç鲁单§Üªv疗ªº参ÉOªÌ¥i¥H进¤J¬ã¨s¡A¦Ó¤£n¨D¤§«e§ù¤Ç鲁单§Üªv疗ªº时间¡C ¦]费¥Î问题©ÎÆÓªk获±o§ù¤ñ卢单§Ü¡]¦p«O险¡^¦Ó°±¤î§ù¤ñ卢单§Üªv疗ªº参ÉOªÌ¡A¥i¥H¦b没¦³n¨D¤§«e§ù¤ñ卢单§Üªv疗时间ªº±¡úG¤U进¤J¬ã¨s¡C Inclusion Criteria: All participants must have prior treatment with dupilumab meeting one of the following conditions: Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab (at labeled dose level) for at least 4 months. Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment. Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab (for example, insurance coverage) may enter the study with no required prior length of dupilumab treatment. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 07:31:50²Ä 5572 ½g¦^À³
|
finance.yahoo.com/news/aslan-pharmaceuticals-commences-clinical-program-111500123.html ¨È´µÄõÃÄ·~¦³¤½¥q ASLAN p¹º©ó 2022 ¦~²Ä¥|©u«×¶}©l TREK-DX¡]EblasaKimab ¦b Dupilumab eXperienced AD ±wªÌ¤¤ªº¸ÕÅç¡^¡A¥Hµû¦ô eblasakimab §@¬°´À¥N¥Íª«»s¾¯¹ï¤w°±¤î¨Ï¥Î dupilumab ªvÀøªº¯SÀ³©Ê¥Öª¢ (AD) ±wªÌªºÀø®Ä©M¦w¥þ©Ê TREK-DX ±N¬ã¨s eblasakimab ¦b±µ¨ü¹L dupilumab ªvÀøªº±wªÌ¤¤ªº¼ç¦b¥Î³~¡A¥H¸É¥R¥¿¦b¶i¦æªº TREK-AD ¸ÕÅç¦b¥Íª«¤Ñ¯uªº±wªÌ¤¤¶i¦æ ¨â¶µ¬ã¨sªºµ²ªG¥i±N¨Ì¥¬©Ô¦è³æ§Ü©w¦ì¬°ªvÀø¤¤«×¦Ü««× AD ªºº¿ï¥Íª«»s¾¯ TREK-DX p¹º¬O¤½¥q²{¦³¹BÀçp¹ºªº¤@³¡¤À¡A¹ï¥ý«e³ø§iªº²{ª÷¶]¹D¨S¦³¼vÅT TREK-DX ªº¶i¤@¨B°Q½×±N¦b 2022 ¦~ 9 ¤ë 15 ¤é¤½¥q¥D¿ìªº¬ãµo¤é´Á¶¡¶i¦æ ¥[§QºÖ¥§¨È¦{ªù¬¥©¬§J©M·s¥[©Y¡A2022 ¦~ 9 ¤ë 14 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (¡§ASLAN¡¨¡A¯Ç´µ¹F§J¥N½X¡GASLN)¡A¤@®aÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¡A¥¦p¹º±Ò°Ê¤@¶µ·sªº eblasakimab Á{§É¸ÕÅç¡A¥Î©óªvÀø¥H«e±µ¨ü¹L dupilumab ªvÀøªº¦¨¤H±wªÌªº¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ (AD)¡C Eblasakimab ¬O¤@ºØ¼ç¦bªº¤@¬y³æ§J¶©§ÜÅé¡A¹v¦V IL-13 ¨üÅé¡A¨ã¦³´£¨Ñ®t²§¤ÆÀø®Ä©M¦w¥þ©Êªº¼ç¤O¡C ASLAN ¹wp±N¦b 2022 ¦~²Ä¥|©u«×©Û¶Ò²Ä¤@¦ì±wªÌ°Ñ¥[¸ÕÅç¡C ¡§»P§Ú̦b¥Íª«ªì©l±wªÌ¤¤¶i¦æªº 2b ´Á¸ÕÅç¬Û¤ñ¡ATREK-DX ±N¨Ï§Ú̯à°÷µû¦ô eblasakimab ¦b·s±wªÌ¸sÅ餤ªº¿W¯S§@¥Î¾÷¨î¡A¡¨ ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤h»¡¡C ¡§§Ú̬۫H¡A³\¦h¥H«e±µ¨ü¹L dupilumab ªvÀøªº±wªÌ¥i¥H±q eblasakimab ¤¤¨ü¯q¡A³o¨Ç¼Æ¾Ú¥i¥H¤ä«ù eblasakimab ¦b¥Íª«¾Ç¤Ñ¯u©M¦³¸gÅ窺±wªÌ¸sÅ餤ªº¨Ï¥Î¡C¡¨ TREK-DX ¸ÕÅç¹wp±N¦b¥_¬ü©Û¶Ò 75 ¦W±wªÌ°Ñ¥[¤@¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¦h¤¤¤ß¸ÕÅç¡A¥Hµû¦ô eblasakimab ¹ï¥ý«e¨Ï¥Î dupilumab ªvÀøªº¤¤«×¦Ü««× AD ±wªÌªºÀø®Ä©M¦w¥þ©Ê¡C¸Ó¸ÕÅç±N©Û¶Ò¦]¥ô¦óì¦]°±¤î dupilumab ªvÀøªº±wªÌ¡A¥]¬A¹ï AD ªº±±¨î¤£¨¬¡BµLªk³X°Ý©Î¤£¨}¨Æ¥ó¡C¸Óp¹º¬O¤½¥q²{¦³¹BÀçp¹ºªº¤@³¡¤À¡A¹ï¨ä¥ý«e³ø§iªº²{ª÷¶]¹D¨S¦³¼vÅT¡C ¸Ó¸ÕÅç±N¥]¬A 16 ¶gªºªvÀø´Á©M 12 ¶gªº¦w¥þÀH³X´Á¡C¥DnÀø®Ä²×ÂI¬OÀã¯l±¿nÄY«©Ê«ü¼Æ (EASI) µû¤À±q°ò½u¨ì²Ä 16 ¶gªº¦Ê¤À¤ñÅܤơCÃöÁ䪺¦¸nÀø®Ä²×ÂI¥]¬A¹F¨ì 0¡]²M°£¡^©Î 1¡]´X¥G²M°£¡^ªº¬ã¨sªÌ¥þ§½µû¦ô (IGA) µû¤Àªº±wªÌ¤ñ¨Ò, EASI (EASI-75) °§C 75% ©Î§ó¦hªº±wªÌ¤ñ¨Ò¡A¹F¨ì EASI-50 ©M EASI-90 ªº±wªÌ¤ñ¨Ò¡A¥H¤Îæ±Äo®pȪºÅܤơC ¡§ Dupilumab ¦bÃÒ©ú¹v¦V AD ¤¤ªº IL4/IL-13 «H¸¹³q¸ôªº¯q³B¤è±µo´§¤F«n§@¥Î¡CµM¦Ó¡A¤@¨Ç±wªÌ¨S¦³ªí²{¥X¹ï dupilumab ªº³Ì¨Î©Î«ùÄò¤ÏÀ³¡A©Î¥X²{µ²½¤ª¢µ¥¤£¨}¨Æ¥ó¡A¦]¦¹´M¨D¤@ºØ¥i¥H´£¨Ñ§ó°ª¦w¥þ©Ê©M¦³®Ä©Êªº´À¥NªvÀø¤è®×¡A¡¨¨È·à±d»sÃĺ®uÀç¾P©x Alex Kaoukhov ³Õ¤h»¡. ¡§¥¿¦p§Ú̦b¨ä¥L¾AÀ³¯g¡]¦p»È®h¯f¡^¤¤©Ò¨£¡A°w¹ï¦P¤@«H¸¹³q¸ôªº¤£¦P¤À¤l¦¨¤À¥i¯à¾ÉP¤£¦PªºÁ{§Éµ²ªG¡A§Ú̬۫H eblasakimab ªýÂ_ 2 «¬¨üÅ骺¿W¯S¤èªk¥i¯à¬° dupilumab ¸gÅçÂ×´Iªº±wªÌ´£¨Ñ¦³®ÄªºªvÀø¡C±wªÌ¡C¡¨ ASLAN ÁÙ¦b¶i¦æ TREK-AD ¸ÕÅç¡A³o¬O¤@¶µ¥þ²yÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¾¯¶q½d³òªº 2b ´ÁÁ{§É¸ÕÅç¡A¥Hµû¦ô eblasakimab ¹ï±w¦³¤¤«×¦Ü««× AD ªº¦¨¤H±wªÌªºÀø®Ä©M¦w¥þ©Ê¡C¬O¥þ¨ªvÀøªºÔ¿ïªÌ¡C¸Ó¸ÕÅ窺¤@½u¼Æ¾Ú¹wp±N¦b 2023 ¦~¤W¥b¦~µo¥¬¡C ASLAN ºÞ²z¼h±N©ó¬ü°êªF³¡®É¶¡ 2022 ¦~ 9 ¤ë 15 ¤é¬P´Á¥|¤W¤È 10:00 ¦Ü¤U¤È 1:30 ¦b¯Ã¬ù·ç¦N°s©±Á|¿ì¬ãµo (R&D) ¤é¬¡°Ê¡Cn¿Ë¦Û©Î¥HµêÀÀ¤è¦¡°Ñ¥[¬¡°Ê¡A½Ð³æÀ»¦¹³B¶i¦æµù¥U¡C¬¡°Ê©Mºt¥Ü§÷®Æªº«¼½±N¦b ASLAN Pharmaceutical ºô¯¸ ir.aslanpharma.com/ ªº§ë¸êªÌÃö«Y³¡¤À´£¨Ñ ASLAN PHARMACEUTICALS LIMITED ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in atopic dermatitis (AD) patients who have discontinued treatment with dupilumab TREK-DX will study the potential use of eblasakimab in patients that have been treated with dupilumab, complementing the ongoing TREK-AD trial in biologic naïve patients Results from both studies could position eblasakimab as the preferred first-choice biologic for the treatment of moderate-to-severe AD TREK-DX program is part of the Company¡¦s existing operating plan and has no impact on previously-reported cash runway Further discussion of TREK-DX will take place during the Company-hosted R&D Day on September 15, 2022 MENLO PARK, Calif. and SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (¡§ASLAN¡¨, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to initiate a new clinical trial of eblasakimab for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with dupilumab. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile. ASLAN expects to enroll the first patient in the trial in the fourth quarter of 2022. ¡§In contrast to our Phase 2b trial in biologic naïve patients, TREK-DX will allow us to evaluate eblasakimab¡¦s unique mechanism of action in a new patient population,¡¨ said Dr Carl Firth, CEO, ASLAN Pharmaceuticals. ¡§We believe that many patients previously treated with dupilumab can benefit from eblasakimab, and this data could support the use of eblasakimab in both the biologic naïve and experienced patient populations.¡¨ The TREK-DX trial is expected to enroll 75 patients in a randomized, double-blind, placebo-controlled, multicenter trial in North America to evaluate the efficacy and safety of eblasakimab in patients with moderate-to-severe AD previously treated with dupilumab. The trial will enroll patients who have discontinued dupilumab treatment for any reason, including inadequate control of AD, loss of access or an adverse event. The program is part of the Company¡¦s existing operating plan and has no impact on its previously-reported cash runway. The trial will consist of a 16-week treatment period and a 12-week safety follow-up period. The primary efficacy endpoint is percentage change in Eczema Area Severity Index (EASI) score from baseline to week 16. Key secondary efficacy endpoints include the proportion of patients achieving Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear), proportion of patients with a 75% or greater reduction in EASI (EASI-75), proportion of patients achieving EASI-50 and EASI-90, and changes in peak pruritus. ¡§Dupilumab has played an important role in demonstrating the benefits of targeting the IL4/IL-13 signaling pathway in AD. However, some patients do not demonstrate an optimal or sustained response to dupilumab, or develop adverse events such as conjunctivitis, and thus seek an alternative treatment option that could offer an improved safety and efficacy profile,¡¨ said Dr Alex Kaoukhov, CMO, ASLAN Pharmaceuticals. ¡§As we have seen in other indications, such as psoriasis, targeting different molecular components of the same signaling pathway can lead to different clinical outcomes and we believe that eblasakimab¡¦s unique approach to blocking the Type 2 receptor may offer an effective treatment for dupilumab-experienced patients.¡¨ ASLAN is also conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of eblasakimab in adult patients with moderate-to-severe AD who are candidates for systemic therapy. Topline data from this trial is expected in the first half of 2023. ASLAN¡¦s management is hosting a Research and Development (R&D) Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York. To attend the event in person or virtually, please click here for registration. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN Pharmaceutical¡¦s website at ir.aslanpharma.com/ |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/9/14 ¤U¤È 07:31:28²Ä 5571 ½g¦^À³
|
ASLAN Pharmaceuticals ±Ò°ÊÁ{§Ép¹º¥H¬ã¨s Eblasakimab ¦b Dupilumab ¸g¾úªº¯SÀ³©Ê¥Öª¢±wªÌ¤¤ªº§@¥Î ASLAN p¹º©ó 2022 ¦~²Ä¥|©u«×¶}©l TREK-DX¡]EblasaKimab ¦b Dupilumab eXperienced AD ±wªÌ¤¤ªº¸ÕÅç¡^¡A¥Hµû¦ô eblasakimab §@¬°´À¥N¥Íª«»s¾¯¹ï¤w°±¤î¨Ï¥Î dupilumab ªvÀøªº¯SÀ³©Ê¥Öª¢ (AD) ±wªÌªºÀø®Ä©M¦w¥þ©Ê TREK-DX ±N¬ã¨s eblasakimab ¦b±µ¨ü¹L dupilumab ªvÀøªº±wªÌ¤¤ªº¼ç¦b¥Î³~¡A¥H¸É¥R¥¿¦b¶i¦æªº TREK-AD ¸ÕÅç¦b¥Íª«¤Ñ¯uªº±wªÌ¤¤¶i¦æ ¨â¶µ¬ã¨sªºµ²ªG¥i±N¨Ì¥¬©Ô¦è³æ§Ü©w¦ì¬°ªvÀø¤¤«×¦Ü««× AD ªºº¿ï¥Íª«»s¾¯ TREK-DX p¹º¬O¤½¥q²{¦³¹BÀçp¹ºªº¤@³¡¤À¡A¹ï¥ý«e³ø§iªº²{ª÷¶]¹D¨S¦³¼vÅT TREK-DX ªº¶i¤@¨B°Q½×±N¦b 2022 ¦~ 9 ¤ë 15 ¤é¤½¥q¥D¿ìªº¬ãµo¤é´Á¶¡¶i¦æ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 02:26:24²Ä 5570 ½g¦^À³
|
9¤ë15¤é R&D ¤é¡A·|¤½§G004¨ä¥L¾AÀ³¯gªº©Pµo®Éµ{¡C 12¤ë´Á¤¤³ø§i¡A©Ò¶Òª÷ÃB¡A¥i¯à¥ý¥Î¨Ó¡A©ú¦~Q1ªº ý³Ý¡BEOEªº¤G´ÁÁ{§É¡C ¤ÎAD¤T´Á¶}®i¡C ©ú¦~4¤ë¸Ñª¼+¼Ú°Ï±ÂÅv +¨p¶Ò¤@¦¸¡C ¥H¤WÓ¤H¦ôp¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 02:09:11²Ä 5569 ½g¦^À³
|
Y¥§¡EASI°´T¸¨¦b75%(dupilumab ¤T´Á70%)¡A ²Ä4¶gªºÆ[¹î¥§¡°50-55%¡A¤w¸g¤j约¬O70%ªºÀø®Ä¤ô·Ç¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤U¤È 01:56:06²Ä 5568 ½g¦^À³
|
Áö¥¼¸Ñª¼¡A«e¤T°w¡A¨C¶g¤@°w¡]0/7/14¡^¡A²Ä¥|¶g¡]28¤Ñ¡^´úEASI¡A¥§¡°´T¬ù50%¥ª¥k¡A¹ï·Ó²Õ¬O35%¡C aslanpharma.com/app/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf ¦p¹Ï¤@¡C ¦³¨C¶gªº¼Æ¾Ú¡AÁö¥¼¸Ñª¼¡A²q¤@²q¡A¤£·|¤ÓÂ÷ÃСH ¤½¥q´±¥Î´Á¤¤¼Æ¾Ú¨Ó¶Ò¸ê¡A¦p¦P¥h¦~3¤ë¶Ò¸ê¤@¼Ë¡A§â´¤«×¥²°ª¤~¹ï¡I |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/14 ¤W¤È 11:37:59²Ä 5567 ½g¦^À³
|
¤@ª½´Á«Ýªº¥¿¦V´Á¤¤¼Æ¾ÚY¦³ÃСA¤~¬O·s·à¤Í¤§ºÖ~~ ´Á¬ß1.¦~©³´Á¤¤¼Æ¾ÚÁ`EASI-75¤@Á|¶W¶V§ù¥²ª¢~ ´Á¬ß2.©ú¦~¸Ñª¼¼Æ¾Ú¹êÅç²Õ3¤Î4(¶¡¹j¥|¶g§ëÃIJÕ)¡A¤@Á|¶W¶V§ù¥²ª¢~ ¥[ªo¦Ñ·à~~~~~~~~~~~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤W¤È 10:50:30²Ä 5566 ½g¦^À³
|
¦]¬ü°ê¤H12¤ë¤¤¦¯¶}©l¥ð¦~°²¡C ¬G12¤ëªì¤½¥¬´Á¤¤³ø§i¥i¯à©Ê³Ì°ª¡C ¶}¥ß¤¤¤ß¥i¯à§ï¬°65Ó¡]¤w¶}¥ß¡^¤Q¼Ú¬w 0¡ã35Ó¡C clinicaltrials.gov/ct2/show/NCT03443024 Lebrikizumab 2b AD Á{§É¦¬280¤H¡þ4²Õ¡A¶}¥ß58Ó¤¤¤ß¡A¥þ¦b¬ü°ê¹Ò¤º¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤W¤È 10:21:16²Ä 5565 ½g¦^À³
|
¥i¯à¶·¤½¥¬2bªº´Á¤¤³ø§i¡A¨Ã¦P®É¶Ò¶°¸êª÷¡C 0¡P8¡ã5.6¬ü¤¸¡]¥«»ù7¬ü¤¸x80%¡^¡þADR ¥»¦¸±Nµo¦æ27¡A564¤dªÑADR ªÑ¥»¡G97¡A308¤dªÑADR The offering Up to 486,543,875 ordinary shares (or 97,308,775 ADSs), including ordinary shares represented by ADSs (as more fully described in the notes following this table), assuming sales of 27,564,102 ADSs in this offering at an offering price of $0.78 per ADS, which was the last reported sale price of ADSs on Nasdaq on September 9, 2022. The actual number of ADSs issued will vary depending on the sales prices under this offering P.8 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/14 ¤W¤È 10:04:09²Ä 5564 ½g¦^À³
|
ir.aslanpharma.com/static-files/23962cfa-f7fc-4e06-aede-b9dc4715b463 21¡A000¡A000¬ü¤¸.¤@¤@¤@¤½¶}¥«³õ¶Ò¸ê¡]³Ì°ª¥i¶Ò150¡A000¡A000¬ü¤¸¡^ ¥Nªí´¶³qªÑªº¬ü°ê¦s°U¾ÌÃÒ §Ṳ́w»P Jefferies LLC ©Î Jefferies ´N¬ü°ê¦s°UªÑ²¼©Î ADS ñq¤F¤é´Á¬° 2020 ¦~ 10 ¤ë 9 ¤é¨Ã©ó 2022 ¦~ 9 ¤ë 13 ¤é×qªº¯S©w¤½¶}¥«³õ¾P°â¨óij¡A©Î¾P°â¨óij¡A¨C¤@Ó¥Nªí¤Ó´¶³qªÑ¡A¥Ñ¥»©ÛªÑ»¡©ú®Ñ¸É¥R©MÀHªþªº©ÛªÑ»¡©ú®Ñ´£¨Ñ¡C ®Ú¾Ú§Ṳ́§«e´£¥æµ¹ÃÒ¨é¥æ©ö©eû·|ªºªí®æ F-3 ©MÀHªþ©ÛªÑ»¡©ú®Ñ¡]µù¥UÁn©ú½s¸¹ 333-234405¡^ªº¥ý«eµn°OÁn©ú¡A§Ú̮ھھP°â¨óij´£¨Ñ©M¥X°â¤FÁ`p 2220 ¸U¬ü¤¸ªº ADS¡A¥H¤Î©ÛªÑ»¡©ú®Ñ¸É¥R¡A¤é´Á¬° 2020 ¦~ 10 ¤ë 9 ¤é¡A¸g×q¡C®Ú¾Ú¾P°â¨óijªº±ø´Ú¡A®Ú¾Ú¥»©ÛªÑ»¡©ú®Ñ¸É¥R¤å¥ó¡A§ÚÌ¥i¯à·|¤£®É³q¹L§@¬°¾P°â¥N²zªº³Ç´I·ç´£¨Ñ©M¾P°âÁ`µo¦æ»ù®æ°ª¹F 21,500,000 ¬ü¤¸ªº ADS¡C §Ú̪º ADS ¦b¯Ç´µ¹F§J¥þ²y¥«³õ©Î¯Ç´µ¹F§J¤W¥«¡A¥N½X¬°¡§ASLN¡¨¡C 2022 ¦~ 9 ¤ë 9 ¤é¡A§ÚÌ ADS ªº³Ì«á³ø§i°â»ù¬°¨C ADS 0.78 ¬ü¤¸¡C §Ú̥ѫDÃöÁp¤½¥q«ù¦³ªº¬y³q´¶³qªÑ©Î¤½²³«ùªÑ¶qªºÁ`¥«È¬ù¬° 6470 ¸U¬ü¤¸¡A³o¬O®Ú¾Ú«DÃöÁp¤½¥q«ù¦³ªº 344,042,734 ªÑ¬y³q´¶³qªÑ©M¨CªÑ 0.188 ¬ü¤¸¡]©Î¨CªÑ¬ü°ê¦s°U¾ÌÃÒ 0.94 ¬ü¤¸¡^pºâ±o¥Xªº) ©ó 2022 ¦~ 8 ¤ë 16 ¤é¦b¯Ç´µ¹F§J³ø§i¡CºI¦Ü¥»©ÛªÑ»¡©ú®Ñ¸É¥R¤é´Á¡A§ÚÌ©|¥¼®Ú¾Ú¤@¯ë«ü¥Ü I.B.5 ´£¨Ñ¥ô¦óÃÒ¨é¡C F-3 ªí®æ¦b«e 12 Ó¤é¾ä¤ë´Á¶¡µ²§ô¡A¥]¬A¥»©ÛªÑ»¡©ú®Ñ¸É¥R¤é´Á¡C®Ú¾Ú¤@¯ë«ü¥O I.B.5¡C®Ú¾Ú F-3 ªí®æ¡A¦b¥ô¦ó±¡ªp¤U¡A¥un§Ú̪º¤½²³¦b¥ô¦ó 12 Ó¤ë´Á¶¡¤º¡A§Ú̳£¤£·|¥X°â»ùȶW¹L§Ṳ́½²³«ùªÑ¤T¤À¤§¤@ªº»ùȶW¹L¥»©ÛªÑ»¡©ú®Ñ¸É¥R³¡¤Àªºµù¥UÁn©ú¤¤µn°OªºÃÒ¨é¯B°Ê¤´§C©ó 7500 ¸U¬ü¤¸¡C US¢C 21¡A000¡A000 American Depositary Shares representing Ordinary Shares We have entered into a certain Open Market Sale AgreementSM, dated as of October 9, 2020, as amended on September 13, 2022, or Sales Agreement, with Jefferies LLC, or Jefferies, relating to American Depositary Shares, or ADSs, each representing five ordinary shares, offered by this prospectus supplement and the accompanying prospectus. We have offered and sold an aggregate of $22.2 million ADSs under the Sales Agreement pursuant to our prior registration statement on Form F-3 and accompanying prospectus (Registration Statement No. 333- 234405), previously filed with the Securities and Exchange Commission, and the prospectus supplement thereunder, dated October 9, 2020, as amended. In accordance with the terms of the Sales Agreement, pursuant to this prospectus supplement we may offer and sell ADSs having an aggregate offering price of up to $21,500,000 from time to time through Jefferies, acting as sales agent. Our ADSs are listed on The Nasdaq Global Market, or Nasdaq, under the symbol ¡§ASLN.¡¨ On September 9, 2022, the last reported sale price of our ADSs was $0.78 per ADS. The aggregate market value of our outstanding ordinary shares held by non-affiliates, or public float, was approximately $64.7 million, which was calculated based on 344,042,734 ordinary shares outstanding held by non-affiliates and a per share price of $0.188 (or $0.94 per ADS) as reported on Nasdaq on August 16, 2022. As of the date of this prospectus supplement, we have not offered any securities pursuant to General Instruction I.B.5. of Form F-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus supplement. Pursuant to General Instruction I.B.5. of Form F-3, in no event will we sell securities registered on the registration statement of which this prospectus supplement is a part with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. ¥»¤å¥ó¤À¬°¨â³¡¤À¡C²Ä¤@³¡¤À¬O©ÛªÑ»¡©ú®Ñ¸É¥R¡A¨ä¤¤´yz¤F¥»¦¸µo¦æªº¨ãÅé±ø´Ú¥H¤Î»P§ÚÌ©M§Ú̪º·~°È¬ÛÃöªº¬Y¨Ç¨ä¥L¨Æ¶µ¡C²Ä¤G³¡¤À¡A§YÀHªþªº©ÛªÑ»¡©ú®Ñ¡A¥]§t¨Ã³q¹L¤Þ¥Î¦X¨Ö¤F¦³Ãö§Ú̪º«n·~°È©M°]°È«H®§¡B§Ú̪º ADS ©M´¶³qªÑªº´yz¥H¤Î¦³Ãö§ÚÌ©M¥»¦¸µo¦æªº¬Y¨Ç¨ä¥L«H®§¡C¥»©ÛªÑ»¡©ú®Ñ¸É¥R©MÀHªþªº©ÛªÑ»¡©ú®Ñ¬O§Ų́ϥΡ§³f¬[¡¨µù¥Uµ{§Ç¦VÃÒ¨é¥æ©ö©eû·|©Î SEC ´£¥æªºµù¥UÁn©úªº¤@³¡¤À¡C ®Ú¾Ú³f¬[µù¥U¬yµ{¡A§ÚÌ¥i¯à·|´£¨ÑÁ`µo¦æ»ù°ª¹F 150,000,000 ¬ü¤¸ªº¬Y¨ÇÃÒ¨é¡C®Ú¾Ú¥»©ÛªÑ»¡©ú®Ñ¸É¥R¡A§ÚÌ¥i¯à¤£®É´£¨ÑÁ`µo¦æ»ù®æ°ª¹F 21,500,000 ¬ü¤¸ªº ADS¡A»ù®æ©M±ø´Ú¥Ñµo¦æ®Éªº¥«³õ±ø¥ó¨M©w¡C ®Ú¾Ú¥»©ÛªÑ»¡©ú®Ñ¸É¥R¥i¯à¥X°âªº 21,500,000 ¬ü¤¸ ADS ¥]§t¦b®Ú¾Úµn°OÁn©ú¥i¯à¥X°âªº 150,000,000 ¬ü¤¸ÃҨ餤¡C ±zÀ³¾\Ū¥»©ÛªÑ»¡©ú®Ñ¸É¥R©MÀHªþªº©ÛªÑ»¡©ú®Ñ¡A¥]¬A³q¹L¤Þ¥Î¨Ö¤J¥»¤å©M¨ä¤¤ªº©Ò¦³¤å¥ó¡A¥H¤Î¤U¤å¡§±z¥i¥H¦b¦ó³B§ä¨ì§ó¦h«H®§¡¨¤¤´yzªº¨ä¥L«H®§¡C³o¨Ç¤å¥ó¥]§t±z¦b°µ¥X§ë¸ê¨M©w®ÉÀ³¦Ò¼{ªº«n«H®§¡C ¥»©ÛªÑ»¡©ú®Ñ¸É¥R¸É¥R¨Ã§ó·s¤F³q¹L¤Þ¥Î¨Ö¤J¥»©ÛªÑ»¡©ú®Ñ¸É¥R©MÀHªþ©ÛªÑ»¡©ú®Ñªº¤å¥ó¤¤¥]§tªº«H®§¡C¤@¤è±¡A¦pªG¥»©ÛªÑ»¡©ú®Ñ¸É¥R¤¤¥]§tªº«H®§»P¦b¥»©ÛªÑ»¡©ú®Ñ¸É¥R¤é´Á¤§«e³q¹L¤Þ¥Î¨Ö¤J¥»©ÛªÑ»¡©ú®Ñ¸É¥Rªº¥ô¦ó¤å¥ó¤¤¥]§tªº«H®§¦s¦b½Ä¬ð¡A«h¥t¤@¤è±¡A±zÀ³¨Ì¿à¥»©ÛªÑ³¹µ{¸É¥R¸ê®Æ¤¤ªº«H®§¡C¦pªG¨ä¤¤¤@¥÷¤å¥ó¤¤ªº¥ô¦óÁn©ú»P¤é´Á¸û±ßªº¥t¤@¥÷¤å¥ó¡]¨Ò¦p¡A³q¹L¤Þ¥Î¨Ö¤J¥»©ÛªÑ»¡©ú®Ñ¸É¥R¤å¥óªº¤å¥ó¡^¤¤ªºÁn©ú¤£¤@P¡A«h¤é´Á¸û±ßªº¤å¥ó¤¤ªºÁn©ú±Nקï©Î¨ú¥N¸û¦ªºÁn©ú¡C±zÀ³°²©w¥»©ÛªÑ»¡©ú®Ñ¸É¥R¸ê®Æ¡B¥»©ÛªÑ»¡©ú®Ñ¸É¥R¸ê®Æ¤¤¤Þ¥Îªº¤å¥ó¡BÀHªþªº©ÛªÑ»¡©ú®Ñ¥H¤Î§Ú̱ÂÅv¥Î©ó¥»¦¸µo¦æªº¥ô¦ó§K¶O®Ñ±©ÛªÑ»¡©ú®Ñ¤¤¥X²{ªº«H®§¶È¦b·í¤é·Ç½T¨º¨Ç¦U¦Ûªº¤å¥ó¡C¦Û³o¨Ç¤é´Á¥H¨Ó¡A§Ú̪º·~°È¡B°]°Èª¬ªp¡B¸gÀç·~ÁZ©M«e´º¥i¯à¤wµo¥ÍÅܤơC This document is in two parts. The first part is the prospectus supplement, which describes the specific terms of this offering and certain other matters relating to us and our business. The second part, the accompanying prospectus, contains and incorporates by reference important business and financial information about us, a description of our ADSs and ordinary shares and certain other information about us and this offering. This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a ¡§shelf¡¨ registration process. Under the shelf registration process, we may offer certain of our securities having an aggregate offering price of up to $150,000,000. Under this prospectus supplement, we may offer ADSs having an aggregate offering price of up to $21,500,000 from time to time at prices and on terms to be determined by the market conditions at the time of the offering. The $21,500,000 of ADSs that may be sold under this prospectus supplement are included in the $150,000,000 of securities that may be sold under the registration statement. You should read both this prospectus supplement and the accompanying prospectus, including all documents incorporated herein and therein by reference, together with additional information described under ¡§Where You Can Find More Information¡¨ below. These documents contain important information that you should consider when making your investment decision. This prospectus supplement adds to and updates information contained in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in any document incorporated by reference into this prospectus supplement that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date (for example, a document incorporated by reference into this prospectus supplement) the statement in the document having the later date modifies or supersedes the earlier statement. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/13 ¤U¤È 07:21:37²Ä 5563 ½g¦^À³
|
ASLAN Pharmaceuticals «Å§G¦b²Ä 51 ©¡¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¾Ç·|¦~·|¤W±µ¨ü¨â½g³Ì·sªº¹q¤l®ü³ø®i¥ÜºKn ¥[§QºÖ¥§¨È¦{ªù¬¥©¬§J©M·s¥[©Y¡A2022 ¦~ 9 ¤ë 13 ¤é (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ¬O¤@®aÁ{§É¶¥¬q¡B¥H§K¬Ì¾Ç¬°«ÂIªº¥Íª«»sÃĤ½¥q¡A¸Ó¤½¥q¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¡G 2022 ¦~ 9 ¤ë 28 ¤é¦Ü 10 ¤ë 1 ¤é¦b²üÄõªü©i´µ¯S¤¦Á|¦æªº²Ä 51 ©¡¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¾Ç·| (ESDR) ·|ij¤W¡A¨â¥÷®i¥Ü eblasakimab ·sÂà¤Æ¼Æ¾ÚªººKn³Q±µ¨ü¬°³Ì·sªº¹q¤l®ü³ø¡C ²Ä 51 ©¡¼Ú¬w¥Ö½§¯f¾Ç¬ã¨s¾Ç·|¹q¤l®ü³ø¸Ô²Ó«H®§ ®ü³ø 1¡GIL-13R£\1 «H¸¹¦b¯SÀ³©Ê¥Öª¢¤¤ªºªÅ¶¡©w¦ì©M¥\¯à§@¥Î ¡]ºKn½s¸¹¡GLB060¡^ ®ü³ø 2¡G³q¹L¨Ï¥Î¨Ì¥¬©Ô¥q°ò³æ§Ü¹v¦V¥Õ²ÓM¤¶¯À 13 ¨üÅé £\1 (IL-13R£\1) ¨Ó¬}¹î·sªºæ±Äo³~®|©M¦Ûµo¯«¸g¤¸¬¡°Ê ¡]ºKn½s¸¹¡GLB061¡^ ®ü³ø¥i¥Î¤é´Á¡G2022 ¦~ 9 ¤ë 28 ¤é¡A¬P´Á¤T¡C finance.yahoo.com/news/aslan-pharmaceuticals-announces-acceptance-two-110000498.html ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting MENLO PARK, Calif. and SINGAPORE, Sept. 13, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that two abstracts showcasing new translational data on eblasakimab have been accepted as late-breaking e-posters at the 51st Annual European Society for Dermatological Research (ESDR) Meeting, taking place from September 28 to October 1, 2022, in Amsterdam, Netherlands. 51st Annual European Society for Dermatological Research e-poster details Poster 1: Spatial localization and functional role of IL-13R£\1 signaling in atopic dermatitis (abstract ID: LB060) Poster 2: Insight into novel itch pathways and spontaneous neuronal activity by targeting interleukin-13 receptor alpha 1 (IL-13R£\1) with eblasakimab (abstract ID: LB061) Poster availability date: Wednesday, September 28, 2022. The posters will be available to view online in the Investor Relations section of ASLAN¡¦s website following presentation: ir.aslanpharma.com/. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/13 ¤U¤È 01:05:54²Ä 5562 ½g¦^À³
|
³o¬O±M·~ªº®t²§¡C FB825 2A ADÁ{§É¡A¦¬¤F66Ó¡]66/99=66%¡^«D¥Ø¼Ð¯f¤H¡C CBP 201 2b AD Á{§É¡A¦¬¤J¬ù1/3§C°ò缐EASI ¦ÓÀø®Ä¬Û¹ï§Cªº¯f¤H¡C Dupilumab ¤T´Á AD¡A¶È¦¬0¡X3.75% ¤T§C¡]§CTRAC¡þ§CIgE/§CEASI¡^¯f¤H¡A¬GÁ׶}«D¤G«¬ª¢¯gMOAªºAD¯f¤H¡C ¦ý¥Lªº§CTRAC²Õ¬ù¦û1/3¡A°t°ªIgE/¤¤EASIªº¥§¡EASIÀø®Ä³Ì¨Î77% vs ¤¤°ªTRAC67%. ³o¬O°µ¤F«Ü¦hÁ{§É©ÒÀò±oªº¸ê®Æ¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/9/13 ¤W¤È 11:56:17²Ä 5561 ½g¦^À³
|
¤W¦¸¦]¦¬®×¿ù»~¡A³y¦¨§ë¸êªÌ·¥¤jªº·l¥¢ ¦Ñ·àÀ³·|°O¨ú±Ð°V¡A¤£·|¦A¥Ç¦P¼Ë¿ù»~¡A³o¤]¬O¸Ó¤½¥q¦b¤@³s¦ê¸Ñª¼¥¢±Ñ«á¡A³Ì«á¤Ï±Ñ¬°³Óªº¾÷·| ¥u¤£¹L²{¦b°µ¦A¦h¨Æ«áÃÒ©ú¬ã¨s¤ÀªR»¡©ú¡A¥«³õÁÙ¬O¤£¤Ó¶R³æ ¥u¯àÀRÆ[¨äÅÜ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/13 ¤W¤È 08:26:56²Ä 5560 ½g¦^À³
|
ÁÙ¬O§Æ±æ¥J²Ó¹LÂo¦¬®×«~½è¡AµM«á¦~©³¦³¥¿¦Vªº2B´Á¤¤¼Æ¾Ú¡A§_«h¥D¤O§ë¸ê¤HµL·P!!!~~~¥[ªo¦Ñ·à |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/13 ¤W¤È 06:56:19²Ä 5559 ½g¦^À³
|
CEO ¶È¤½¶}9¤ë¥÷¤½¥q²³ø¡C(19¤ÀÄÁ) CEO vs §ë¸êªÌªº¤@¹ï¤@现³õ°Ýµª¥¼¤½¶}¡C ¡K¡K¡K¡K¡K9¤ë12¤é¡AH.C. Wainwright¥þ²y§ë¸êªÌ24©¡¦~«×¤j·| |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/12 ¤U¤È 08:42:16²Ä 5558 ½g¦^À³
|
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) rose 13.3% to $0.8850 in pre-market trading. ASLAN Pharmaceuticals, last week, presented new data on Eblasakimab in multiple posters at European Academy of Dermatology and Venereology Congress. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)¦b盘«e¥æ©ö¤¤¤W涨13.3%¦Ü0.8850¬ü¤¸¡CASLAN¨î药¤½¥q¡A¤W©P¦b欧¬w¥Ö肤¯f学©M©Ê¯f学¤j会¤W¥H¦h张®ü报®i¥Ü¤FEblasakimabªº·s数Õu¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/9/12 ¤W¤È 08:53:58²Ä 5557 ½g¦^À³
|
¬ü°ê¥Í§Þ¤½¥q Arena Pharmaceuticals(ÁÙ¨S®³¨ìÃÄÃÒ) (110.12.14¤½§i³Q½÷·ç¨ÖÁÊ¡B111.03.30¤T´Á¸Ñª¼¦¨¥\) ªÑ¥»¡G67,000,000ªÑ ¼ìºÅ©Êµ²¸zª¢¬O¤@ºØ¼vÅT¬ü°ê300¸U¤HªººC©Êª¢Äp©Ê¸z¯f ³Ì°ª¾P°âÃB¥i¹F 25»õ¬ü¤¸ Etrasimod ¥¿³B©ó«á´Áªº¬ã¨s¶¥¬q¡AªvÀø®ÄªG±N¤ñ Bristol Myers Squibb(BMY-US) (¦Ê®É¬ü¬I¶QÄ_)ÃļtºX¤Uªº Zeposia §ó¦³®Ä ½÷·ç¦P·N¥H 67»õ¬ü¤¸¦¬ÁÊ¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬° 100 ¬ü¤¸ ¬ü°ê¥Í§Þ¤½¥qTurning Point Therapeutics, Inc. (ÁÙ¨S®³¨ìÃÄÃÒ) (111.06.04¤½§i³Q¥²ªv§´¬I¶QÄ_¨ÖÁÊ¡B³Q¨Ö·í¤U¬°¤G´ÁÁ{§É¸ÕÅ礤) ªÑ¥»¡G53,947,368ªÑ ªÍÀù¬°¥þ²y²Ä¤G¤jÀù¯g¡A2022¦~¦ô¥þ²y±wªÌ¦ô¬°250¸U¤H¡C ³Ì°ª¾P°âÃB¥i¹F 10»õ¬ü¤¸ ¸ÓÃÄ¥¿³B©ó2bÁ{§Éªº¬ã¨s¶¥¬q¡ATurning Point¤â¤¤´¤¦³¥i¯à¤ñÄvª§¹ï¤â½÷·ç¡]Pfizer¡^©Mù¤ó¡]Roche¡^§ó¨ãÀu¶Õªº«D¤p²ÓMªÍÀù (NSCLC)ªvÀøÃĪ«¡C ¬I¶QÄ_¦P·N¥H41»õ¬ü¤¸¦¬ÁÊ¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬° 76 ¬ü¤¸ ·s¥[©Y¥Í§Þ¤½¥q ASLAN Pharmaceuticals(ÁÙ¨S®³¨ìÃÄÃÒ) ªÑ¥»¡G69,663,404ªÑ ²§¦ì©Ê¥Ö½§ª¢¬O¤@ºØ¼vÅT¬ü°ê2,400¸U¤H(¥þ²y¶W¹L2»õ)ªººC©Êª¢¯g ³Ì°ª¾P°âÃB¥i¹F 120»õ¬ü¤¸(§ùÁת¢) 004¥¿³B©ó2bÁ{§Éªº¬ã¨s¶¥¬q¡AªvÀø®ÄªG±N¤ñÁÉ¿ÕµáÃļtºX¤Uªº§ùÁת¢§ó¦³®Ä XXX¦P·N¥H 000»õ¬ü¤¸¦¬ÁÊ¡A´«ºâ¨CªÑ¦¬Áʳø»ù¬°???¬ü¤¸ ------------------------------------------------------------------------------------------------------------------------------------ «ö·Ó¥þ²y¯f±w¤H¼Æ¡B³Ì°ª¾P°âÃB¡BªvÀø®ÄªG³Ì¦nµ¥µ¥±À¦ô ¦¬Áʨȷà±d»ù®æÀ³¸Ó°ª©ó00»õ¬ü¤¸¡C ½Ð¦U¦ì¤j¤j«ü±Ð¡K¡K |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/12 ¤W¤È 07:39:52²Ä 5556 ½g¦^À³
|
journey.ct.events/view/b8b40ba3-fe5a-475b-b2ca-01693eb78ef8 ¥xÆW®É¶¡¤µ¤é±ß¤W22:30 ½u¤Wª½¼½ CEO vs ¨é°Ó¥D«ù¤Hªº现³õ°Ýµª¡C H.C. Wainwright ¥þ²y§ë¸êªÌ24©¡¦~«×¤j·| H.C. Wainwright 24th Annual Global Investment Conference - September 12-14, 2022 ASLAN Pharmaceuticals Live on Monday, 9/12 at 10:30 AM (Eastern Standard Time) Please register to view. First Name Last Name Company Email you@example.com |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2022/9/10 ¤U¤È 02:48:42²Ä 5555 ½g¦^À³
|
ÁÂÁ¡ã¤Ñ©R¤j¤jªº»¡©ú |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/10 ¤W¤È 09:23:03²Ä 5554 ½g¦^À³
|
Dupilumab ¤wÀòAD&EoE ¤G±iBTD¡A预¦ô³Ì°ªÀ禬140»õ¬ü¤¸¡C ASLAN004 ¦P¸ô½uM0A¡A¤£¦P§@¥ÎÂI¡A¦P¥i®É§í¨îIL4/IL13¡A ¦ý¥Ø«emITT¤ÀªR¡A 2b¥Ø¼ÐÀø®Ä EASI 75, 73% vs Dupilumab 51% vs¹ï·Ó²Õ 15% Àø®ÄÀu©ó¤G±iBTDªºdupilumab 40%(73% vs 51%) µ²½¤ª¢°Æ§@¥Î§C¡C ¼ç¦b³Q¨ÖÁÊ»ùÈ 70»õ¬ü¤¸~140»õ¬ü¤¸¡A ´N¬Ý2b ¸Ñª¼¼Æ¾Ú¡C û¡GROGER588910148151 µoªí®É¶¡:2022/9/10 ¤W¤È 08:58:12²Ä 1638 ½g¦^À³ ¤jÃļt¦¬Áʤp¼t3±iBTDªº»ùÈ! §Ú¤åµ§¤£¦n¤]¤£³ßÅw¥´«Ü¦h¦r¡A¦ÛÓ¨à·Q¹³¤ß®®2±iBTD¸Ó¦³ªº»ùÈ? 2022.5.10-Turning Point«Å¥¬repotrectinibÀò±o²Ä3ÓBTD 2022.6.3-BMSªá41»õ¬ü¤¸¦¬ÁÊTurning Point finance.sina.com.cn/jjxw/2022-06-07/doc-imizmscu5610474.shtml ...¦pªG±q·~ÁZ¼h±¤ÀªR¡ATurning PointÂåÀø¨ÌµM¬O¤@®a³B©óÁ«·l¤¤ªºªì³Ð¤½¥q¡A§¹¥þ½æ¤£¤W41»õ¬ü¤¸ªº»ù®æ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/10 ¤W¤È 08:13:52²Ä 5553 ½g¦^À³
|
EADV2022 004ªº¤TÓ1b ADÁ{§É¼Æ¾Úªº³ø§i¡C ½Ð¦U¦ì¤j¤j¸Ô²Ó¾\Ū¡C °ß¬ì¾Ç¼Æ¾Ú¤è¯à¦w¦¼¤§¤ß¡I »ùÈ«D¤Z vs ¤@¤å¤£È aslanpharma.com/news/?cat=publications |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/10 ¤W¤È 08:03:32²Ä 5552 ½g¦^À³
|
¤ÀªR¡G 1b´Á¬ã¨sªºÀø®Ä¤ÀªR±Ä¥Î¤Fקï«áªºªvÀø·N¦V¡]mITT¡^¤H¸s¡A¨ä¤¤¦³9¦W¬ã¨s±wªÌ¦b¤@Ó¦a点±µ¨üªvÀø¡C ªvÀø¡]mITT¡^ªº¤H¸s¡A¨ä¤¤¤@Ó¬ã¨s点ªº9¦W±wªÌ¦b¸Ñª¼«e³Q±qITT¤ÀªR¤¤±Æ°£¡C ³o9¦W±wªÌ³Q±Æ°£¦b¸Ñª¼«eªºITT¤ÀªR¤§¥~¡A¦]¬°³o9¦W±wªÌªº¯e¯f¯SÄp¤£²Å¦X¤¤«×¦Ü««×AD¡C Efficacy analysis in the Phase 1b study used a modified Intent to Treat (mITT) population in which 9 study patients from one site were excluded from the ITT analysis prior to unblinding as the the participants did not have disease characteristics consistent with moderate to severe AD. ¦bASLN ´Á¥Zºô页¤W¡A©ñ¤W欧¬w¥Ö½§¦~·|¤Wªº¤TÓ®ü³ø¡C ¨ä¤¤¤GÓ®ü³ø¥ÎmITT¤ÀªR¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥ß§»¤j¡A ¤µ¤éªº½L«á¡A¥Î45Kªº¤j¶q¡A¤w将ªÑ»ù©Ô¤W0.885¤¸ ¤U¶g¤@¬üªF®É¶¡(9¤ë12¤é10:30)CEOn¦b¨é°Óªº§ë¸ê»¡©ú·|¤W²³ø¡C ¤U¶g¥|R&D¤é¡A(9¤ë15¤é 10:00-13:30) ¤½¥q¹ïªÑ»ù©Ô¤W1¬ü¤¸ªº¥Î¤ß±j¯P¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/9 ¤U¤È 07:00:15²Ä 5551 ½g¦^À³
|
aslanpharma.com/app/uploads/2022/09/EADV-2022-Biomarker-Poster_P0243_upload.pdf Eblasakimab, a Monoclonal Antibody Targeting IL‑13R£\1 Reduces Serum Biomarkers Associated with Atopy and Correlated with Disease Severity in Patients With Moderate‑to‑Severe Atopic Dermatitis ¥Íª««ü¼Ð 0~20¶gÅܤÆÁͶչÏmITT |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/8 ¤U¤È 10:44:48²Ä 5550 ½g¦^À³
|
ÂåÀø«O°·ªO¶ô¦³«Ü¦hȱo¼ÖÆ[ªº¦a¤è¡A¦]¬°¤T¦ì¤ÀªR®vèè¹ïCymaBay Treeutics(cBay-Research Report)¡BAslan PharmPharmticals(ASC.N¡G¦æ±¡)©MASC.N(AX.N¡G¦æ±¡)«ù¼ÖÆ[ºA«×.ASLN-¬ã¨s³ø§i)©MPraxis Precision Medicines(PRAX-¬ã¨s³ø§i)«ù¬Ýº¦±¡ºü¡C ¦b¤µ¤Ñµo§Gªº¤@¥÷³ø§i¤¤¡AH.C.Wainwrightªº³¯¼Ý«¥Ó¤F¹ïªü´µÄõ»sÃĪº¶R¤Jµû¯Å¡A¥Ø¼Ð»ù¬°$7.00¡C¸Ó¤½¥qªÑ»ù¤W¶g¤T¦¬©ó0.76¬ü¤¸¡A±µªñ0.36¬ü¤¸ªº52©P§CÂI¡C Aslan Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.00. ªü´µÄõ»sÃĪº¤ÀªR®v¦@ÃѬO¾A«×¶R¤J¡A¥Ø¼Ð»ù¦@ÃѬ°7.00¬ü¤¸¡C |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2022/9/8 ¤U¤È 08:54:03²Ä 5549 ½g¦^À³
|
ÁÂÁÂ🙏¤Ñ©R¤j¤jªº¦^ÂÐ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/8 ¤U¤È 08:21:05²Ä 5548 ½g¦^À³
|
¥ß§»¤j¡A ªÑ»ù¬O¤jªÑªFªº¨Æ¡A´N¹³¥_·¥¬P ¤jªÑªF¼W资30»õ¡A¨CªÑ10¶ô«e¡A¥B¤@¤j¬q®É¶¡¡C µM«áº¦¨ì200¤¸¡A¤pªÑªF¤~»¡¥¦n¸¤F¡I ¦Ñ¶§¤j¡A10¤¸¥s¤j®a¦sªÑ¡A187¤¸«Å§iÅ@¬Pµ²§ô¡I |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2022/9/8 ¤U¤È 08:04:35²Ä 5547 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¤j¡F³o¦¸ªº¼Æ¾Ú¬°¤°»ò¨S¦³®ø°£¤W¦¸¤U¶^📉ªººÃ¼{¡H |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/9/7 ¤U¤È 07:48:03²Ä 5546 ½g¦^À³
|
·Pı³ø§iÁÙÆZ¥¿±ªº §Æ±æªÑ»ù¦¤é¤W1¬ü¤¸ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/7 ¤U¤È 07:21:22²Ä 5545 ½g¦^À³
|
¦b®ü³ø3¡]®ü报编号0343¡^¤¤, 结ªG: ª½±µ¥H mITT¤H¸s ¤ÀªR (¥¼¨ÌITT¤ÀªR), ¥Nªí2b Á{§É ¿z¿ï«DAD±wªÌ·|«ÜÄYÂÔ,¥¼¨ÓÁ{§Éµ²ªG·|¨ÌmITTÀø®Ä¬°°ò¦¦Óµo®i. ¤£¨ÌITT¤ÀªR --------------------- ®ü报3¡]®ü报编号0343¡^ ¦b¤@项随Éó¡B双ª¼¡B¦w¼¢剂对·Óªº1´Á¬ã¨s¤¤¡A®J³Õ©Ô¦è单§Ü§ïµ½¤F¤¤««×¯S应©Ê¥Öª¢¦¨¦~±wªÌªº¦hÏú¯e¯f«ü标 讨论 ®ü报¤¶绍¤F随Éó¡B¦w¼¢剂对·Ó¡B双ª¼ªº1´ÁPoC试验对¤¤««×¦¨¤H¯S应©Ê¥Öª¢±wªÌªºAD临§É¯g状评¦ô结ªG¡A¦}üL调¤F¨Ï¥Î¥ì¥¬©Ô¦è单§Üªv疗¦Z¯e¯f«ü标ªº§ïµ½¡C疗®Ä评¦ô¥]¬A湿¯l±积©M严«µ{«×«ü数¡]EASI¡^¡B¬ã¨sªÌ¥þ²y评¦ô¡]IGA¡^©MÊ^ªí±积¡]BSA¡^评¤Àªº变¤Æ¡CmITT¤H¸s¤¤ªº±wªÌ±µ¨ü200²@§J¡]N=4¡^¡B400²@§J¡]N=6¡^¡B600²@§J¡]N=16¡^©Î¦w¼¢剂¡]N=13¡^ªº¨Ì¥¬©Ô¦è单§Ü¡C 结ªG ¦bmITT¤H¸s¤¤¡AÉO¦w¼¢剂¬Û¤ñ¡AEASI评¤À¦b¦´Á´N¥X现¤F©ú显ªº§ïµ½¡A¦}¦b¾ã个试验过µ{¤¤¤£断发®i¡A400²@§J©M600²@§Jªº剂¶q组产¥Íªº¤Ï应¤ñ200²@§Jªº剂¶q组¤j¡C¦b²Ä8©P¡A600²@§J组ÉO¦w¼¢剂¬Û¤ñ¡AEASI评¤À从°ò线变¤Æªº¥§¡¦Ê¤À¤ñ¦³©ú显§ïµ½¡]65% vs 27%¡AP=0.014¡^¡A¥ì¥¬©Ô¦è单§Ü600²@§J剂¶q组¦³69%ªº±wªÌ达¨ìEASI-75¡A¦Ó¦w¼¢剂¦³15%¡]P=0.005¡^¡CEblasakimabªº@¨ü©Ê¨}¦n¡A¦b²Ä8©P¡A600mg组ªºIGAÉO¦w¼¢剂¬Û¤ñ¤]¦³©ú显ªº§ïµ½¡]44% vs 15%¡^ |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/7 ¤U¤È 07:10:52²Ä 5544 ½g¦^À³
|
ªü´µÄõ»sÃĤ½¥qº®uÂåÀø©x¨È¾ú§J´µ¡P¦Ò¬ì¤Òµû½×説¡A·s¤½§Gªº¥Íª«¼Ð»xª«¼Æ¾Ú¬°§Ú̦b²Ä¤@¶¥¬q¸ÕÅ礤Æ[¹î¨ìªºÁ{þHÀø®Ä´£¨Ñ¤F±j¦³¤Oªº«ÈÆ[°ò¦¡CEblasakimab¨Ã¤ä«ù¨ä¬°AD±wªÌ´£¨Ñ©úÅã®t²§¤ÆªvÀø¿ï¾Üªº¼ç¤O¡C¦b¬°´Á8©Pªº¬ã¨s´Á¶¡¡A§ÚÌÆ[¹î¨ìæ±Äo©MºÎ¯v¯Ê¥¢ªºÅãµÛ§ïµ½¡A³oªí©ú©µªøªvÀøªº®ÄªG¥i¯à§ó¤j¡A§ÚÌ¥¿¦b¶i¦æªº2b¶¥¬q¬ã¨s¤¤¹ï¦¹¶i¦æ¤F½Õ¬d¡CÁ`Åé¦Ó¨¥¡AEADV´£¥æªº¼Æ¾Úµ¹¤F§ÚÌÄ~Äò½Õ¬dªº¥¨¤j«H¤ß©ö¤R©Ô³Í³æ§Ü¦bAD©M¥¼¨Óªº¨ä¥L¾AÀ³¯g¤¤ªº§@¥Î¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/7 ¤U¤È 07:00:45²Ä 5543 ½g¦^À³
|
ªü´µÄõ»sÃĤ½¥q«Å§G¦b¦ÌÄõÁ|¦æªº2022¦~¼Ú¬w¥Ö½§¯f©M©Ê¯f¾Ç¾Ç·|(EADV)¦~·|¤W®i¥Ü·sªºeblasakimab¼Æ¾Ú¡C9¤ë7¤é¦Ü10¤é±Nµo§G¤T±i®ü³ø¡C®ü³ø¥]¬A¥H«e¥¼µoªíªºÃö©ó¥Íª«¼Ð°Oª«©M¥Í¬¡½è¶q´ú¶qªº¼Æ¾Ú¡A¥H¤Î¥ý«e³ø¹DªºeblasakimabªvÀø¤¤««×¯SÀ³©Ê¥Öª¢(AD)ªº²Ä¤@¶¥¬q¦h¦¸»¼¼W¾¯¶q¬ã¨sªºÁ{þH¼Æ¾Úªº·sªºÃB¥~¤ÀªR¡C³o¨Ç¼Æ¾Ú¦b8©Pªº¬ã¨s´Á¶¡Æ[¹î¨ìæ±Äo©MºÎ¯v¤£¨¬ªºÅãµÛ§ïµ½¡A³oªí©ú©µªøªvÀøªº®ÄªG¥i¯à§ó¤j¡AAslan¥¿¦b¶i¦æ2b¶¥¬q¬ã¨s¡CEblasakimab¬O¤@ºØ°w¹ïIL-13Ralpha1ªº³æ§Ü¡A¥¦¥i¥H°§C¤¤¨ì««×¯SÀ³©Ê¥Öª¢±wªÌªº¦å²M¥Íª«¼Ð»xª«¡A³o¨Ç¥Íª«¼Ð»xª«»P¯SÀ³©Ê©M¯e¯fÄY«µ{«×¬ÛÃö¡CEblasakimabªvÀø°§C¤F´`Àô¤¤ªºTARC/CCL17¡BIgE©MLDH¤ô¥¡A³o»PADªº¯e¯fÄY«µ{«×¦³Ãö¡C¦b¤@¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº1´Á¬ã¨s¤¤¡AEblasakimab§ïµ½¤F¤¤««×¯SÀ³©Ê¥Öª¢¦¨¤H±wªÌªºæ±Äo©MºÎ¯v¯Ê¥¢¡C¦b²Ä8©P¡A600 mg¾¯¶q²Õªº±wªÌ³ÌÄY«ªºæ±Äo¯gª¬§ïµ½¤F48%¡A¦Ó¦w¼¢¾¯²Õªº§ïµ½´T«×¬°13%¡C¦bªA¥Î600²@§Jeblasakimabªº±wªÌ¤¤¡A56%ªº±wªÌªí²{¥X¦Ü¤Ö¨âÂI¥§¡ºÎ¯v·l¥¢ªº§ïµ½¡A³o¦bÁ{þH¤W¬OºÎ¯v³à¥¢ªºÅãµÛ§ïµ½¡A¦Ó¦w¼¢¾¯²Õªº³o¤@¤ñ¨Ò¬°15%¡C¦b¤@¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº1´Á¬ã¨s¤¤¡AEblasakimab§ïµ½¤F¤¤««×¯SÀ³©Ê¥Öª¢¦¨¤H±wªÌªº¦hºØ¯e¯f«ü¼Ð¡C³o±i®ü³ø±j½Õ¤F¨Ï¥ÎeblasakimabªvÀø«á¯e¯f±¹¬Iªº§ïµ½¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/7 ¤U¤È 06:10:39²Ä 5542 ½g¦^À³
|
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress finance.yahoo.com/news/aslan-pharmaceuticals-presents-data-eblasakimab-100000503.html Wed, September 7, 2022 at 6:00 PM In this article: ASLAN¨î药¤½¥q¦b²Ä31届欧¬w¥Ö肤¯f学©M©Ê¯f学学会¡]EADV¡^¦~会¤Wªº¦h张®ü报¤¤®i¥Ü¤FEblasakimabªº·s数Õu 2022¦~9¤ë7¤é¡A¬P´Á¤T¡A¤U¤È6:00 ¦b这½g¤å³¹¤¤¡C ¦bEADV¤j会¤Wº¦¸¤½¥¬ªº数Õu显¥Ü¡A¨Ì¥¬©Ô¦è单§Ü¥i§í¨î¯S应©Ê¥Öª¢ªº¤U´åª¢¯g¥Íª«标§Óª«¡A¦b³Ì¦Z¤@¦¸¥Î药¦Z«ù续4-6©P ºÎ¯v质¶q«ü标¦³©ú显§ïµ½¡A¨Ï¥Î¥ì¥¬©Ô¦è单§Ü¦Z报§iºÎ¯v»Ù碍ªº±wªÌú£¤Ö ®J³Õ©Ô¦è单§Ü显µÛ°§C¤FP-NRS¡]æ±Ö}¡^评¤À¡A¦}¥B¦b©Ò¦³剂¶q组ªº8©P疗µ{¤¤«ù续§ïµ½¡C ¥[¦{门¬¥©¬§J©M·s¥[©Y¡A2022¦~9¤ë7¤é¡]GLOBE NEWSWIRE¡^ -- ASLAN Pharmaceuticals¡]纳´µ达§J¡GASLN¡^¬O¤@®a处¤_临§É阶¬q¡B专ª`¤_§K¬Ì学ªº¥Íª«¨î药¤½¥q¡A¥¿¦b开发§ï变±wªÌ¥Í¬¡ªº创·s疗ªk¡A¤µ¤Ñ«Å¥¬¦b·N¤j§Q¦Ì兰举¦æªº2022¦~欧¬w¥Ö肤¯f©M©Ê¯f学会¡]EADV¡^¦~会¤W¤½¥¬¤F·sªº¥ì¥¬©Ô¦è单§Ü数Õu¡C¦b2022¦~9¤ë7¤é¦Ü10¤éªº¾ã个¤j会´Á间¡A将¦³¤T张®ü报¥H电¤l®ü报ªº§Î¦¡®i¥Ü¡C 这¨Ç®ü报¥]¬A¥H«e¥¼发ªíªº¥Íª«标§Óª«©M¥Í¬¡质¶q测¶q数Õu¡A¥H¤Î对¥H«e报¹Dªº¥ì¥¬©Ô¦è单§Üªv疗¤¤«×¦Ü««×¯S应©Ê¥Öª¢¡]AD¡^ªº¦h级剂¶q1´Á¬ã¨s¤¤ªº临§É数Õu进¦æªº·sªº补¥R¤ÀªR¡C ASLAN¨î药¤½¥qº®u医疗©xAlex Kaoukhov评论说¡G·s´£¥Xªº¥Íª«标§Óª«数Õu为§Ú们¦beblasakimabªº1´Á试验¤¤观¹î¨ìªº临§É疗®Ä´£¨Ñ¤F¦³¤Oªº«È观¨ÌÕu¡A¦}¤ä«ù¨ä为AD±wªÌ´£¨Ñ©ú显®tÉݤƪv疗选择ªºýͤO¡C§Ú们¦b8©Pªº¬ã¨s´Á内观¹î¨ìæ±Ö}©MºÎ¯v¤£¨¬ªº©ú显§ïµ½¡A这ªí©ú随þÓªv疗时间ªº©µ长¦³¥i¯à产¥Í§ó¤jªº®ÄªG¡A§Ú们¥¿¦b进¦æªº2b´Á¬ã¨s¤¤对¦¹进¦æ¬ã¨s¡C总ªº来说¡A¦bEADV¤W®i¥Üªº数Õu给¤F§Ú们Ìå¤jªº«H¤ß¡A¦b¥¼来继续¬ã¨seblaskaimab¦bAD©M¨ä¥LÓì应¯g¤¤ªº§@¥Î¡C 2022¦~EADV电¤l®ü报详±¡ ®ü报1(®ü报#0243) Eblasakimab¬O¤@Ïú¹v¦VIL-13R£\1ªº单§J¶©§ÜÊ^¡A¥iú£¤Ö¤¤«×¦Ü««×¯S应©Ê¥Öª¢±wªÌªº¦å²M¥Íª«标§Óª«¡A这¨Ç标§Óª«ÉO¯S应©Ê¦³关¡A¦}ÉO¯e¯f严«µ{«×¬Û关¡C 讨论 AD¬O¤@Ïú¥H2«¬ª¢¯g¯S©º为¥Dªº¥Ö肤¯f¡C³q过2«¬¨üÊ^ªº«H号传导诱导¦hÏú标记¤À¤lªºªí达¡AÉO¯e¯fªº严«µ{«×¬Û关¡C标§Ó¤À¤l¦p¯Ý¸¢¿E¬¡调节细M¦]¤l¡]TARC/CCL17¡^¡B§K¬Ì²y³J¥ÕE¡]IgE¡^©M¨Å»Ä脱氢酶¡]LDH¡^¦b严«¯e¯f±wªÌ¤¤¤É°ª¡C®ü报显¥Ü¤F¥ì¥¬©Ô¦è单§Ü¦b¤¤«×¦Ü««×¯S应©Ê¥Öª¢¦¨¤H±wªÌ¤¤ªº·§©À验证¡]PoC¡^试验ªº±wªÌý©¥»结ªG¡C对ý©¥»进¦æ¤F¦å²MTARC¡BIgEªº§K¬Ì测©w¡A¦}对LDH进¦æ¤F检测¡C 结ªG Eblasakimabªv疗ú£¤Ö¤FTARC/CCL17¡BIgE©MLDHªº´`环¤ô¥¡Aªí©úEblasakimab针对IL-13R£\1ªº独¯S§@¥ÎÉó¨î©Mªý断IL-4©MIL-13³q过2«¬¨üÊ^ªº«H号传导ÉOAD1¤¤ÉO¯e¯f严«µ{«×¬Û关ªº¥Íª«标§Óª«¤À¤lªºªí达ú£¤Ö¦³关¡C¦¦bTARC/CCL17¡]²Ä4¤Ñ¡^¡BIgE¡]²Ä15¤Ñ¡^©MLDH¡]²Ä15¤Ñ¡^ªº²Ä¤@¦¸°ò线¦Z评¦ô¤¤´N观¹î¨ì¤F从°ò线开©lªºú£¤Ö¡A600²@§JÉO¦w¼¢剂¤§间ªºTARC/CCL17¦b²Ä8©P¨³³t开©l¦}¦³©ú显®tÉÝ¡]¥§¡È为-62.23 vs -17.83¡AP<0.001¡^¡C¦b³Ì¦Z¤@¦¸¥Î药¦Zªº¥|¦Ü¤»©P内¡A¦å²M¥Íª«标§Óª«¦b¥ì¥¬©Ô¦è单§Ü组¤¤´¶¹M«O«ù§í¨î¡C ¾ã个8©Pªºªv疗过µ{¤¤«ù续§ïµ½¡C¦b²Ä8©P¡A600²@§J剂¶q组ªº±wªÌ¦b³Ì严«ªºæ±Ö}¤è±¦³48%ªº§ïµ½¡A¦Ó¦w¼¢剂组¥u¦³13%ªº§ïµ½ 报2¡]®ü报编号0342¡^ ¦b¤@项随Éó¡B双ª¼¡B¦w¼¢剂对·Óªº1´Á¬ã¨s¤¤¡AEblasakimab§ïµ½¤F¤¤««×¯S应©Ê¥Öª¢¦¨¦~±wªÌªºæ±Ö}©M¥¢¯v状úG 讨论 ºC©Êæ±Ö}¬OADªº¤@个标§Ó¡A80%¥H¤Wªº±wªÌ³£会¥X现这Ïú±¡úG2¡Cæ±Ö}¬O±wªÌ报§iªº³ÌÁc«ªº¯g状¡AÉOºÎ¯v»Ù碍±K¤Á¬Û关¡F¦b´¶³q¤H¸s¤¤¡A¦h达48%ªº¦¨¦~¤H¦³ºÎ¯v»Ù碍¡A¦ý¦b±w¦³ADªº¦¨¦~¤H¤¤¡A这¤@数¦r°ª达90%3¡C®ü报¤¶绍¤F¤¤««×¯S应©Ê¥Öª¢¦¨¤H±wªÌ¥ì¥¬©Ô¦è单§ÜPoC试验ªº±wªÌ报§i结ªG¡A¥]¬Aæ±Ö}¯g数¦r评¤Àªí¡]P-NRS¡^©M±wªÌ导¦Vªº湿¯l测¶q¡]POEM¡^ªº¤ÀªR¡A¨ä¤¤¥]¬A单¤@ªººÎ¯v损¥¢¦¨¤À¡C 结ªG ¦bקï¦Zªºªv疗·N¦V¡]mITT¡^¤H¸s¤¤¡AEblasakimab显µÛ°§C¤F©Ò¦³剂¶q组ªºP-NRS评¤À¡A¦}¥B¦b¾ã个8©Pªºªv疗过µ{¤¤«ù续§ïµ½¡C¦b²Ä8©P¡A600²@§J剂¶q组ªº±wªÌ¦b³Ì严«ªºæ±Ö}¤è±¦³48%ªº§ïµ½¡A¦Ó¦w¼¢剂组¥u¦³13%ªº§ïµ½¡]P=0.05¡^¡C¦b600mg eblasakimab组¤¤¡A56%ªº±wªÌ¦bºÎ¯v损¥¢¤è±ªí现¥X¦Ü¤Ö两点ªº¥§¡§ïµ½¡A这¬OºÎ¯v损¥¢¤è±ªº临§É显µÛ§ïµ½¡A¦Ó¦w¼¢剂组则为15%¡C ®ü报3¡]®ü报编号0343¡^ ¦b¤@项随Éó¡B双ª¼¡B¦w¼¢剂对·Óªº1´Á¬ã¨s¤¤¡A®J³Õ©Ô¦è单§Ü§ïµ½¤F¤¤««×¯S应©Ê¥Öª¢¦¨¦~±wªÌªº¦hÏú¯e¯f«ü标 讨论 ®ü报¤¶绍¤F随Éó¡B¦w¼¢剂对·Ó¡B双ª¼ªº1´ÁPoC试验对¤¤««×¦¨¤H¯S应©Ê¥Öª¢±wªÌªºAD临§É¯g状评¦ô结ªG¡A¦}üL调¤F¨Ï¥Î¥ì¥¬©Ô¦è单§Üªv疗¦Z¯e¯f«ü标ªº§ïµ½¡C疗®Ä评¦ô¥]¬A湿¯l±积©M严«µ{«×«ü数¡]EASI¡^¡B¬ã¨sªÌ¥þ²y评¦ô¡]IGA¡^©MÊ^ªí±积¡]BSA¡^评¤Àªº变¤Æ¡CmITT¤H¸s¤¤ªº±wªÌ±µ¨ü200²@§J¡]N=4¡^¡B400²@§J¡]N=6¡^¡B600²@§J¡]N=16¡^©Î¦w¼¢剂¡]N=13¡^ªº¨Ì¥¬©Ô¦è单§Ü¡C 结ªG ¦bmITT¤H¸s¤¤¡AÉO¦w¼¢剂¬Û¤ñ¡AEASI评¤À¦b¦´Á´N¥X现¤F©ú显ªº§ïµ½¡A¦}¦b¾ã个试验过µ{¤¤¤£断发®i¡A400²@§J©M600²@§Jªº剂¶q组产¥Íªº¤Ï应¤ñ200²@§Jªº剂¶q组¤j¡C¦b²Ä8©P¡A600²@§J组ÉO¦w¼¢剂¬Û¤ñ¡AEASI评¤À从°ò线变¤Æªº¥§¡¦Ê¤À¤ñ¦³©ú显§ïµ½¡]65% vs 27%¡AP=0.014¡^¡A¥ì¥¬©Ô¦è单§Ü600²@§J剂¶q组¦³69%ªº±wªÌ达¨ìEASI-75¡A¦Ó¦w¼¢剂¦³15%¡]P=0.005¡^¡CEblasakimabªº@¨ü©Ê¨}¦n¡A¦b²Ä8©P¡A600mg组ªºIGAÉO¦w¼¢剂¬Û¤ñ¤]¦³©ú显ªº§ïµ½¡]44% vs 15%¡^¡C ¦b会议¤W®i¥Üªº®ü报¥i¦b¦¹¬d阅¡C ASLAN PHARMACEUTICALS LIMITED Data presented at EADV for the first time show eblasakimab suppresses downstream inflammatory biomarkers of atopic dermatitis, continuing 4-6 weeks after the last dose Notable improvements in quality-of-sleep measures, with fewer patients reporting sleep disturbance on eblasakimab Eblasakimab significantly reduced P-NRS (itch) scores and improvements continued throughout 8-week course of treatment across all dose cohorts MENLO PARK, Calif. and SINGAPORE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of new eblasakimab data at the 2022 European Academy of Dermatology and Venereology (EADV) annual congress in Milan, Italy. Three posters are being presented as e-posters throughout the duration of the congress from September 7 to 10, 2022. The posters include previously unpublished data on biomarkers and quality-of-life measures, and new, additional analyses of clinical data from the previously reported Phase 1 multiple-ascending dose study of eblasakimab in moderate-to-severe atopic dermatitis (AD). Alex Kaoukhov, Chief Medical Officer, ASLAN Pharmaceuticals, commented, ¡§The newly presented biomarker data provide a robust, objective basis for the clinical efficacy we observed in the Phase 1 trial of eblasakimab and support its potential to offer a clearly differentiated treatment option for AD patients. We observed significant improvements in itch and sleep loss within the 8-week study period, suggesting the potential for a greater magnitude of effect with prolonged treatment and we are investigating this in the ongoing phase 2b study. Collectively, the data being presented at EADV gives us great confidence to continue investigating eblaskaimab¡¦s role in AD and other indications in the future.¡¨ 2022 EADV e-poster details Poster 1 (Poster #0243) Eblasakimab, a monoclonal antibody targeting IL-13R£\1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis Discussion AD is a skin disease with a predominant Type-2-inflammatory signature. Signaling through the Type 2 receptor induces expression of a multitude of marker molecules, correlating with disease severity. Marker molecules such as thymus activation regulated cytokine (TARC/CCL17), immunoglobulin E (IgE), and lactate dehydrogenase (LDH) are elevated in patients with severe disease. The poster shows results of patient samples from the proof-of-concept (PoC) trial of eblasakimab in adults with moderate-to-severe atopic dermatitis. Samples were immunoassayed for serum TARC, IgE and tested for LDH. Results Eblasakimab treatment reduced circulating levels of TARC/CCL17, IgE, and LDH, suggesting eblasakimab¡¦s unique mechanism of action targeting IL-13R£\1 and blocking the signaling of IL-4 and IL-13 through the Type 2 receptor is associated with reduced expression of the biomarker molecules associated with disease severity in AD1. Reductions from baseline were observed as early as the first post-baseline assessment for TARC/CCL17 (day 4), IgE (day 15) and LDH (day 15), with a rapid onset and significant difference at week 8 between 600 mg vs placebo for TARC/CCL17 (mean values of ‑62.23 vs ‑17.83, P<0.001). Serum biomarkers generally remained suppressed in the eblasakimab groups for four to six weeks following the last dose. Poster 2 (Poster #0342) Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study Discussion Chronic itch is a hallmark of AD and occurs in over 80% of patients with the disease2. Itch is the most burdensome symptom reported by patients and is strongly linked to sleep disturbances; in the general population, up to 48% of adults experience sleep disturbances, but in adults with AD this figure is up to 90%3. The poster presents patient reported outcomes from the PoC trial of eblasakimab in adults with moderate-to-severe atopic dermatitis and includes analyses of pruritus numeric rating scale (P-NRS) and Patient Oriented Eczema Measure (POEM) with a single sleep loss component. Results Eblasakimab significantly reduced P-NRS scores across all dose cohorts in the modified Intent to Treat (mITT) population and improvements continued throughout the 8-week course of treatment. At week 8, patients in the 600mg dose group showed a 48% improvement in worst itch, versus a 13% improvement in the placebo group (P=0.05). 56% of patients in the 600mg eblasakimab group demonstrated at least a two point mean improvement in sleep loss, a clinically significant improvement in sleep loss, versus 15% in the placebo group. Poster 3 (Poster #0343) Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study Discussion The poster presents results on assessments of clinical signs of AD from the randomized, placebo controlled, double-blinded Phase 1 PoC trial of eblasakimab in adults with moderate-to-severe AD and highlights improvements in disease measures after treatment with eblasakimab. Efficacy assessments include changes in eczema area and severity index (EASI), Investigators Global Assessment (IGA) and Body Surface Area (BSA) score. Patients in the mITT population received eblasakimab at 200 mg (N=4), 400 mg (N=6), 600 mg (N=16) or placebo (N=13). Results In the mITT population, significant improvements in EASI score were seen early and progressed throughout the trial compared with placebo, with the 400mg and 600mg dose cohorts producing a greater response than the 200mg dose. At week 8, significant improvements were noted in the mean percentage change from baseline in EASI score in the 600mg group versus placebo (65% vs 27%, P=0.014), and 69% of patients achieved EASI-75 in the eblasakimab 600mg dose group versus 15% on placebo (P=0.005). Eblasakimab was well tolerated with notable improvements also seen in IGA versus placebo (44% vs 15%) in the 600mg group at week 8. The posters presented at the conference are available to access here. |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/7 ¤W¤È 11:36:26²Ä 5541 ½g¦^À³
|
§Y¨Ï50¬ü¤¸¡A ¤@¯ë¤HY¦³20000ªÑ¡A ¦©±¼¦¨¥»¡A®Ä¯q¤]¨¬Åý¤H±ÅS·L¯º¤F¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/7 ¤W¤È 09:49:57²Ä 5540 ½g¦^À³
|
ASLAN004 ³Ì®tªºÀø®Ä预测´N¦Pµ¥Dupilumab 须»ù®æ¥´8§é¡A§C²´·úµ²½¤ª¢©MDupilumab¥¤À¥«³õ¡C ¦b¨ä¥é¥ÍÃÄ¥¼¶i¥«³õ«e(约2036¦~©³)¡A¥¤À¤@½u¥«Ô·¡C ¥«³õ³Ì°ª销°â140/2¡Ñ§é»ù»ùȧé´î70%=约50»õ¬ü¤¸¡C ¥H¤W¬OÓ¤H³Ì®tªº预¦ôÈ¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/7 ¤W¤È 08:54:43²Ä 5539 ½g¦^À³
|
¨S¿ù¡A¦bªÑ¥«¤@©wn¦³¹Ú·Q¡A ¦Ó¥B¤ÀªR«á¥i¦æ¡A´Nn°í«ù¹Ú·Q¡I Eylea ¡B¥_·¥¬P³£¬O«Ü¨å«¬¦¨¥\ªº¨Ò¤l¡A §ë¸ê¤@©w¦³·ÀI¡B¤]¤£·|¤@¦|·¶¶¡A ¹J¨ì·®ö¡A´N·Q¹³¤@¤U150Áâ/ªÑ¼µ¹L¥h¡I n¦³«H©À¡A°£¤F±M·~ª¾ÃÑ¡A¥«³õ°T®§¡AÅý¦Û¤v¤ß¦³©w¨£¥~¡A¨ä¥L§ë¸êªÌªº¦hªÅ¬Ýªk¥i¥H°Ñ¦Ò¡A ¦ý¤£¬O¥Dn¡AY¨Ì¾Ú§O¤Hªº¦hªÅ·Qªk¡A±N¶i°h¥¢¾Ú¡AÓ¤H¤£»{¬°·|ÁȪº¤F¤°»ò¤j¿ú¡I ÁȤ£ÁÈ¿ú¡A´N¦b¦Û¤vªº¤ß©w»P¤£©w¡I ¦@«j¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/6 ¤U¤È 07:53:23²Ä 5538 ½g¦^À³
|
¤jÁx°µ¹Ú·Q :Lucentis ---ªvÀø¶À´³³¡¯fÅÜ,°w¾¯,2006¦~¤W¥«,2012¦~,¦~¾P24»õ¬ü¤¸. Eylea---ªvÀø¶À´³³¡¯fÅÜ,°w¾¯,2011/11¤W¥« 2¡BRegeneron¦´Áµo®i«Ü¤£¶¶§Q¡A ¶}µoªº²Ä¤@ÁûÃÄ¡A°µ¨ìÁ{§É¤T´Á¥¢±Ñ¤F¡A Ä~Äò¬ãµo²Ä¤GÁûÃÄ¡A°µ¨ì¤T´Á¤S¥¢±Ñ¤F¡A «á¨Ó²Ä¤TÁûÃÄÂê©wµo®iªºÃĪ«ªöµø©ú¡]Eylea¡^¡A ¸g¹L8¦~¬ãµo²×©ó¦¨¥\¡A¨ú±o2011¦~11¤ëFDA»{ÃҨäW¥«¾P¡C 3¡B²Ä¤TÁûÃĤ~¦¨¥\¡A ÅýRegeneron´X¥Gªá¤F§Ö20¦~ªº®É¶¡¡A ¤~¦b2009¦~©³®iÅSÀY¨¤¡A ªÑ»ù¤]±q18¬ü¤¸¥ª¥k¡A ¤Wº¦¦Ü2015¦~ªñ600¬ü¤¸(¥«È600»õ¬ü¤¸)¡Adupilumab 2014/10 ÀòBTD,¨Ã¶i¤J¤T´Á. º¦´T¶W¹L30¿¡I |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/9/6 ¤U¤È 07:36:43²Ä 5537 ½g¦^À³
|
¤H¬On¦³¹Ú·Q ¦ýÀH®É¶¡±À²¾ ¹Ú·Q·|³vº¥¦a²H¤Æ ¸g¹L³o´X¦~¿i½m ¾Ç²ßºCºC©ñ¤U ¦¹¬Û«D¬Û¦¹ªÅ«DªÅ ÀR«Ýµ²ªG ·PÁ¦U¦ì·à¤Í §ó·PÁ¤ѩR¤jªº¥I¥X ³oùرÁÙ¦³¤@¦ì©ú¤Ñ¹L«á¤j¤j §A¹ï»ù¦ì¤ÀªR¶W¯Å¯«·Ç §Æ±æ§A¯àºÉÄÀ«e¶û¡A«·sÂk¶¤ ¤£§[¬°¤j®a´£¨Ñ¨ô¨£ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/6 ¤U¤È 07:33:26²Ä 5536 ½g¦^À³
|
Webcasts & Presentations 1.Webcasts ASLAN Hybrid R&D Day Sep 15, 2022 at 10:00 AM ET Webcast link Add to Outlook Add to Google Calendar 2.H.C. Wainwright Global Investment Conference Sep 12, 2022 - Sep 14, 2022 Webcast link Live on Monday, 9/12 at 10:30 AM (Eastern Standard Time) ir.aslanpharma.com/webcasts-presentations |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/9/6 ¤W¤È 08:32:33²Ä 5535 ½g¦^À³
|
¦~©³«e¥ý¤½¥¬Ó¥¿¦V´Á¤¤¼Æ¾Ú¡AÅý¤j®a®¶¾Ä¤@¤U§a! |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/5 ¤U¤È 08:42:35²Ä 5534 ½g¦^À³
|
150~210¬ü¤¸/ªÑ¡A³o¤Ñ¨ì¨Ó¡A¤j®a¤@°_§â°s°ªºq¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/5 ¤U¤È 12:01:36²Ä 5533 ½g¦^À³
|
¤HÃþ¦]¹Ú·Q¦Ó°¶¤j!!!!! ASLN 2b ©ú¦~4¤ë¸Ñª¼ Y¦pÀø®Ä¹w´Á EASI 75=ASLAN004 73% VS ¹ï·Ó²Õ15%----(Dupilumab ¤T´Á 51% vs 15%) //Àø®Ä¤ñ(73%/51%=143%) IGA 0,1=ASLAN004 58% VS ¹ï·Ó²Õ10%----(Dupilumab ¤T´Á 38% vs 10% )//Àø®Ä¤ñ(58%/38%=153%) ----------------------- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020 ------------------------- YªÑ»ù©Ô¤W20¬ü¤¸/ªÑ, ¥[¼Ú¬w±ÂÅvª÷¬°Lebrikizuamb 3¿ «hASLN¤½¥q ¤@ª½°µ¨ì¨úFDA AD Ãĵý(2026¦~©³¨ú±o) ¥Bý³Ý¤G´Á¦¨¥\,¤w¶i¤J¤T´Á. ASLN ¸ê¥»ÃB200,000¤dªÑADR ASLN004 ³Ì°ª¾P°âª÷ÃB¦ô100~140»õ¬ü¤¸ ³Q¨ÖÁʪ÷ÃB ¤W¬Ý300~420»õ¬ü¤¸ 150~210¬ü¤¸/ªÑ ------(¥i°µ¤j¹Ú)---------------- ¤HÃþ¦]¹Ú·Q¦Ó°¶¤j!!!!! --------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/8/21 ¤U¤È 01:58:23 ASLAN004 AD¤Îý³Ý³Ì¨ÎÀøªk¼ç¤O ---ASLAN004 1b ´Á¤¤ AD ¸gÀٮįq57% Àu©óDupilumab 3´Á ¨Ì¾ÚEylea vs Lucentis , -----Eylea¸gÀٮįq35% Àu©ó Lucentis ¾P°â¥«³õÂX¥R¼Ò¦¡ ¡A ASLAN004 ¥¼¨Ó¤W¥««e¥|¦~ ¾P°â¦ôp¦p¤U ASLAN004 ¾P°â¦ôdupilumab(2026-2029) ¦ôp2026¦~¤W¥«²Ä¤@¦~¾P°â 36»õ¬ü¤¸¬°dupilumab 30%(120*30%=36) ²Ä¤G¦~¾P°â 60»õ¬ü¤¸¬°dupilumab 50%(120*50%=60) ²Ä¤T¦~¾P°â 78»õ¬ü¤¸¬°dupilumab 65%(120*65%=78) ²Ä¥|¦~¾P°â115»õ¬ü¤¸¬°dupilumab 120%(96*120%=115), -------- Dupilumab ¹w¦ô120»õ¬üª÷³Ì°ª¦~¾P°â(¬ü°êªÑ¥«¥«³õ»{µý),2020¾P40»õ¬ü¤¸, 2021¦ô¾P57»õ¬ü¤¸. -------- ¥«³õÄvª§ ¤@¡AÀø®Ä: 1.ASLAN004 1b ´Á¤¤ADÁ{§É/QW*8¶g Àu¶Õ¼Æ¾Ú VS Dupilumab 3 ´Á AD /QW*16¶g , 1.1 ASLAN004 1b´Á¤¤¸Ñª¼³ø§i 400mg /600mg EASI-75 (¤T´Á¥Dn«ü¼Ð¤§¤@)¹F67% ¹ï·Ó²Õ¬°0%, Dupilumab 3 ´Á,¨C¶g¤@°w*16¶g EASI-75 =50% , ¹ï·Ó²Õ¬°13.5% Aslan004 1b /Dupilumab p3/QW=67%/50%=134%. (°ò½u¼ÆȬ۪ñ) ¥DnÀø®Ä«ü¼Ð Aslan004 1b Àu34% ©ó Dupilumab 3 ´Á,¨C¶g¤@°w*16¶g 1.2 ASLAN004 1b´Á¤¤¸Ñª¼³ø§i 400mg /600mg EASI-50(ªvÀø16¶g«á¥¼¹FEASI-50ªÌ,«OÀI¤½¥q¤£¦A¤ä¥I) ¹F89% ,¹ï·Ó²Õ¬°40%, Dupilumab 3 ´Á,¨C¶g¤@°w*16¶g EASI-50 =61% , ¹ï·Ó²Õ¬°23.5% Aslan004 1b /Dupilumab p3/QW=89%/61%=146%. (°ò½u¼ÆȬ۪ñ) ¦¸nÀø®Ä«ü¼ÐEASI-50 , Aslan004 1b Àu46% ©ó Dupilumab 3 ´Á ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb 1.3 ¸gÀٮįq®t²§ EASI-75 34% + EASI-50, +46%/2= 23% =57% Aslan004 1b ¸gÀٮįq Àu©ó Dupilumab 3 ´Á 57% ªº¼ç¤O(°²³]¥¼¨ÓÀøµ{¶O¬Û¦P) ( Dupilumab ¥DnÀø®Ä«ü¼ÐIGA 0/1 °ª1.33~2¿ ©ó¨ä¥L ¥u¯à§í¨îIL-13¡Ï³¡¤ÀIL-4/ ³æ§í¨îIL-13 ªº Lebrikiumab 75% of dupilumab /Tarlokinumab 50% of dupilumab) 2.¦w¥þ©Ê/°Æ§@¥Î :ASLAN004 µL Dupilumab ªº°ª¤ñ²vµ²½¤ª¢.(38%%¦³µ²¼Òª¢, ¹ê»Ú¨Ï¥Î241¤H¬ã¨s®×) 3.¥´°wÀW²v ASLAN004 ¥|¶g¤@°w 600mg*4=2400mg ¹w´Á VS. Dupilumab*¤G¶g¤@°w/ 300mg*9=2700mg ----------------------------------- Eylea ¥«³õ°»ù66.6%,¥«³õ¾P°âÂX¥R76»õ¬ü¤¸¡AÂX¥R²v176%. ¥«Ô·º¯³z²v(¤H¼Æ)ÂX¥R265%,(176%/66.6%=265%) 2015 Lucentis ³Ì°ª¾P°â43»õ¬ü¤¸ 2019¦~ ¨âÃľP°â¦Xp119»õ¬ü¤¸ ¨ì2019¦~¥«³õ¼W¥[119-43=76»õ¬ü¤¸ 76/43=176% ¼W¥[²v.-----(¥¼º¡¨¬¥«³õ,°»ù¬O¦³¥Îªº) 2012: Eylea ¤W¥«²Ä¤@¦~¾P°â¬°Lucentis¤w¤W¥«6¦~ 36%. 2013: Eylea ¤W¥«²Ä¤G¦~¾P°â¬°Lucentis¤w¤W¥«7¦~ 51%. 2014: Eylea ¤W¥«²Ä¤T¦~¾P°â¬°Lucentis¤w¤W¥«8¦~ 65%. 2015: Eylea ¤W¥«²Ä¥|¦~¾P°â¬°Lucentis¤w¤W¥«9¦~ 120%. 2012 ¨âÃľP°â¦Xp32.7»õ¬ü¤¸ 2013 ¨âÃľP°â¦Xp50.96»õ¬ü¤¸ 2015 ¨âÃľP°â¦Xp74.8»õ¬ü¤¸ 2016 ¨âÃľP°â¦Xp88.38»õ¬ü¤¸ 2019 ¨âÃľP°â¦Xp119»õ¬ü¤¸ ¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) PK ¡X- A:Lucentis) //B:(Eylea)**B/A**¦XpA+B 2006(¤W¥«//) 2009¡V20.35//¡]Eylea 11¤ë FDA ®Öã¤W¥«) 2012¡V24.00//8.70**B/A=36%**32.7 --------(Eylea²Ä¤@¦~¾P°â, ¦~«×¶O¥Î16,000¬ü¤¸¨C2Ӥ르¤@°w vs Lu centis 24000¬ü¤¸/¨C¤ë¤@°w) 2013¡V39.53//20.43**B/A=51%**50.96 ¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00**B/A=65%**71 2015¡V34.00//40.8.00**B/A=120%**74.8 (Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38**B/A=161%**88.38 2017¡V33.00//62.82**B/A=190%**95.82 2018¡V37.00//67.00**B/A=181%**104 2019¡V41(¦ô)//78.52**B/A=191%**119 ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- AMD¡X¡X°w¾¯ Ävª§¥v¡]ªvÀø¡X²´·ú¶À¯Z³¡¯fÅÜ¡^ ¤@¡BLucentis¡]Ranibizumab¡^¡X¡X2006¦~6¤ë¡AFDA®Öã¤W¥«,ù¤ó(¬ü°ê¾P°â)/¿ÕµØ(¨ä¥L¦a°Ï¾P°â) ¡A¨C¤ë¤@°w¡A¨C¦~24,000¬ü¤¸Àøµ{¶O¥Î ¤G¡BEylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)¡A¨C2¤ë¤@°w¡A¨C¦~16,000¬ü¤¸Àøµ{¶O¥Î¡C Lucentis¡]Ranibizumab¡^ ©MEylea¡]aflibercept¡^ ¬O¥Ø«e¼sªx¥Î©ó²´¬ì¯e¯fªºÀøªk¡AªvÀø¥]¬A·s¥Í¦åºÞ¡]Àã©Ê¡^¦~ÄÖ¬ÛÃö©Ê¶À´³ÅÜ©Ê¡Bµøºô½¤ÀR¯ßªý¶ë«á¶À´³¤ô¸~¡B¿}§¿¯f©Ê¶À´³¤ô¸~¡]DME¡^©MDME¦ñ¦³¿}§¿¯f©Êµøºô½¤¯fÅÜ¡C ¨âªÌ§¡¬°§Ü¦åºÞ¤º¥Ö¥Íªø¦]¤l¡]VEGF¡^Àøªk¡C2018¦~¡A³o¨â´ÚÃĪ«ªº¥þ²y¾P°âÃB±µªñ110»õ¬ü¤¸¡A¶È¦b¬ü°êªº¾P°âÃB´N¶W¹L¤F58»õ¬ü¤¸¡C Lucentis¦b¬ü°êªº±M§Q±N©ó2020¦~¨ì´Á¡A¦ý¹w´ú2021¦~¾P°âÃB¤´±N¹F¨ì41»õ¬ü¤¸¡C 2015¦~²Ä¤@Ó¥é¥ÍÃÄ¡A¦L«×¤W¥« 75%»ù®æ¡C Eyleaªº¤@¶µÃöÁä±M§Q¦b¬ü°ê±N©ó2023¦~¨ì´Á¡A¦b¼Ú¬w¨ì2025¦~¤~¨ì´Á¡A¹wp2021¦~¾P°âÃB±N¹F¨ì70»õ¬ü¤¸¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/5 ¤W¤È 10:46:49²Ä 5532 ½g¦^À³
|
¸`¿ý¦Ûºô¸ô ¥DÃD¡G¦A¥Í¤¸Regeneron(Dupilumab ªº¤½¥q)ªºµo®i¸ô®|±aµ¹¥xÆW¥Í§Þ²£·~¨º¨Çû£¥Ü©O¡H ¶È¨Ñ°Ñ¦Ò¡AY¦³¿ù»~¡AÅwªï¤£§[½ç±Ð¡I 1¡B¸ô¤Õ©ú»¡¡A ¥L´¿¸g»P¦P¤¯Ì¬ã¨s¹L«Ü¦h¤½¥q¡A «á¨Óµo²{³Ð¥ß¦Ü¤µ34¦~¡B Á`¥«È¥H¶W¹L660»õ¬ü¤¸ªºRegeneron¡]¦A¥Í¤¸¡^³o®a¤½¥q¡A ¬O¤@®aȱo¾Ç²ßªº¼Ò½d¡C 2¡BRegeneron¦´Áµo®i«Ü¤£¶¶§Q¡A ¶}µoªº²Ä¤@ÁûÃÄ¡A°µ¨ìÁ{§É¤T´Á¥¢±Ñ¤F¡A Ä~Äò¬ãµo²Ä¤GÁûÃÄ¡A°µ¨ì¤T´Á¤S¥¢±Ñ¤F¡A «á¨Ó²Ä¤TÁûÃÄÂê©wµo®i¶À´³³¡¯fÅܪºÃĪ«ªöµø©ú¡]Eylea¡^¡A ¸g¹L8¦~¬ãµo²×©ó¦¨¥\¡A¨ú±o2011¦~11¤ëFDA»{ÃҨäW¥«¾P¡C 3¡B²Ä¤TÁûÃĤ~¦¨¥\¡A ÅýRegeneron´X¥Gªá¤F§Ö20¦~ªº®É¶¡¡A ¤~¦b2009¦~©³®iÅSÀY¨¤¡A ªÑ»ù¤]±q18¬ü¤¸¥ª¥k¡A ¤Wº¦¦Ü2015¦~ªñ600¬ü¤¸(¥«È600»õ¬ü¤¸)¡A º¦´T¶W¹L30¿¡I Eylea ¾P°âªñ100»õ¬ü¤¸-2021¦~ Dupilumab ¾P°âªñ80»õ¬ü¤¸-2022¦~¦ô/2021¦~64»õ¬ü¤¸,¤½¥q¦ô130»õ¼Ú¤¸ªº³Ì°ª¾P°â.(2017¦~3¤ë¨ú¬ü°êÃĵý) 4¡B¦A¥Í¤¸ªºµo®i¸ô®|±aµ¹¥xÆW¥Í§Þ²£·~¨º¨Çû£¥Ü©O¡H ¤@¤è±¡A³q¹L¤º³¡¬ì¾ÇÅX°Êªº³Ð·sµo²{¡A ¦A¥Í¤¸¯à°÷¤£Â_«õ±¸©Mµo²{¯e¯f·s¹vÂI¡A ɧUVelociSuite¥¥x¸Ñ¨MÃĪ«§Î¦¡ªº¥~¦b§½¡A ¦¨¬°¦A¥Í¤¸²£«~ºÞ½u¤£Â_§§¤jªº·½¬u¡C ¥t¤@¤è±¡AɧUÂà¤Æ¬ã¨s¤¤ªº·s¦¨ªG¡A §Ö³tÅçÃÒÁ{§É»ùȨö}µo¯e¯f¼Ò«¬¡A ¤]Åý¦A¥Í¤¸¨«¥X¤F·sÃĶ}µoªº·s³t«×¡C 5¡B³Ð·s©M§Þ³N¥¥xªº¬Û±o¯q¹ü¡A Åý¦A¥Í¤¸¦¨¬°¤j®aªº¡u¤ß¤¤¼Ò¼Ë¡v¡C ³Ð·s§ó¬O³e¬ï¦A¥Í¤¸µo®iªº®Ö¤ß¡A ¦Ó§Þ³N¥¥xªº«h¬O¬°¤F¬ð¯}ÃĪ«µo²{¹Lµ{¤¤ªº¨î©M²~ÀV¡A ¥»½è¤W¤]¬O³Ð·sªºµ²ªG¡C 6¡B¥xÆWªº²³¦hBiotech¤½¥q±Á{ªº³Ì¤j°ÝÃD¦ü¥G¬O¦p¦ó¬¡¤U¥h¡A ¦Ó³oÓ°ÝÃD´¿¸g¤]¬O¦A¥Í¤¸ªº§x¹Ò¡C º]¼Ëªº¤O¶qÁ`¬OµL½aªº¡A ºËãÃĪ«ªº¾Ô³Nfollow ¥u¯àÅý§Ú̦¨¬°¸òÀHªÌ¡A n¦¨¬°¥xÆW³Ð·sÃĪº»â³S¡B ¥xÆWª©¡u¦A¥Í¤¸¡v¡A ³Ì°ò¥»ªºn¨D¬On¨ã³Æ¿W¥ßªº¡B ¯u¥¿·N¸qªº³Ð·s¯à¤O¡A ±q·½ÀY¸Ñ¨M©M±´¯Áº¡¨¬¯u¥¿Á{§É»Ý¨Dªº³Ð·sÃĵo®i¸ô®|¡C ¦P®É¡A§óÀ³¨ã³Æ¨â¦ì¦A¥Í¤¸³Ð¿ì¤H ¨º¯ë°í©wªº·N§Ó¡A¤£¬ÈÁ}Ãø¡B¤£Äß®À§é¡C ¦³«H©À¡A¤~¦³¦¨¥\. |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/9/2 ¤U¤È 08:17:49²Ä 5531 ½g¦^À³
|
¥[¦{门¬¥©¬§J©M·s¥[©Y2022¦~9¤ë2¤é电 -- ASLAN Pharmaceuticals纳´µ达§JªÑ²¼¥N码¡GASLN¤µ¤Ñ«Å¥¬º®u执¦æ©xCarl Firth³Õ¤h将¤_2022¦~9¤ë12¤é¬P´Á¤@东³¡时间¤W¤È10:30¦bH.C. Wainwright²Ä24届¦~«×¥þ²y§ë资¤j会¤W亲¦Û发ªí¤½¥q报§i¡C该会议将¤_2022¦~9¤ë12¤é¦Ü14¤é¦b乐¤Ñ纽约¬Ó宫°s©±¥H虚úQ©M现场ªº¤è¦¡举¦æ¡C 从¬ü东时间9¤ë12¤é¤W¤È10:30开©l¡A¦bASLANÊI¯¸ªº§ë资ªÌ关¨t³¡¤À¡]www.ir.aslanpharma.com¡^将´£¨Ñºt讲ªº点¼½录µ¡A¤]¥i¥H³q过这个链±µª½±µ访问¡C ¦b会议´Á间¡AºÞ²z层将ÉO§ë资ªÌ进¦æ¤@对¤@ªº会谈¡C请联¨t±z¦bH.C. Wainwrightªº¥Nªí¡A¥H¦w±Æ会议¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/1 ¤W¤È 10:31:36²Ä 5530 ½g¦^À³
|
Lebrikizumab AD 2b ¸Ñª¼ ¸ê®Æ´Á¥Z³ø§i : ¦p¤U www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/ Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial §¨Ó¦b2019¦~2¤ëDerm¤½¥qªºLebrikizumab AD 2b ¸Ñª¼«á¶}©l±µÄ²¬ã¨s¡A½Í§P¡A¬ù10Ó¤ëÂù¤è¦P·N¨ÖÁʮסC |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/9/1 ¤W¤È 10:25:32²Ä 5529 ½g¦^À³
|
§¨Ó¦b2019¦~2¤ëDerm¤½¥qªºLebrikizumab AD 2b ¸Ñª¼«á¶}©l±µÄ²¬ã¨s¡A½Í§P¡A¬ù10Ó¤ëÂù¤è¦P·N¨ÖÁʮסC ɥΤѩR¤j¸ê°T ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/29 ¤W¤È 06:41:40 9¤ë15¤éªºR&D day ¡A¬ã¨s&µo®i ³ø§i¡C ¦ôp 1¡K. 2.ADªº2Ó¤T´ÁÁ{§É©ú¦~10¤ë¶}©l¡K¡K --------------------------------------------------------------------------------- ¥t¡A¨È·à±d2020¦~¦~³ø´¦ÅS ¡K¡K¡§±N»P¼ç¦bªº¦X§@¹Ù¦ñ¬¢½Í«áÄò¬ãµo¤ÎÂà¥X±ÂÅv¡¨¡K¡K ºî¤W 1.004©ú¦~4¤ë2bÁ{§É¸ÕÅç¦p¥¿¦V¸Ñª¼«á¡A¤£·|¸òLebrikizumab¤@¼Ë¡A(004¦]¦³¦X§@¹Ù¦ñ)¤£·|ªá¨ì10Ӥ몺®É¶¡¦b°Q½×¨ÖÁÊ°ÝÃD¡C 2.004¤w¸g¦³¦X§@¹Ù¦ñ°Ñ»P¬ã¨s¡A¹w¦ô¦X¨Ö°ÝÃDªº°Q½×¥iÀ£ÁY¦b10Ó¤ë¥H¤º¡A ¼È©w112¦~©³«e§¹¦¨¨ÖÁʮסA¥B¨ÖÁÊ«á¤~·|°õ¦æ¤T´ÁÁ{§É¸ÕÅç¡C 3.ªÑ»ù¥ý¦æ¡C©ú¦~4¤ë¸Ñª¼«á¨ì©ú¦~©³«eªº¨ÖÁÊ¡AªÑ»ù±N·|´£«e¤ÏÀ³¡C (§ë¸ê¦³·ÀI¡A¬ÕÁ«½Ð¦Ût) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/1 ¤W¤È 08:06:18²Ä 5528 ½g¦^À³
|
2030¦~ ¤¤-««×ADÃĪ«¾P°â¹w´ú:168»õ¬ü¤¸/ (2020¦~64»õ¬ü¤¸¡C) Dupilumab: 62»õ¬ü¤¸¡C(¨Ì«á¨ÓDupilumab¤w½Õ°ª30%ªº¾P°â¥Ø¼Ð130»õ¼Ú¤¸pºâ¡A62¡Ñ130%=80»õ¬ü¤¸¡C 130¦X§½ Lebrikizumab & Tralo: 22»õ¬ü¤¸¡C ¡K¡K(¥Ø«eªº¨é°Ó±NASLAN004 ªºµû»ù¾P°â¤ô·Ç¡A¶È约µ¥©óLebrikizumab. ©Ò¥H¤@¦~¥Ø¼Ð»ù¶È7¬ü¤¸/ªÑ)¡C ¡K¡K¡K¡K¡K¡K JAK2¤fªAÃÄ:35»õ¬ü¤¸(¦³«°Æ§@¥Î)¡K¡K¡K¡K¡K¡K¥Íª«¨î¾¯µL®Ä«á¤~¯à¨Ï¥Î¡K¡KFDA ¼ÐÅÒÀÉ The atopic dermatitis (AD) market is expected to grow from a value of $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets at a compound annual growth rate (CAGR) of 10.1%, according to GlobalData. www.thepharmaletter.com/article/growth-in-atopic-dermatitis-market-to-exceed-10-at-cagr 2022/04/05 Ramla Salad, healthcare analyst at GlobalData, said: ¡§Biologics are expected to retain a large market share during the forecast period for the treatment of moderate to severe AD. Dupixent (dupilumab) is anticipated to be market leader with estimated peak sales of $6.2 billion in 2030. Furthermore, it is already known as the gold standard for the treatment of moderate to severe AD across the 7MM.¡¨ GlobalData expects that upcoming interleukin (IL) inhibitors - LEO Pharma¡¦s Adtralza/Adbry (tralokinumab), Eli Lilly¡¦s (NYSE: LLY) lebrikizumab, and Galderma¡¦s nemolizumab - will take market share from Sanofi (Euronext: SAN) and Regeneron¡¦s (Nasdaq: REGN) Dupixent and other immunomodulators over the forecast period as they are all targeting the moderate to severe patient population, with combined 2030 sales of $2.2 billion. Innovation on the way Oral JAK inhibitors are also expected to see strong growth during the forecast period with combined sales of $3.5 billion, and AbbVie¡¦s (NYSE: ABBV) Rinvoq (upadacitinib) leading the pack. Amgen (Nasdaq: AMGN) and Kyowa Kirin¡¦s (TYO: 4151) anti-OX40 inhibitor, KHK4083, and Pfizer¡¦s (NYSE: PFE) sphingosine-1-phosphate receptor (S1PR) modulator, etrasimod, are two new therapies in the late-stage development and hold huge promise. Ms Salad said: ¡§Based on insight from key opinion leaders (KOLs) interviewed by GlobalData, enthusiasm for these late-stage agents is due to their new mechanisms of action and the innovation they would bring to the market; if approved they would both be the first in their respective classes.¡¨ An increasing uptake of topical therapies for the treatment of mild to moderate AD is expected to greatly improve the overall control of flare-ups and consequently decrease the use of traditional therapies such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI). Notable therapies include topical JAKs, Incyte¡¦s (Nasdaq: INCY) Opzelura (ruxolitinib) and LEO Pharma¡¦s Corectim (delgocitinib) and phosphodiesterase-4 (PDE-4) inhibitors, AstraZeneca¡¦s (LSE: AZN) roflumilast and Otsuka Pharmaceutical¡¦s (TYO: 4578) Moizerto (difamilast). Peak sales for topical JAK and PDE-4 inhibitors are expected to reach combined sales of $630.6 million. ¡¦Very dynamic space¡¦ Ms Salad added: ¡§The AD market is a very dynamic space as exemplified by the pipeline activity, but there are some barriers to growth which could limit the uptake of these therapies. Pipeline topical JAK inhibitors will be entering a considerably competitive landscape where more expensive options, such as Eucrisa (crisaborole), are struggling to increase patient uptake. While KOLs were excited at the prospect of new pipeline drugs, many of them have a high ACOT, which will prevent uptake. As a result, physicians are likely to continue prescribing TCs, TCIs, and systemic immunomodulators. ¡§Although these barriers will have some impact on growth, the market is expanding at an impressive rate and ample opportunities exist for developers to further improve the AD treatment landscape for all ages and severities.¡¨ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/31 ¤U¤È 10:47:28²Ä 5527 ½g¦^À³
|
ASLN CEO ¤w¦h¦¸¦b¦U¨é°Ó·|ij¤¤.´£¤Î¶·Ä¹¹LDupilumabÀø®Ä¡B¦¨¥»¡A §_«h±N¸¨¤J¤G½uÃÄ¡C ¥«³õÄvª§«Ü²{¹êªº¡C Ĺ®a³q¦Y¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/8/31 ¤U¤È 10:08:48²Ä 5526 ½g¦^À³
|
¤G´ÁÁ{§É¬O¥¢±Ñ²v³Ì°ªªºÁ{§É´Á§O, §âASLAN 004Á¿ªº¤Ó¦n·|¦³«Ü¤j·ÀI, ¦³¦h¤Ö¼Æ¾Ú»¡¦h¤Ö¸Ü,¼Æ¾Ú¦³¦h¦n¹Ú·Q¤~¯à¦³¦h¤j, Åwªï§åµûÂI¥X¯ÊÂI,¤£»{¬°¤½¥q¥¼¨Ó·|«Ü¦n,¦³¤@¤Ñ¼Æ¾Ú¥X¨Ó«ÜÅåÆA, ±i¤O°÷¤jªÑ»ù¤Ï¦Ó·|¤jº¦, ªÑ¥«¨«¦V´N¬O³o»ò´I¦³²`¶øõ²z ¥Ø«e¥u¯à»¡ 1 ASLAN 004¬O¤@Áû«Ü¦³¼ç¤OªºÃÄ 2 ASLAN 004¤@´ÁÁ{§É³q¹L·§©À©ÊÅçÃÒ»P¦w¥þ©Êµû¦ô¨Ã¬Ý¨ìªì¨BÀø®Ä 3 ¨È·à±d¥Í§Þ¤½¥q¸ê°T¤½¶}³z©ú,µ¦²¤½Õ¾ã§Ö³t¦³®Ä²v 4 2022¦~¤K¤ë¤¤ HC Wainwright ªºYi Chen«¥Ó¤F¹ï Aslan Pharmaceuticals ( ASLN ¡V Research Report )ªº¶R¤Jµû¯Å¡A¥Ø¼Ð»ù¬° 7.00 ¬ü¤¸ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/29 ¤U¤È 05:25:39²Ä 5525 ½g¦^À³
|
¤¤°êÃҺʷ|»P¬ü°ê¤½²³¤½¥q·|pºÊ·þ©eû·| (PCAOB) ¤W©P¤«Å¥¬¡AÂù¤èñ¸p¤F´N¦b¬ü¤W¥«ªº¤¤°ê¤½¥q¼fp¤u§@©³½Z¶i¦æÀˬdªº¦X§@¨óij¡A¤¤°ê°]¬F³¡¤]¤wñ¸p³o¶µ¨óij¡C ¬ü¤¤©ó¤W©P¤±ß¶¡ªºÁn©úÅã¥Ü¡A¬ü°ê©xû±N¨ú±o¤¤°ê¤½¥qªº¼fp©³½Z¡A³o¬O³o¨ÇªÑ²¼¯à°÷Ä~Äò¦b¬ü°êªº¥æ©ö©Ò¥æ©öªºÃöÁä¤@¨B¡CPCAOB ªí¥Ü¡A¥L̹wp¦b 9 ¤ë¤¤¦¯¤§«e¡A©ó¤¤°ê¬£¾n¹ê¦aÀˬdû¡A¨Ã¦b 12 ¤ë½T©w¤¤°ê¬O§_¤´¦bªýêÀò¨ú¼fp°T®§¡C °ª²±ªí¥Ü¡A¦b¥_¨Ê©MµØ²±¹y¹F¦¨³Ì²×¨óij¡B¤¤°êªÑ²¼¡u¤£¤U¥«¡vªº³Ì¨Î±¡ªp¤U¡A¦b¬ü°ê¤W¥«ªº¤¤°ê¤½¥q©M MSCI ¤¤°ê«ü¼Æ ¦ôÈ¥i¯à¤À§O¤Wº¦ 11% ©M 5%¡C ¦ý¦pªG³o¨ÇªÑ²¼³Q±j¨î¤U¥«¡A°ª²±¦ôp¡A¬ü°ê¦s°U¾ÌÃÒ©M MSCI ¤¤°ê«ü¼Æ±N¤À§O¤U¶^ 13% ©M 6%¡C ³ø§i»{¬°¡A¾¨ºÞ¤U¥«¤è±ªº¤£½T©w©Ê«ùÄò¦s¦b¡A¦ý¥Ñ©óºÊºÞ¤è±ªºªý¤O¦³¤F¦nÂà¥B¦ôȧC·G¡A°ª²±¤´¬Ý¦n¼W«ù¬ì§Þ¡B´CÅé©M¹q«H¦æ·~¡C «í¥Í¬ì§Þ«ü¼Æ¤µ¦~¨´¤µ¤´¤U¶^¬ù 25%¡Aì¦]¬O¹ï¤¤°ê¸gÀÙ¼Wªø©ñ½wªº§ó¼sªxºÃ¼{¡A©M¥ø·~Àò§Qª¬ªp¤£¤@¡APªÑ»ù©ÓÀ£¡C °ª²±«ü¥X¡A¾¨ºÞ¼fpÀˬd¨óij¥i¯à·|°§C¼sªx¤U¥«ªº·ÀI¡A¦ý³ò¶¶T©ö¡B§Þ³N¡B¸ê¥»¥«³õ©M¦a½t¬Fªvµ¥ÃöÁä¾Ô²¤»â°ìªº¤¤¬üºò±i§½¶Õ¡A¨ä¤£½T©w©Ê±NÄ~Äò¦s¦b¡C news.cnyes.com/news/id/4942454 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/29 ¤W¤È 11:33:01²Ä 5524 ½g¦^À³
|
The U.S. Food and Drug Administration (FDA) granted lebrikizumab Fast Track designation in AD in December 2019 ¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½ (FDA) ©ó 2019 ¦~ 12 ¤ë¦b AD ¤¤±Â¤© lebrikizumab §Ö³t³q¹D«ü©w 2019 ¦~ 2 ¤ë 7¤é lebrikizumab AD 2b ¸Ñª¼. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/29 ¤W¤È 11:13:17²Ä 5523 ½g¦^À³
|
¤é´Á ¤å³¹ 2022 ¦~ 6 ¤ë 7 ¤é§åã FDA §åã Dupixent (dupilumab) §@¬° 6 Ó¤ë¦Ü 5 ·³¨àµ£¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº²Ä¤@ºØ¥Íª«ÃĪ« 2022 ¦~ 5 ¤ë 20 ¤é§åã FDA §åã Dupixent (dupilumab) §@¬°¦¨¤H©M 12 ·³¤Î¥H¤W¶Ý»Ä©Ê¹ºÞª¢¨àµ£ªºº¿ïªvÀøÃĪ« 2021 ¦~ 10 ¤ë 20 ¤é§åã FDA ÂX¤j Dupixent (dupilumab) ªº§åã½d³ò¡A¥]¬A 6 ¦Ü 11 ·³±w¦³¤¤«×¦Ü««×ý³Ýªº¨àµ£ 2020 ¦~ 6 ¤ë 19 ¤é§åã FDA §åã·sªº Dupixent (dupilumab) ¹w¶ñ¥Rµ§¡A¦®¦b¤ä«ù§ó¤è«Kªº¦Û§ÚºÞ²z 2020 ¦~ 5 ¤ë 26 ¤é§åã FDA §åã Dupixent (dupilumab) §@¬° 6 ¦Ü 11 ·³¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¨àµ£ªº²Ä¤@ºØ¥Íª«ÃĪ« 2019 ¦~ 6 ¤ë 26 ¤é FDA §åã Dupixent (dupilumab) ¥Î©óªvÀø¦ñ¦³»ó®§¦×ªººC©Ê»óÄuª¢ 2019 ¦~ 3 ¤ë 11 ¤é§åã FDA §åã Dupixent (dupilumab) ¥Î©ó«C¤Ö¦~¤¤««×¯SÀ³©Ê¥Öª¢ 2018 ¦~ 10 ¤ë 19 ¤é§åã FDA §åã Dupixent (dupilumab) ¥Î©ó¤¤«×¦Ü««×ý³Ý 2017 ¦~ 3 ¤ë 28 ¤é §åã FDA §åã Dupixent (dupilumab) ¥Î©óÀã¯l 2016 ¦~ 9 ¤ë 26 ¤é ÁÉ¿Õµá (Sanofi) ©M¦A¥Í¤¸ (Regeneron) «Å¥¬ Dupilumab ¥Íª«»s«~³\¥i¥Ó½ÐÀò¬ü°ê FDA ±µ¨üÀu¥ý¼f¬d 2014¦~/11¤ë23¤é ÀòFDA ªºBTD (¬ð¯}©ÊÀøªk).----¨Ì2b AD Á{§É,2014¦~7¤ë¸Ñª¼, ¥Ó½ÐBTD,. Date Article Jun 7, 2022 Approval FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis May 20, 2022 Approval FDA Approves Dupixent (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis Oct 20, 2021 Approval FDA Expands Approval of Dupixent (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma Jun 19, 2020 Approval FDA Approves New Dupixent (dupilumab) Pre-Filled Pen Designed to Support More Convenient Self-Administration May 26, 2020 Approval FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis Jun 26, 2019 Approval FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis Mar 11, 2019 Approval FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents Oct 19, 2018 Approval FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma Mar 28, 2017 Approval FDA Approves Dupixent (dupilumab) for Eczema Sep 26, 2016 Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/29 ¤W¤È 06:41:40²Ä 5522 ½g¦^À³
|
9¤ë15¤éªºR&D day ¡A¬ã¨s&µo®i ³ø§i¡C ¦ôp 1.´¦ÅS AD 2b Á{§É100Ó©Û¶Ò¤¤¤ß¶}¥ß§¹¦¨¡C 预p11¤ë¤¤¦¯§¹¦¨³Ì«á¤@¦ì©Û¶Ò¡C ©ú¦~¥|¤ë¸Ñª¼¡C ¤j约§¹¦¨¬I¥´²Ä¤@°wªÌ¡A50%-55% 2.ADªº2Ó¤T´ÁÁ{§É©ú¦~10¤ë¶}©l¡A¥Î18Ӥ맹¦¨¸Ñª¼¡C ¦ô2025¦~2¤ë¸Ñª¼¡A 3.AD¨úFDAÃĵý¦b2026¦~©³¡C 4.¨ä¥L004ªº¾AÀ³¯g¶}µo®Éµ{规¹º ý³Ý EOE ºC©Ê»óª¢ 5.³Ì·s004 ADªºMOA 6.004 AD 1bÁ{§É¡A ³Ì·s¸Ñª¼«áªº¥Íª«¼Ð»x¤Î·s资®Æ¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/8/26 ¤U¤È 03:17:18²Ä 5521 ½g¦^À³
|
ɥΤѩR¤j¤j¸ê°T¡G ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/4/19 ¤W¤È 10:28:34 ctee.com.tw/news/real-estate/629241.html ASLAN004 ¤¤-««×AD 2b Á{§É¼W¥[¤@Ó·s¥[©Yªº¦¬®×¤¤¤ß¡A²Öp20Ó¦¬®×¤¤¤ß¡C ¡K¡K¬ü¡B¿D¡B纽¡B·s¡C------- --------------------------------------------------------------------------------------------------- 4¤ë18¤é®É¦¬®×¤¤¤ß¦¨¥ß¼Æ¦³20³B(¬ù60¤H)¡A 60¤H¦û¸ÕÅç¤H¼Æ5¤À¤§1(°÷¤F)(¤w¶W¹L1b¸ÕÅç¤H¼Æ¤F) ¥[16¶gªvÀø«á=8¤ë8¤é ¤½¥q°ª¼hÁö¥¼¸Ñª¼¡A¦ý¥i²M·¡¤F¸Ñ¨C2¶gªºÀø®Ä¶i®i¤F¡C ¤½¥q°ª¼hµo²{±Ä¥ÎBelle.ai ¼v¹³¸É®»§Þ³N¦³§U©ó´£°ªÁ{§É¸ÕÅ禨¥\¾÷²v¡A¤~»P¨äñ¬ù¡C (¤w¸Õ¥Î¦b³o60Ó¨ü¸ÕªÌ¨¤W¤F¡Aµo²{¦³§U©ó´£°ªÁ{§É¸ÕÅ禨¥\¾÷²v) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/8/26 ¤U¤È 02:09:23²Ä 5520 ½g¦^À³
|
¦³¤F³o¶µ¦X§@»P¼v¹³¸É®»§Þ³N ³o¦³§U©ó´£°ªÁ{§É¸ÕÅ禨¥\¾÷²v Belle.ai ¬° ASLAN ©M°Ñ»P§ÚÌ¥þ²y¬ã¨sªº¬ã¨s¤Hû´£¨Ñ¤F¤@ºØ©ö©ó¨Ï¥Îªº¸Ñ¨M¤è®×¡A¸Ó¸Ñ¨M¤è®×³q¹L¹Ï¹³®·Àò¦¬¶° AD ¯e¯fÄY«µ{«×ªº¼Ð·Ç¤Æ°O¿ý¡C ASLAN Pharmaceuticals º®uÂåÀø©x Alex Kaoukhov ³Õ¤h»¡¡G¡§³o¶µ§Þ³N¨Ï§Ú̯à°÷¼W±j§Ú̪º½è¶q±±»sµ{§Ç¡A¦ÓµL»Ý¦b³o¶µ¥¿¦b¶i¦æªº¬ã¨s¤¤½Õ¾ã§Ú̪º¤è®×¡C§Ú̬۫H¥¦¥i¥H¦¨¬°¬ã¨s¤Hûªº±j¤j¤u¨ã¡A¤¹³\«ùÄò¼f¬d ¦bÁ{§É¸ÕÅç²{³õµû¦ô¯e¯fÄY«µ{«×ªº«ÈÆ[·Ó¤ùÃÒ¾Ú¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/25 ¤U¤È 09:19:24²Ä 5519 ½g¦^À³
|
²¤¥h^¤å(»P¤Ñ©R¤j¶Ç¡A¦P¥ó¨Æ¡A°Ñ¦Ò) ªü´µÄõ»sÃĤ½¥q»PBelle.aiñ¸p¦b¯SÀ³©Ê¥Öª¢Á{þH¸ÕÅ礤¨Ï¥Î¹Ï¹³³n¥óªº³\¥i¨óij ¬ü°êªF³¡®É¶¡2022¦~8¤ë25¤é¤W¤È08¡G20(MT Newswres)--Aslan PharmPharmticals(ASLN)©MBelletorus(¤SºÙBelle.ai)¶g¥|ªí¥Ü¡A¥L̤w¸g¹F¦¨¤@¶µ¨óij¡A®Ú¾Ú¸Ó¨óij¡A³o®aÁ{þH¶¥¬qªº¥Íª«»sÃĤ½¥q±N±ÂÅvBelleStudy¼Æ¦r¹Ï¹³®·Àò³n¥ó¡A¥H¨ó§U¨äªvÀø¯SÀ³©Ê¥Öª¢ªºÁ{þH¸ÕÅç¡C ¥LÌ説¡Aªü´µÄõ±N¦V¥¿¦b¶i¦æªºeblasakimab 2b¶¥¬q¸ÕÅ窺©Ò¦³½Õ¬d¤Hû´£¨Ñ¹Ï¹³®·Àò³n¥ó²Õ¥ó¡A¹wp±N¦b2023¦~¤W¥b¦~²£¥ÍI½u¼Æ¾Ú¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/25 ¤U¤È 07:33:52²Ä 5518 ½g¦^À³
|
finance.yahoo.com/news/aslan-pharmaceuticals-signs-license-agreement-110300204.html ªü´µ兰¨î药¤½¥qÉObelle.ai签¸p许¥i协议¡A¦b¯S应©Ê¥Öª¢临§É试验¤¤¨Ï¥Îbellestudy™图¹³ªö¶°软¥ó ¥[¦{门¬¥©¬§J¡B·s¥[©Y©M马萨诸¶ë¦{§¢¥¬¨½©_2022¦~8¤ë25¤é电 /¬ü³qªÀ/ -- BelleTorus¤½¥q¡]Belle.ai¡^©MASLAN¨î药¤½¥q¡]纳´µ达§J¡GASLN¡^¤µ¤Ñ«Å¥¬¡AASLAN¤w经±Â权¨Ï¥ÎbelleStudy™数¦r图¹³ªö¶°软¥ó¡A¥H¤ä«ùASLAN¦b¥þ²y¦h个¦a点进¦æªº¯S应©Ê¥Öª¢¡]AD¡^ªº临§É试验¡CASLAN将¦VTREK-ADªº©Ò¦³¬ã¨s¤H员´£¨ÑbelleStudy™ªº图¹³ªö¶°软¥ó组¥ó¡ATREK-AD¬O¨ä¥¿¦b进¦æªº¥ì¥¬©Ô¦è单§Ü¥þ²y2b´Á试验¡A预计将¦b2023¦~¤W¥b¦~产¥Í顶线数Õu¡C Belle.ai为ASLAN©M参ÉO§Ú们¥þ²y¬ã¨sªº调¬d¤H员´£¨Ñ¤F¤@个©ö¤_¨Ï¥Îªº¸Ñú¨¤è®×¡A³q过图¹³ªö¶°¦¬¶°AD¯e¯f严«µ{«×ªº标ã¤Æ记录¡C这项§Þ术¨Ï§Ú们¯àû{¥[üL§Ú们ªº质¶q±±¨îµ{§Ç¡A¦Ó¤£¥²¦b这项¥¿¦b进¦æªº¬ã¨s¤¤调¾ã§Ú们ªº¤è®×¡AASLAN¨î药¤½¥qªºº®u医疗©xAlex Kaoukhov³Õ¤h说¡C§Ú们¬Û«H¥¦¥i¥H¦¨为调¬d¤H员ªº¦³¤O¤u¨ã¡A¤¹许¦b临§É试验现场«ù续审¬d¯e¯f严«µ{«×评¦ôªº«È观·Ó¤ù证Õu¡A¦}将¼WüL§Ú们¬ã¨s¤¤¨Ï¥Îªº现¦³¦¨¹³¤èªk¡C ´¼¯à¤âÉó¬ÛÉó¤WªºbelleStudy™图¹³®·®»软¥ó«ü导临§É¬ã¨s¤H员¦b¤W传¨ì¤ªºÝ¤§«e²M´·ãÚ̦a®·®»ADªº·Ó¤ù¡CBelle.aiªººëṲ́H¤u´¼¯àºâªk为¯S应©Ê¥Öª¢©M1000¦hÏú¥Ö肤¯f´£¨Ñ©w©Ê评¦ô¡]识别¡^©M©w¶q评¤À¡]严«µ{«×¡^¡A´£¨Ñ¦yºÝªº数¦r¸Ñú¨¤è®×¡AASLAN¥i¥H¦b¥¼来ªºAD¬ã¨s¤¤§Q¥Î这¨Ç¸Ñú¨¤è®×¡C ¤À´²¦¡临§É试验ªº¥¼来¬O将üL¤j¥B©ö¤_¨Ï¥Îªº¤H¤u´¼¯à¤u¨ã¥æ¨ì调¬d¤H员¤â¤¤¡A¥H«K从¥@¬É¥ô¦ó¦a¤è获¨ú临§É数Õu¡A§Ú们«Ü°ª兴¯àû{为ASLAN¨î药¤½¥q°µ¨ì这¤@点¡ABelle.aiªºº®u医疗©xCliff Perlis³Õ¤h补¥R¹D¡C§Ú们ªº§Þ术¤]¥i¥Hª½±µ³Q¯f¤H¨Ï¥Î¡A¥L们¥i¥H¦b¦Û¤v®a¨½ªº隐¨p¤¤¸ò踪ªv疗进®i¡A¦}ãÚÌ©M统¤@¦a¦¬¶°数Õu¡A这¼W¥[¤F对临§É终点¦Ü关«nªºÆÓ数Õu¬y¡C ASLAN PHARMACEUTICALS SIGNS LICENSE AGREEMENT WITH BELLE.AI TO USE BELLESTUDY™ IMAGE CAPTURE SOFTWARE IN ATOPIC DERMATITIS CLINICAL TRIALS MENLO PARK, Calif. and SINGAPORE and CAMBRIDGE, Mass., Aug. 25, 2022 /PRNewswire/ -- BelleTorus Corporation (Belle.ai) and ASLAN Pharmaceuticals (Nasdaq: ASLN), today announced that ASLAN has licensed belleStudy™ digital image capture software in support of ASLAN¡¦s clinical trials for atopic dermatitis (AD) across several global sites. ASLAN will make the image capture software component of belleStudy™ available to all investigators of TREK-AD, its ongoing global phase 2b trial of eblasakimab, expected to generate topline data in the first half of 2023. Belle.ai provides ASLAN and the investigators participating in our global studies with an easy-to-use solution that collects a standardized record of AD disease severity through image capture. This technology allows us to enhance our quality control procedures without having to adjust our protocols in this ongoing study, said Dr. Alex Kaoukhov, Chief Medical Officer, ASLAN Pharmaceuticals. We believe it can be a powerful tool for investigators, allows ongoing review of objective photographic evidence of disease severity assessment at the clinical trial site and will augment the current imaging methods used in our studies. The belleStudy™ image capture software on a smartphone camera guides clinical investigators to clearly and accurately capture photos of AD before being uploaded to a cloud. Belle.ai¡¦s precise AI algorithms provide qualitative assessment (identification) and quantitative scoring (severity) of atopic dermatitis and over 1,000 skin conditions, delivering cutting edge digital solutions which could be leveraged by ASLAN in future AD studies. The future of decentralized clinical trials is putting powerful and easy-to-use AI tools in the hands of investigators to capture clinical data from anywhere in the world, and we are pleased to be able to do this for ASLAN Pharmaceuticals, added Dr. Cliff Perlis, Chief Medical Officer of Belle.ai. Our technology can also be used directly by patients, who can track treatment progress in the privacy of their own homes and collect data accurately and uniformly, which adds an unlimited stream of data critical to clinical endpoints. |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/24 ¤U¤È 09:28:35²Ä 5517 ½g¦^À³
|
Asln½L«e0.9650 |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2022/8/24 ¤U¤È 07:55:44²Ä 5516 ½g¦^À³
|
À³¸Ó9¡þ15¤½§G·sªºMOA©M1bªº·s¼Æ¾Ú ³Ì¤Ö´Nn¬ð¯}1¤¸¤F ¨S¬Ý¨ì¤Ï«ü¼Ð¤S¥X¨Ó°Û°I¤F¶Ü¡H ¦Ñ·à¨S¦³1¤¸«Ì»Ùªº°ÝÃD |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/8/24 ¤U¤È 04:54:54²Ä 5515 ½g¦^À³
|
8¤ë1¤é¤½¥¬45Ó¦¬®×¤¤¤ß¦¨¥ß¡A¶È¦¬¨ü¸ÕªÌ¬ù135¤H¡AµLªk¥X´Á¤¤³ø§i¡C 8¤ë23¤é¤½¥¬65Ó¦¬®×¤¤¤ß¦¨¥ß¡A¦¬¨ü¸ÕªÌ¬ù195¤H¡A¹F¥X´Á¤¤³ø§i±ø¥ó¡C 8¤ë23¤é¥[4Ó¤ëªvÀø´Á+¦A¥[1Ó¤ë¼Æ¾Ú¾ã²z=112¦~1¤ë23¤é«áµo¥¬´Á¤¤³ø§i¡C Y10¤ë¤¤100Ó¦¬®×¤¤¤ß¦¨¥ß¡A¸Ñª¼®É¶¡¸¨¦b112¦~²Ä2©u¡A´Á¤¤³ø§i¦n¹³¤]¤£¤@©wn´¦ÅS¤F¡C (¤½¥q¤]¨S»¡n¤½¥¬´Á¤¤³ø§i) ---------------------------------------------------------------------------------------------------- ¥t 9/7~9/10¸q¤j§Q½×¾Â 9/15¯Ã¬ùR&D¤é ¦pµLªk±NªÑ»ù©Ô¦Ü1¬ü¤¸¥H¤W¡A9/29(3¤ë©³µ¹ªº´Á)±N¥i¦A©µ¥b¦~¡A§Y112¦~3¤ë©³¡C ©¡®ÉYªÑ»ùÁÙ§C©ó¤@¤¸¡A¬Ý¨ÓÁÙ¬O±o¤½¥¬´Á¤¤³ø§i¡C ---------------------------------------------------------------------------------------------------- ©Ò¥H¡A¥ÑªÑ»ù¨Ó¨M©w¬O§_»Ýn¤½¥¬´Á¤¤³ø§i¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/8/24 ¤U¤È 01:59:13²Ä 5514 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº°T®§¡A±z¹ï¸Ñª¼¦³«H¤ß¼W¥[¡A§Ú¤]¹ï¦~©³¦³¥¿¦Vªº´Á¤¤¼Æ¾Ú¤]·U¨Ó·U¦³´Á«Ý~¦Ñ·à¥[ªo! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/24 ¤W¤È 11:56:30²Ä 5513 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023 8/23 ³Ì·s§ó·s ASLAN002 AD 2b Á{§É. ¤w¶}65Ó¤¤¤ß,¼W¥[®³¤j°ê®aªº7Ó¤¤¤ß,¦ý¥¼¨£¼Ú¬w¥ô¦ó¤¤¤ß. ¨ÌASLN¤¸¤ë¤½§in¶}100Ó¤¤¤ß¬O¯uªº. ¥Î100Ó¤¤¤ß¿z¿ï¥D¤O59¤H/arm, 2bªº¥Ø¼ÐÀø®Ä·|«Ü¤£¿ù.¥Ø¼ÐEASIÀø®Ä73% VS 15%,·U¨Ó·U¦³«H¤ß. ---«D¶Ç²Î AD ±wªÌ,±NÃø¥H¶i¤JÀH¾÷¤À°t. ---¥D¤Oarm °ò½u¥§¡EASI ¦ô27~30, °¾»´/¯g. ---¥§¡3¤H/¤¤¤ß,¥i°§C°h¥X²v.¼W¥[§¹§@16¶gªvÀø¤ñ²v. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/23 ¤W¤È 07:57:52²Ä 5512 ½g¦^À³
|
Dupilumab ¶}µop¹º¡A2020¦~6¤ë,¬ü°ê¥«³õ¥¼¨ü±±¨î AD 226.5¸U¤H///56% ý³Ý 97.5¸U¤H/// 24% ¨ä¥L¾AÀ³¯g 84¸U¤H///20% ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¤pp¡C 408¸U¤H ///100% Dupilumab ³Ì°ª销°â¦ô140»õ¬ü¤¸,¦U¾AÀ³¯g¾P°âª÷ÃB¤Î¤ñ²v¦ôp¦p¤U: AD 56%=140x56%=78»õ¬ü¤¸ ý³Ý 24% =140x24%=34»õ¬ü¤¸ ¨ä¥L 20% =140x20%=28»õ¬ü¤¸ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/23 ¤W¤È 06:42:03²Ä 5511 ½g¦^À³
|
YASLAN004 2b¸Ñª¼¦p¥Ø¼Ð EASI75=73% vs 15% 赢¹LDupilumab ¤T´Áªº51% vs 15% 73% /51%=143% ³o¬OAD·~¬Éªº¤j¨Æ¥ó¡C ¥NªíASLAN004¥i¦¨¬°¤U¤@¥NªºDupilumab¡C ¤W¥«4-5¦~¡AÀç¾i额¥i±æ¶W¶VDupilumab. |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/8/22 ¤U¤È 10:20:35²Ä 5510 ½g¦^À³
|
¬Ý¦h¬ÝªÅ¥»¨Ó´N¬O¬ÝÓ¤H ¤§«e¤U¶^¹Lµ{¦³Ó¬ÝªÅªº¤j¤j´N«Ü¼F®`(¯u·Ç) ¦ý¥Ø«e¨È·à±d³o¶ÕÀYÁÙ¥X¨Ó¬ÝªÅ¥s¤H½æ´N©~¤ß¥r´ú §A¨º¨Ç¹ï¨R°òª÷ªº¤j¤á¤]¤£¬O¦Y¯Àªº¡A¦³¥i¯à¤£°µ¤@ªi´N³o¼Ë½ß¿ú¦¬³õ¶Ü ¤§«e1.5¤¸¡B3¤¸4¤¸¨p¶Ò¶i¨Óªº·|¥Ì¤ß´N³o¼ËÅýªÑ»ù¤U¥h ¤£ºÞ·à¤l³Ì«á¼Æ¾Ú«ç¼Ë¦¨¤£¦¨¥\ ©ê¨ì²{¦b«o½æªÑªº³£¬O³ÌÄø ¹ï¤F...²{¦b¬ü¤¸«ü¼Æ¥Í¨ì108¡A¤Q¦~¤½¶Å§Q²v¤É¨ì3% ¬üªÑ²{¦b¤j¶^¤¤¡A¦ý·à¤l«o¬Oº¦ªº §A«on½æ¤F¥¦? |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/22 ¤U¤È 09:21:17²Ä 5509 ½g¦^À³
|
ASLAN Pharmaceuticals«Å¥¬将¤_2022¦~9¤ë15¤é¬P´Á¥|¤W¤È10:00¦Ü¤U¤È1:30 ¦b纽约ªºSt.Regis°s©±举办¬ã发¤é¬¡动¡C 该¬¡动将¥]¬AºÞ²z层¥H¤Î¥Ö肤¯f学关键·N见领³S¡B ¦è¥_¤j学S§B®æ医学°|ªºPeter A. Lio³Õ¤h©M 约¿«ÀN´¶ª÷´µ¤j学ªºShawn Kwatra³Õ¤hªººt讲¡F ¥L们将讨论·s¥X现ªº¥¼满¨¬»Ý¨D¡Bªv疗«e´º©MADªº¤À¤lÉó¨î¡CASLANªº领导团队¡A¥]¬ACarl Firth³Õ¤h¡BStephen Doyle¡BAlex Kaoukhov³Õ¤h©M°ª级¬ã发ºÞ²z团队ªº¨ä¥L¦¨员¡A将讨论¥Heblasakimab为ºªººÞ线组¦X¡A这¬O¤@Ïúýͦbªº·s«¬¡B¤@¬yªº单§J¶©§ÜÊ^¡A针对IL-13¨üÊ^£\1亚单¦ì¡A¥¿¦b开发¥Î¤_ªv疗¤¤«×¦Ü««×AD¡C 该¬¡动将´£¨Ñ关¤_eblasakimab开发项¥Øªº¥þ±§ó·s¡A¥]¬A¡G eblasakimab独¯S§@¥ÎÉó¨îªº转¤Æ数Õu¡F eblasakimabªº1b´Á·§©À验证¬ã¨sªº临§É数Õu¡F eblasakimabªº发®i战²¤©M¤W¥«¸ô径·§z¡F AD¬ã¨sªº³Ì·s进®i¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/22 ¤U¤È 07:06:33²Ä 5508 ½g¦^À³
|
ASLAN PHARMACEUTICALS LIMITED Mon, August 22, 2022 at 7:00 PM In this article: ASLN +3.87% ASLAN PHARMACEUTICALS LIMITED ASLAN PHARMACEUTICALS LIMITED Management team will host R&D day on Thursday, September 15, from 10am ET in New York City with Key Opinion Leader (KOL) participation Pipeline and business update, translational and clinical data on eblasakimab in development for moderate-to-severe atopic dermatitis (AD) and other topics related to the AD landscape to be discussed with a live webcast option MENLO PARK, Calif. and SINGAPORE, Aug. 22, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will be hosting a R&D Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York, NY. The event will include presentations from management as well as Key Opinion Leaders (KOLs) in dermatology, Peter A. Lio, MD of Northwestern University Feinberg School of Medicine, and Shawn Kwatra, MD of Johns Hopkins University, who will discuss the emerging unmet needs, therapeutic landscape and molecular mechanisms underlying AD. ASLAN¡¦s leadership team including Carl Firth PhD (Founder and CEO), Stephen Doyle (Chief Business Officer), Alex Kaoukhov MD (Chief Medical Officer), and other members of the senior R&D management team will discuss the pipeline portfolio led by eblasakimab, a potential novel, first-in-class monoclonal antibody that targets the IL-13 receptor £\1 subunit (IL-13R£\1) being developed for the treatment of moderate-to-severe AD. The event will provide a comprehensive update on the eblasakimab development program, including: Translational data on eblasakimab¡¦s unique mechanism of action Clinical data from the Phase 1b proof-of-concept study of eblasakimab Overview of eblasakimab¡¦s development strategy and path to market Update on the latest in AD research Formal presentations will be followed by a KOL panel discussion. To attend the event in person or virtually, please click here for registration. For in-person attendance, please register in advance as space is limited. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN¡¦s website at ir.aslanpharma.com/ ªü´µ兰¨î药¦³¤½¥q Mon, August 22, 2022 at 7:00 PM ¦b这½g¤å³¹¤¤¡C 证¨é¥N码¡GASLN +3.87% ªü´µ兰¨î药¦³¤½¥q ºÞ²z团队将¤_¬ü国东³¡时间9¤ë15¤é¬P´Á¥|¤W¤È10点°_¦b纽约¥«举办¬ã发¤é¬¡动¡A关键·N见领³S¡]KOL¡^将参ÉO¨ä¤¤ 将³q过ÊI络ª½¼½ªº¤è¦¡讨论ºÞ¹D©M业务§ó·s¡B¥¿¦b开发ªºªv疗¤¤«×¦Ü««×¯S应©Ê¥Öª¢¡]AD¡^ªº¥ì¥¬©Ô¦è单§Üªº转¤Æ©M临§É数Õu¥H¤ÎÉOAD¬Û关ªº¨ä¥L话题 ¥[¦{门¬¥©¬§J©M·s¥[©Y¡A2022¦~8¤ë22¤é¡]GLOBE NEWSWIRE¡^ -- ASLAN Pharmaceuticals¡]纳´µ达§J¡GASLN¡^¬O¤@®a处¤_临§É阶¬q¡B¥H§K¬Ì学为«点ªº¥Íª«¨î药¤½¥q¡A¥¿¦b开发§ï变±wªÌ¥Í¬¡ªº创·s疗ªk¡A¤µ¤Ñ该¤½¥q«Å¥¬将¤_2022¦~9¤ë15¤é¬P´Á¥|东³¡时间¤W¤È10:00¦Ü¤U¤È1:30¦b纽约ªºSt. 这¦¸¬¡动将¥]¬AºÞ²z层¥H¤Î¥Ö肤¯f学ªº关键·N见领³S¡]KOL¡^¡B¦è¥_¤j学S§B®æ医学°|ªºPeter A. Lio³Õ¤h©M约¿«ÀN´¶ª÷´µ¤j学ªºShawn Kwatra³Õ¤hªººt讲¡A¥L们将讨论·s¥X现ªº¥¼满¨¬»Ý¨D¡Bªv疗«e´º©MADªº¤À¤lÉó¨î¡C ASLANªº领导团队¡A¥]¬ACarl Firth³Õ¤h¡]创©l¤Hݺ®u执¦æ©x¡^¡BStephen Doyle¡]º®u°Ó务©x¡^¡BAlex Kaoukhov³Õ¤h¡]º®u医疗©x¡^©M¨ä¥L°ª级¬ã发ºÞ²z团队¦¨员将讨论¥Heblasakimab为ºªººÞ线组¦X¡A这¬O¤@Ïúýͦbªº·s«¬¡B¤@¬yªº单§J¶©§ÜÊ^¡A针对IL-13¨üÊ^£\1亚单¦ì¡]IL-13R£\1¡^¡A¥¿¦b开发¥Î¤_ªv疗¤¤«×¦Ü严«ªºAD¡C 这¦¸¬¡动将´£¨Ñ关¤_eblasakimab开发项¥Øªº¥þ±§ó·s¡A¥]¬A¡C eblasakimabªº独¯S§@¥ÎÉó¨îªº转¤Æ数Õu eblasakimabªº1b´Á·§©À验证¬ã¨sªº临§É数Õu eblasakimabªº发®i战²¤©M¤W¥«¸ô径·§z AD¬ã¨sªº³Ì·s进®i ¥¿¦¡ºt讲¦Z¡A将举¦æKOL¤p组讨论¡C ¦pªG·Q亲¦Û©Î¥H虚úQ¤è¦¡参¥[该¬¡动¡A请点击这¨½进¦æª`册¡C¥Ñ¤_¦W额¦³¡A请´£«e报¦W参¥[¡C¬¡动ªº«¼½©Mºt讲§÷®Æ将¦bASLANÊI¯¸ªº§ë资ªÌ关¨t³¡¤À´£¨Ñ¡Gir.aslanpharma.com/ ³q过www.DeepL.com/Translator¡]§K费ª©¡^½译 |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/22 ¤U¤È 05:47:30²Ä 5507 ½g¦^À³
|
¦h®a¹ï½Ä°òª÷³Ìªñ½Õ¾ã¤F¹ïAslnªº«ùªÑ¡C ¤ô©¤°]´I¤½¥q¦b²Ä¥|©u«×ÁʶR¤Fªü´µÄõ»sÃĤ½¥qªº·sªÑ¥÷¡A»ùȬù¬°30.2¸U¬ü¤¸¡C ¤dÁHºÞ²z¦³³d¥ô¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĪºÀY¤o¼W¥[¤F2.8%¡C Millennium Management LLC¦b¤WÓ©u«×¤SÁʶR¤F43,949ªÑ«á¡A²{¦b¾Ö¦³1,613,113ªÑ¸Ó¤½¥qªÑ²¼¡A»ùÈ80.4¸U¬ü¤¸¡C ´_¿³¬ì§Þ¦³¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĤ½¥qªºÀY¤o¼W¥[¤F574.1%¡C ´_¿³¬ì§Þ¦³³d¥ô¤½¥q²{¦b¾Ö¦³475,896ªÑ¸Ó¤½¥qªÑ²¼¡A»ùÈ23.6¸U¬ü¤¸¡A¦b¤WÓ©u«×¤SÁʶR¤F405,296ªÑ¡C ¬ü°ê»È¦æDE¦b²Ä¤@©u«×±N¨ä¦bAslan PharmPharmticalsªºÀY¤o¼W¥[¤F34.4%¡C¬ü°ê»È¦æDE¥Ø«e«ù¦³259,722ªÑ¸Ó¤½¥qªÑ²¼¡A»ùÈ23.3¸U¬ü¤¸¡A¦¹«e¸Ó¤½¥q¦b¤W¤@©u«×¤SÁʶR¤F66,544ªÑ¡C ³Ì«á¡A¹F¤Ò¯Ç¸ê¥»ºÞ²z¦³³d¥ô¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĪºÀY¤o´£°ª¤F41.0%¡C Dafna Capital Management LLC¦b¤WÓ©u«×¤SÁʶR¤F10¸UªÑ¡A²{¦b¾Ö¦³343,720ªÑ¸Ó¤½¥qªÑ²¼¡A»ùÈ17¸U¬ü¤¸¡C38.65%ªºªÑ²¼¥Ñ¾÷ºc§ë¸êªÌ©M¹ï½Ä°òª÷«ù¦³¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/8/22 ¤U¤È 05:27:35²Ä 5506 ½g¦^À³
|
±z¦ÑÀã ³oùجO°Q½×¨È·à±dªÑ²¼ªº¦a¤è ¸ò¤¤¤Ñ¦X¤@µLÃö¡AÃþ¦üªº¥u¦³fb825¸ò004³£¬OªvÀøadªº·sÃÄ n°Q½×¦X¤@½Ð²¾¾rcmoney°Q½×°Ï ¤£n¨Ó³oùضçåµû ´L«¦Û¤v¤Î§O¤H §Ú¤]¦³¶R¤¤¤Ñ¤Î¦X¤@ªÑ²¼ §Ú¥u¦b¥Lªºª©°Q½× |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/22 ¤U¤È 04:51:29²Ä 5505 ½g¦^À³
|
¦X¤@5¤ë©³¦¬½L»ù205¤¸¡A¤µ¤é200¤¸¡C ASLN5¤ë©³¦¬½L»ù0.40¬ü¤¸¡A«e¤@¦¬½L0.92¬ü¤¸¤@¡I¡A º¦´T¶W¹L125%¡C ¦]ªG¤£¬N¡I |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/8/22 ¤U¤È 04:34:32²Ä 5504 ½g¦^À³
|
¦X¤@¥[¤µ¤Ñ³o®ÚÁÙ¤£¬O½ß¦º¤@°ï¤H ¦³¤ñ¨È·à±d¦n¦h¤Ö? ªL¥S¤S«çª¾¹D¨È·à±d¤@©w¤£·|¦¨¥\,¦¨¥\«á¤£·|ÁȪº¤ñ¦X¤@¦h? ¥ú¬O¨È·à±d¨¦b¬üªÑ´N¤ñ¨¦b¥xªÑªº¦X¤@¦n ¬Ý¬ÝÀò§QÅå¤Hªº¯è¹B¤T¶¯´Nª¾¹D ¥xªÑ®Ú¥»´N¬O¯«©_ªº¥«³õ |
|
|
·|û¡GªL³Ò¬I10152784 µoªí®É¶¡:2022/8/22 ¤U¤È 04:19:31²Ä 5503 ½g¦^À³
|
§ó¥¿! ¤Z©Ò¦³¬Û¬Òµê¦k¡AY¨£½Ñ¬Û«D¬Û¡A§Y¨£¦p¨Ó¡I<ª÷è¸g> ³o¦b»¡:¨È·à±dÁ{§É¬Ý°_¨Ó¼ÖÆ[, ¨ìÀY¨Ó¥²¤@³õªÅ µL¤£ÅÜ©Ê¡AµL³æ¤@©Ê¡BµL¥D®_©Ê¡C ¹ê¬Û¬°«D¬Û¡AªÅ¬Û¡C ¥»¨ÓµL¤@ª«¡A¦ó³B·S쯮J¡H ³o´N¦b»¡:¨È·à±dªºÃÄÃÒ¥»¨Ó´N®³¤£¨ì, ¦ó¥²¥²°õµÛ¦b³oÃÄÃÒ®³¨ì¾÷²v¶W§CªºªÑ²¼! ¬Ý¬Ý¤H®a¦X¤@, USAÂå§÷¹L¤F, ¶}©l¦Y»³Ü»¶ªº ¦º¦u ¬üªÑ¨È·à±d, ËÀY¨Ó¤@³õªÅ, ¥»¨Ó´N¨S¦³ªº, ¦Û¥H¬°¦³, °õ©À¤Ó«¤£¦Ûª¾, ¤Þ¥Î¦ò¸g¨Óªí²{¥XµL°õ©À ¹ê¦b¬O¤ß¤f¤£¤@°Ú! |
|
|
·|û¡GªL³Ò¬I10152784 µoªí®É¶¡:2022/8/22 ¤U¤È 04:13:20²Ä 5502 ½g¦^À³
|
¤Z©Ò¦³¬Û¬Òµê¦k¡AY¨£½Ñ¬Û«D¬Û¡A§Y¨£¦p¨Ó¡I<ª÷è¸g> ³o´N¦b»¡:F-¨È·à±dªºÁ{§É, ¼Æ¦r¬Ý°_¨Ó¼ÖÆ[, ¨ìÀY¨Ó¥²¤@³õªÅ µL¤£ÅÜ©Ê¡AµL³æ¤@©Ê¡BµL¥D®_©Ê¡C ¹ê¬Û¬°«D¬Û¡AªÅ¬Û¡C ¥»¨ÓµL¤@ª«¡A¦ó³B·S쯮J¡H ³o´N¦b»¡:F-¨È·à±dªºÃÄÃÒ¥»¨Ó´N®³¤£¨ì, ¦ó¥²¥²°õµÛ¦b³oÃÄÃÒ®³¨ì¾÷²v¶W§CªºªÑ²¼! ¬Ý¬Ý¤H®a¦X¤@, USAÂå§÷¹L¤F, ¶}©l¦Y»³Ü»¶ªº ¦º¦uF-¨È·à±d, ËÀY¨Ó¤@³õªÅ, ¥»¨Ó´N¨S¦³ªº, ¦Û¥H¬°¦³, °õ©À¤Ó«¤£¦Ûª¾, ¤Þ¥Î¦ò¸g¨Óªí²{¥XµL°õ©À ¹ê¦b¬O¤ß¤f¤£¤@°Ú! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/22 ¤W¤È 07:45:38²Ä 5501 ½g¦^À³
|
ASLAN ³Ì¤jªÑªFTang Capital(§ë¸ê20¦h®a¤p«¬·sÃĪÑ)¡A«ùªÑªñ8%¡A5555¤dªÑADR¡A¥h¦~²Ä¤T©u¥H¨Ó¤@¦~¡A©u©u«ØÜ¡I |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/8/21 ¤U¤È 11:01:27²Ä 5500 ½g¦^À³
|
¦³¦n®ø®§5.5¤¸¶W¯Å²³æ ¥h¦~¥úÄw¸ê¦¨¥\´Nº¦¤@ªi¨ì6¤¸¦h §ó¤£¥Î»¡¸Ñª¼¦¨¥\¡B±ÂÅv¬Æ¦Ü¨ÖÁʳo¨Ç |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/21 ¤U¤È 10:24:37²Ä 5499 ½g¦^À³
|
Asln¥Ø«eªº±¡ªp»P¹L¥hªº¥_·¥¬P·¥¬°¬Û¦ü¡A ¦pªG¬Û«HAslnªº±N¨Ó¡A¨Ì¦Û¤v¯à¤O¡AÀ³¸Ó¬O¥i¥H³v¨B«Ø¥ßܦì¡A ¥Ø«eÓ¤H¥¿¦p¬O¶i¦æ¡C ·PÁ¤ѩR¤j¹ïAslnªºåªR¡I ¥H¤Î¦òªkªº¶}¥Ü¡I ·P®¦¡I |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/8/21 ¤U¤È 02:22:18²Ä 5498 ½g¦^À³
|
§Ú»{¬°¤¤¤Ñ¶°¹Î¤§¦X¤@on101 ¯à¨ú±o¬ü°êÂå§÷»{ÃÒ¡A¬O¥xÆW¥Í§Þ©Ò§ÞÂন¥\ªº¨å½d¡Aȱo®¥³ß ¨Ã¤w¦b¥xÆW¨ú±oÃÄÃÒ ¦b¥xÆW§Ú¦³¿Ë¤H¥Î¹L¡A¹ï¿}§¿¯f¨¬DFU ±wªÌ«D±`¦³®Ä¡AµL°Æ§@¥Î ´Nºâ²¤¶Q§Ú»{¬°¯à¤j¤j´î»´¯f¤HµhW «D±`ȱo |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/21 ¤W¤È 07:17:31²Ä 5497 ½g¦^À³
|
¬ü°ê¬F©²¤Î«OÀI¤½¥q©ú¥O¡A¬Û¦PÀø®Ä¤U¡A«K©yªºÃÄ¥ý¥Î¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/21 ¤W¤È 06:37:25²Ä 5496 ½g¦^À³
|
1.FDA 510K Premarket Notification, 510(k):510(k)¬O¦VFDA´£¥Xªº¤W¥««e¥Ó½Ð¤å¥ó¡A¥Øªº¬OÃÒ©ú¥Ó½Ð510(k)ªºÂåÀø¾¹§÷不»Ý¶i¦æ¤W¥««e®Öã(PMA)¥B»P¤w¦Xªk¤W¥«¤§²£«~¨ã¬Û¦P¦w¥þ©Ê¤Î¦³®Ä©Ê¡A¦¹§Y¹ê½è¬Ûµ¥©Ê(substantially equivalent)¡C 2.FDA Ãĵý ¥Ó¬dªº¬O©M¹ï·Ó组PK¡A(1)¡AÀø®ÄªºÀu¶V©Ê¡AP<0.05 (2)¦w¥þ©Ê Àø®Ä:¹ê½è¬Ûµ¥©Ê¡A YONxxx ©w»ù670¬ü¤¸/±øx4±ø¡A ¦Ó¹ï·Ó组¬O§C»ùªºÃÄ¥¬(约10¬ü¤¸/¶ôx15¶ô/¤ë¡Ñ4Ó¤ë=600¬ü¤¸)¡C»ù®æ¤ñ¬ù4/1=4¿¡C ¾P°â¬D¾Ô©Ê¬Û·í°ª¡C ¦Ó |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/21 ¤W¤È 06:04:00²Ä 5495 ½g¦^À³
|
¬ü°êFDA 510k²¤¶ www.fda510k.com.tw/index.php/intro-of-fda-510-k FDA 510(k) ¤W¥««e³qª¾¥Ó½Ð¤¶²Ð ¥ô¦ó¤H©Î»s³y°ÓYn±NÂåÀø¾¹§÷²£«~¡]Class I,II,III¡^¦æ¾P¨ì¬ü°ê¡A°£³¡¤À§K510(k)«~¶µ¤ÎµL¶·¶i¦æ¤W¥««e®Öã¡]Premarket Approval, PMA¡^¥~¡A³£¥²¶·¦b¶i¤f¬ü°ê¦Ü¤Ö90¤Ñ«e¦V¬ü°ê¹«~ÃÄ«~ºÞ²z§½¡]U.S.Food and Drug Administration,²ºÙFDA¡^´£¥X¤W¥««e³qª¾¡]Premarket Notification,PMN¡^¥Ó½Ð¡A¨ú±o¿é¤J³\¥i¡]510(k) Clearance Letter¡^¡C Premarket Notification, 510(k):510(k)¬O¦VFDA´£¥Xªº¤W¥««e¥Ó½Ð¤å¥ó¡A¥Øªº¬OÃÒ©ú¥Ó½Ð510(k)ªºÂåÀø¾¹§÷不»Ý¶i¦æ¤W¥««e®Öã(PMA)¥B»P¤w¦Xªk¤W¥«¤§²£«~¨ã¬Û¦P¦w¥þ©Ê¤Î¦³®Ä©Ê¡A¦¹§Y¹ê½è¬Ûµ¥©Ê(substantially equivalent)¡C ¥Ó½Ð¤H©Î¤½¥q¥²¶·±N±ý¥Ó½Ð¤W¥«ªºÂåÀø¾¹§÷»P¤w¦b¬ü°êFDA¤W¥«¤§¤@ºØ©Î¦hºØ¬Û¦ü²£«~°µ¤ñ¹ï¡AÃÒ©ú¨ä¨ã¹ê½è¬Ûµ¥©Ê¡C ¦Xªk¤W¥«¤§¾¹§÷¤§©w¸q¬°¦b1976年5¤ë28¤é¤§«e¦Xªk¤W¥«ªº¾¹§÷ (Preamendment device)¡A©ÎªÌ±q²ÄIIIÃþ¤¤«·s¤ÀÃþ¤JII©ÎIÃþªº¾¹§÷¡A©ÎªÌ³q¹L510(k)¥Ó½Ðµ{§ÇÃÒ©ú¨ã¹ê½è¬Ûµ¥©Êªº¾¹§÷¡A©ÎªÌ¨ÌIII ÃþÂåÀø¾¹§÷µû¦ô©w¸qªº¾¹§÷¡C³o¨ÇÂåÀø¾¹§÷³QºÙ¬°¡§predicate device(s)¡¨¡C ¥Ó½ÐªÌ¥²¶·´£¥X´yz©Êªº¸ê®Æ¡A¥²nªº®ÉÔ¡An´£¥X¥\¯à©Ê³ø§i¨ÓÃÒ©ú»Ppredicate deviceªº¹ê½è¬Ûµ¥©Ê¡C©Ò¥H510(k)ªº¸ê®Æ¬OÅã¥Ü¤ñ¹ï©Êªº¸ê®Æ¡A§Y·s¾¹§÷»Ppredicate deviceªº¹ê½è¬Ûµ¥©Ê¡C ºî¦X¥H¤W¤º®e¥iª¾¡Aµ´¤j³¡¤À²£«~¦b§¹¦¨¥ø·~µù¥U¡B²£«~¦C¦W©MGMP«~½è¨t²Î¡A§¹¦¨510¡]k¡^¥Ó½Ð«á¡A§Y¥i¤W¥«¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/8/20 ¤U¤È 04:45:06²Ä 5494 ½g¦^À³
|
To:ª©¥D¤j¤H ½Ð±N¼ÐÃD§ï¬°¥H¤U~~·PÁ±z ¡§2022¦~²×±N¨È·à±dªº¥«È±a¤W10»õ¬üª÷¡A±z´N¬O¨ô¶VªºCEO¡¨ |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/8/20 ¤U¤È 01:34:05²Ä 5493 ½g¦^À³
|
§ÚµL´c·N ·PÁÂ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/20 ¤W¤È 10:44:30²Ä 5492 ½g¦^À³
|
¦Ê¤dªkªù¡A¦PÂk¤è¤o ; ªe¨F§®¼w¡AÁ`¦b¤ß·½¡C ¤@¤Á·Ð´o¡A¥»¨ÓªÅ±I: ¤@¤Á¦]ªG¡A¬Ò¦p¹Ú¤Û¡C µL¤T¬É¥X¡AµLµÐ´£¨D¡C ¤H»P«D¤H¡A©Ê¬Û¥µ¥¡C ¥ô¤ß¦Û¦b¡A²ö§@Æ[¦æ¡A ¿º¿ºµLê¡A¥ô·NÁa¾î¡C ¦æ¦í§¤ª×¡AIJ¥Ø¹J½t¡A §Ö¼ÖµL¼~¡A¬G¦W¬°¦ò¡C <¥|×ùD«H> |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/20 ¤W¤È 10:40:06²Ä 5491 ½g¦^À³
|
©ú¤ß¨£©Ê ¤@¡B©Ò¿×¡u©ú¤ß¡v§Y¬O¡Ð¡uÃѦۥ»¤ß¡v¡A»{ÃѦۤv¥»¨Óªº¤ß¡C ¬O¤ßÅý±z¹Lªº ¡@¡@¦Û¦b¡B§Ö¼Ö¡B·Ð´o¡Bµh W¡B¬Ò¥ÑÍ¢¨M©w¡C ±z¥i¥H¦¨¸t¦¨¤Z¡B¦¨´¼¦¨·M¡A ¡@¡@¡@¡@³£¬O¤ßªº§@¥Î¡C ¤G¡B©Ò¿×¡u¨£©Ê¡v§Y¬O¡Ð¡u¨£¦Û¥»©Ê¡v¡AÅéÃÒ¦Û¤v¥»¨Óªº¦ò©Ê¡A¥»©Ê¬O¦ò¡A¬G¤ê¡G¡u¨£©Ê¦¨¦ò¡v¡C ¤F¸Ñ¦Û¤v¡A´N¯àÅ鮩¦ò©Ê¡C ¤ßªÌ¥Í©R¤§¡u§@¥Î¡v¡A©ÊªÌ¥Í©R¤§¡u¥»Åé¡v¡A ¤F¸ÑÅé¥Î¡A«Kª¾¤@¤Á¡A¦W¬°¡u©ú¤ß¨£©Ê¡v ¤T¡B¸U¬Û¬ÒªÅ©Ê¡A¹ê¬Û¬OªÅ¬Û¡A°ß¥»©Ê(¤£µÛ¬Û¤§¤ß)¤£ªÅ¡C ¥|¡B¦p¦ó¨£¦Û©Ê¡H ²z¸Ñ¤Z©Ò¦³¬Û¬Òµê¦k¡A¥»¨ÓµL¤@(¯u¹ê)ª«¤§¬Û¡A ¦]¦Ó¨£¬Û¦Ó¤ß¦Û¤£µÛ¡A§Y¨£ªÅ¬Û¡A§Y¨£¦p¨Óªk¨¡A§Y¨£¥»©Ê¡C §Y¨£¦Û©Ê¦ò¡I ¤¡B®©©Ê¤§¤T¼w(±o) : <¯ëY¼w¡Aªk¨¼w¡B¸Ñ²æ¼w> 1¡Bªk¨¼w¡A¬°¦ò¤§¥»Åé¡A¥H±`¦í¤£·À¤§ªk©Ê¬°¨ªÌ¡C 2¡B¯ëY¼w¡A¯ëYĶ¤ê´¼¼z¡Aªk¬Û¦p¹êı¤FªÌ¡C 3¡B¸Ñ²æ¼w¡A»·Â÷¤@¤Á¤§Ã´¿£¡A¦Ó±o¤j¦Û¦bªÌ¡C ¦¹¤TªÌ¦U¦³±`¼Ö§Ú²b¤§¥|¼w¡A¬G¦W¤T¼w |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/20 ¤W¤È 08:35:28²Ä 5490 ½g¦^À³
|
m.youtube.com/watch?v=_gveT-SqjrE ª÷è¸gªº¤Q¥yºë¸Ñ¡K¡K¡K¡K±o¹D¦æªÌ¤§ºë¸Ñ¡C ¨C¤@¥y¬Ò¥i§U¤¯ªÌ©ú¤ß¨£©Ê¡I¨£©Ê¦¨¦ò¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/20 ¤W¤È 08:25:30²Ä 5489 ½g¦^À³
|
¤Z©Ò¦³¬Û¬Òµê¦k¡AY¨£½Ñ¬Û«D¬Û¡A§Y¨£¦p¨Ó¡I<ª÷è¸g> 0.355 0.912 5.000 30.00 50.00 µL¤£ÅÜ©Ê¡AµL³æ¤@©Ê¡BµL¥D®_©Ê¡C ¹ê¬Û¬°«D¬Û¡AªÅ¬Û¡C ¥»¨ÓµL¤@ª«¡A¦ó³B·S쯮J¡H ¦]ªG¤£ÒΡI ¦p¨Ó»¡ºÖ¼w¡A§Y«DºÖ¼w¡A¬O¦WºÖ¼w¡I |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/20 ¤W¤È 07:41:53²Ä 5488 ½g¦^À³
|
³o¥u¬O¥H5¦Ê¦h%¨Ó°µ°²³]¡A¤£¬O»¡asln¥u¦³5.5¤¸¡F 5.5¤¸¬O¥Ø«e¬ã¨s¾÷ºc¸û´¶¹Mªº¦@ÃÑ»ù¡A ¦A²Âªº¤]ª¾¹DY±ÂÅv«áªº»ù®æµ´«D¦p¦¹¡C ¨S¤H§Æ±æ¥u¦³5.5¤¸¡A¤ß¯Ý¶}ÁïÂI¡A ¤£n»~·|§O¤Hªº¦n·N¡I |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/8/19 ¤U¤È 11:54:07²Ä 5487 ½g¦^À³
|
¦b³oùتº·à¤Í¡A§ë¸ê¨È·à±d¤w«Ü¦h¦~ ±q¥xÆW¾Ô±Ñ«á¡A§ïÅܾԳõ¨ì¬ü°ê «Ü¦h¤H¤w¶Ë²ªõìõì¡A¦ý«o¨¸g¦Ê¾Ô ¤ß²z«Ø³]¤]¤w¸g«Ü¦n¡A ¸m©ó¦º¦a¦Ó«á¥Í ¤£¤Ó¦b·N¤w§ë¤J¦h¤Ö¸êª÷ ¦ý¬O§Ú̥ؼлù¡Aµ´«D5¶ô¦h¬üª÷ ¯¬çĤj®a |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/19 ¤U¤È 09:30:56²Ä 5486 ½g¦^À³
|
®¶¾Ä¤@¤U¤h®ð ¡§¤µ¦~7¤ë¡A¬ü°ê«n¥[¦{¤j¾Ç¥Í¡B¦~¶È20·³ªº¦ò¨½°Ò¡]Jake Freeman¡^³z¹L¨ä³]¥ßªº¸ê²£ºÞ²z¤½¥q¥H¨CªÑ¬ù5.5¬ü¤¸¶R¤J¤F3B®a©~550¸UªÑ¡A¥»©P¤G¥L¦b³oÀɪѲ¼¼Éº¦«á¥þ³¡¥X²M¡A¤jÁÈ1.1»õ¬ü¤¸¡¨ ⋯⋯⋯⋯⋯⋯⋯⋯ 5.5¬ü¤¸¶R¤J¡A°²³]¦b³Ì°ªÂI30¬ü¤¸½æ¥X¡A¤j¬ùÀò§Q545%¡C ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ Asln⋯⋯¦@Ãѥؼлù5.5¬ü¤¸¡A¤]¬O¤£¹N¦hÅý¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/19 ¤U¤È 06:57:34²Ä 5485 ½g¦^À³
|
ASLAN004 2023¦~ 3/4¤ë¼Ú¬w°Ï±ÂÅv,¨ÌLebrekiumab´©Åvª÷¼ÒÀÀ : 1¿ ±ÂÅvª÷ : 1.98(«eª÷+¤T´Á+¨úµý+°Ó·~¤Æ)+2.1(5/30*12.5¡K¡K5»õ¬ü¤¸销°â°ò¦/¾P°â¨½µ{ª÷)¡A约4»õ¬ü¤¸ 2¿ ,约8»õ¬ü¤¸ 3¿ ,约12»õ¬ü¤¸ ------------------------------- ¤@.©ú¦~2023¦~3/4¤ë ASLAN004 AD 2b¸Ñª¼ ¹w¦ô¥Ø¼ÐÀø®Ä EASI 75= 73% VS 15%(¹ï·Ó²Õ), 73%-15%=58%, 73%/15%=4.9 ¼Ú¬w°Ï±ÂÅv¨ÌLebrekiumab´©Åvª÷,¼ÒÀÀ 1¿ ±ÂÅvª÷1.98+2.1(5/30*12.5¡K¡K5»õ¬ü¤¸销°â°ò¦)¡A约4»õ¬ü¤¸ 2¿ 约8»õ¬ü¤¸ 3¿ 约12»õ¬ü¤¸ +¾P°â¤À¼í10%-20% ¤G. Lebrikiumab 2019/02/07 2b¸Ñª¼, EASI 75= 60% VS 24%(¹ï·Ó²Õ), 60%-24%=36%, 60%/24%=2.5 ¤G.1¡B®Ú¾ÚLebrikiumab³Q±ÂÅvAlmirall ¼Ú¬w°Ï ¦X约/2019/02/14 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C ¡K¡K«eª÷+¶}µoùµ{ª÷1.98»õ¬ü¤¸+12.5»õ¬ü¤¸¡A³Ì°ª¾P°âùµ{ª÷(30»õ¬ü¤¸³Ì°ª¾P°â) +¾P°â¤À¼í10%-20% ±ÂÅvª÷1.98+2.1(5/30*12.5¡K¡K5»õ¬ü¤¸销°â°ò¦)¡A约4»õ¬ü¤¸¡C 4»õ¬ü¤¸/20%(欧¬w区)=20»õ¬ü¤¸¡K¡K¾ãÅéLebrikiumab±ÂÅvª÷AD»ùÈ¡K¡KB Lebrikizumab ¼Ú¬w°Ï±ÂÅv¦X¬ù(2019/02) www.sec.gov/edgar/search/?r=el#/q=Dermira ùµ{ª÷(1)3000+(1.1)5000+(2)3000+(3)4000+(4)4500=19,500(¸U¬ü¤¸) +(5)®ÚÕulebrikizumab¦b欧¬wªº¦~净销°â额达¨ì8600ÉE¬ü¤¸¦Ü30亿¬ü¤¸ªº¬Y¨Ç门槛¡A ¤ä¥I³Ì¦h12.5亿¬ü¤¸ªº´Ú项¡A¨C笔ýͦbªº¨½µ{¸O¦¡¥I´Ú约¥eÓì¥Î净销°â额门槛ªº7%¦Ü15%¡F¥H¤Î ¾P°â¤À¼í(6)°ò¤_欧¬wlebrikizumab¦~净销°â额¬Û应S围ªº层级¦Ê¤À¤ñS围ªº¯S许权¨Ï¥Î费¤ä¥I¡A¨ä¤¤²Ä¤@¦~净销°â额层级ªº¦Ê¤À¤ñ从§C两¦ì数开©l¡A³Ì°ª净销°â额层级ªº¦Ê¤À¤ñ¼W¥[¨ì§C¤G¤Q¦ì数¡C ®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C (1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C (1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C (2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C (3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C (4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C (5)®ÚÕulebrikizumab¦b欧¬wªº¦~净销°â额达¨ì8600ÉE¬ü¤¸¦Ü30亿¬ü¤¸ªº¬Y¨Ç门槛¡A¤ä¥I³Ì¦h12.5亿¬ü¤¸ªº´Ú项¡A¨C笔ýͦbªº¨½µ{¸O¦¡¥I´Ú约¥eÓì¥Î净销°â额门槛ªº7%¦Ü15%¡F¥H¤Î (6)°ò¤_欧¬wlebrikizumab¦~净销°â额¬Û应S围ªº层级¦Ê¤À¤ñS围ªº¯S许权¨Ï¥Î费¤ä¥I¡A¨ä¤¤²Ä¤@¦~净销°â额层级ªº¦Ê¤À¤ñ从§C两¦ì数开©l¡A³Ì°ª净销°â额层级ªº¦Ê¤À¤ñ¼W¦Ü20% ------------------------------------------- ¤T.¦X¤@ªºFB825 ¥þ²y±ÂÅvLEO ,±ÂÅvª÷ : 5.3»õ¬ü¤¸(2b §t¥H«áªºÁ{§É°õ¦æ/¶O¥Î¬ÒÂkLEO) ------------------------------------------ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/19 ¤W¤È 11:38:57²Ä 5484 ½g¦^À³
|
www.sec.gov/edgar/search/?r=el#/q=Dermira §¨Ó¦b2019¦~2¤ëDerm¤½¥qªºLebrikizumab AD 2b ¸Ñª¼«á¶}©l±µÄ²¬ã¨s¡A½Í§P¡A¬ù10Ó¤ëÂù¤è¦P·N¨ÖÁʮסC ⋯⋯¤@¤@¤@ Derm¤½¥q(Lebrikizmab),2020.2.10 ³Q§¨Ó11»õ¬ü¤¸¨ÖÁʪºµû¦ô³ø§i¡C ¦ôp¥X¨C¦~ªº¦¬¤J¡B¦¨¥»¡B¬Õ¾l¡B²{ª÷¬y¤J«á¡A ¦A§é现ªº¦ô»ùªk¡C ¥t°Ñ¦ÒªÑ²¼¥«»ù¡A¤À§é®vªº¥Ø¼Ð»ù¡A¥«³õ¨ÖÁÊ»ù¡A ȱo¦U¦ì¤j¤j²`¤J¬ã¨s¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/8/19 ¤W¤È 11:21:50²Ä 5483 ½g¦^À³
|
ÅÞ¿è«ä¦ÒÃD¡I º¥ý¤Þ¥Î 1. ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/15 ¤U¤È 12:48:18 ¼Ú¬w°Ï±ÂÅvµ{§Ç¥i¯à¤xû£°Ê¡A°t¦X9¤ë7-10¤é¦b¼Ú¬w¥Ö½§Âå¾Ç¨ó·|µoªí¤T½g½×¤å¡A¤~¯à¦b¸Ñª¼«á°¨¤Wñ¸p¡C 2. ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/17 ¤U¤È 12:13:49 Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ) Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7) ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô 73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9) -----------------------------------------ÅÞ¿è«ä¦Ò----------------------------------------- ºî¤W¡A ¨È·à±d¦Û¤v·|¥h§ä¤jÃļt½Í±ÂÅv¡A§ä´X®a?3®a©Î5®a©Î¡K¡K ±µ¤U¨Ó A.¦b9/7~9/10¸q¤j§Q¦ÌÄõ½×¾Â«á¡A¦UÃļt¤ß¸Ì¦³©³¡A¬On³Q±ÂÅv©Î¨Ö¨È·à±d¤F¡C B.«á±ÁÙ¦³9/15ªº¯Ã¬ùR&D day C.¦~©³´Á¤¤³ø§i(9/26«eªÑ»ù¤W1¬ü¤¸³sÄò10¤Ñ´N¤£¥Î´¦ÅS´Á¤¤³ø§i¤F) D.112¦~3/4¤ë¥¿¦V¸Ñª¼ ¾ã¦XA.B.C.D. ©ú¦~3/4¤ë¸Ñª¼«á¡A¥u¦³¨È·à±d¦Û¤v§äªºÃļt¦³¿ìªk·í¤U°µ¨Mµ¦¡A ¬On³Q±ÂÅv©Î¨Ö¨È·à±d¤F¡C ¹ï«á¨Ó¤~ª¾¹DÅåÆv¸Ñª¼¼Æ¾Úªº¤jÃļt¤£¤½¥¡K¡K ¥u¯à´Á«Ý²{¶¥¬q¨È·à±d§äªº¼Ú¬w°Ï±ÂÅv¼t°Ó³£¬Oª¾¦W¤jÃļt¡C (²{¶¥¬q¤jÃļt·|²z§A³o¨S¨SµL»Dªº¤p¤½¥q) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/18 ¤W¤È 10:51:03²Ä 5482 ½g¦^À³
|
«Øij¤½¥q ¤T´ÁÁ{§É ¼W¥[Dupilumab ¤@²ÕÁ{§É,¦¬Ó100¤H´N¨¬¤w¥´±ÑDupilumab. P=0.00015 EASI75 PK ¼ÒÀÀ 1.ASLAN004 73% VS Dupilumab 51% °²³]N=200:100 ,(100 ¦¬®×Ó¤¤¤ß) x^2 14.31176384 P= 0.00015 «Øij¤½¥q ¤T´ÁÁ{§É ¼W¥[Dupilumab ¤@²ÕÁ{§É,¦¬Ó100¤H´N¨¬¤w¥´±ÑDupilumab. CIBINQO ¤fªAÃĤT´Á¦³PK Dupilumab,¦Ó«ÅºÙCIBINQOÀø®ÄÀu©óDupilumab. ¥i±¤CIBINQO¦³ÄY«°Æ§@¥Î,¦Ó³QFDA¦C¬°¥Íª«»s¾¯ªº«á½u虊. ------------------------------------------------------- EASI75 Àø®Ä PK---×1 ¤@.Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ) Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7) ¤G.Lebrikizumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) V 1 59%(¹êÅç²Õ) VS 16%(¹ï·Ó²Õ)(59%-16%=43%, 59%/16%=3.7) V 2 51%(¹êÅç²Õ) VS 18%%(¹ï·Ó²Õ)(51%-18%=33%, 51%/18%=2.8)---¦]MOA¬G,¤£Ã©w¤§Àø®Ä ¤T.ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô 73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9) |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/8/17 ¤U¤È 02:18:47²Ä 5481 ½g¦^À³
|
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c ²³ø²Ä16¶004¹ï©óIL-13R£\1ªºµ²¦X¤O¤j©óIL-13¨üÅé¬ù60¿¡A³o¼Ëªº¯SÂI¬O¥i¯àĹ¹L§ù¥²ª¢ªº§Q¾¹¡AY¥H¤U¨â²Õ¸ÕÅç¯à§e²{ªvÀøªº²Îp·N¸q¨Ã¦bEASIĹ¹L¦Ñ§ù¡A´N¯à·íKing of A.DªvÀø~~~´Á«Ý2B´Á¤¤¼Æ¾Ú¤Î¸Ñª¼«á³o¨â²Õ¸ÕÅ窺¤ÀªR~~~¥[ªoªü·à Experimental-3: ASLAN004 400 mg every four weeks (q4w) ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14. Experimental-4: ASLAN004 600 mg q4w ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/17 ¤U¤È 12:13:49²Ä 5480 ½g¦^À³
|
EASI75 Àø®Ä PK---×1 ¤@.Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ) Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7) ¤G.Lebrikizumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) V 1 59%(¹êÅç²Õ) VS 16%(¹ï·Ó²Õ)(59%-16%=43%, 59%/16%=3.7) V 2 51%(¹êÅç²Õ) VS 18%%(¹ï·Ó²Õ)(51%-18%=33%, 51%/18%=2.8)---¦]MOA¬G,¤£Ã©w¤§Àø®Ä ¤T.ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô 73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/17 ¤U¤È 12:05:19²Ä 5479 ½g¦^À³
|
EASI75 Àø®Ä PK ¤@.Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ) Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7) ¤G.Lebrikizumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) V 1 59%(¹êÅç²Õ) VS 16%(¹ï·Ó²Õ)(59%-16%=43%, 59%/16%=3.7) V 2 51%(¹êÅç²Õ) VS 19%%(¹ï·Ó²Õ)(51%-19%=32%, 51%/19%=2.7)---¦]MOA¬G,¤£Ã©w¤§Àø®Ä ¤G.ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô 73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/17 ¤W¤È 09:06:11²Ä 5478 ½g¦^À³
|
ASLAN004 2b EASI75Àø®Ä ³]p¦ô: 1B EASI75 Àø®Äì³]p¦ô: = A²Õ(°ò½u/¤¤µý=EASI31):11¤H/16¤H=69% + B²Õ(°ò½u/»´¯gEASI=19): 5¤H/6¤H=83%--) A²Õ+B²Õ=¦Xp16/22=73% ---¤£±M·~ªº¦¬¤J«D¶Ç²ÎAD , 6¦ì¹êÅç²Õ±wªÌ+3¦ì¹ï·Ó²Õ, ¨Ï±o¸Ó²Õ6¦ì¹êÅç²Õ±wªÌ EASI75 Àø®Ä=0%. ¨Ï±oITT¤ÀªR EASI75 =¹êÅç²Õ(11+0)/22=50% VS ¹ï·Ó²Õ13% --------------------------------------- 2022¦~6¤ë7¤é ASLN CEO «Å§i: 2bÁ{§É¿z¿ï®É±N¥ý±Æ°£«D¶Ç²ÎAD±wªÌn©M Dupilumab ¤T´ÁÁ{§É¤@¼Ëªº±wªÌ²Õ¦¨µ²ºc(¥i¯à¥ý±Æ°£«D¶Ç²ÎAD±wªÌ,§CEASI/§CIgE/§CTRAC²Õ¥u¦³0%~3%ªº¾÷²v). ¦]¦¹2023¦~ASLAN004 AD 2b ¸Ñª¼, Y°ò½u¥§¡EASI27~30¤§³]p©Û¶Ò(¦PASLAN004 1b/¦PLebrikizumab 2b) EASI75 ªº¥Ø¼ÐÀø®Ä¬ù73% VS ¹ï·Ó²Õ15%.(¹êÅç²ÕÀø®ÄÀu¹ï·Ó²Õ 73%-15%=58%, 73%/15%=4.9¿) Lebrikizumab 2b, EASI75=60% VS 24%(¹ï·Ó²Õ), (¹êÅç²ÕÀø®ÄÀu¹ï·Ó²Õ 60%-24%=36%, 60%/24%=2.5¿) Dupilumab ¤T´Á¹êÅç²Õ §CTRAC²Õ(°ò½uEASI25), Àø®Ä¥§¡EASI°´T77%(©Û¶Ò¤H¼Æ¤ñ1/3) ¤¤TRAC²Õ(°ò½uEASI31), Àø®Ä¥§¡EASI°´T67%(©Û¶Ò¤H¼Æ¤ñ1/3) °ªTRAC²Õ(°ò½uEASI41), Àø®Ä¥§¡EASI°´T66%(©Û¶Ò¤H¼Æ¤ñ1/3) ------------------------------------------ ¥§¡ (°ò½uEASI31),Àø®Ä¥§¡EASI°´T70% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/17 ¤W¤È 07:26:40²Ä 5477 ½g¦^À³
|
www.sec.gov/edgar/search/?r=el#/q=Dermira Derm¤½¥q(Lebrikizmab),2020.2.10 ³Q§¨Ó11»õ¬ü¤¸¨ÖÁʪºµû¦ô³ø§i¡C ¦ôp¥X¨C¦~ªº¦¬¤J¡B¦¨¥»¡B¬Õ¾l¡B²{ª÷¬y¤J«á¡A ¦A§é现ªº¦ô»ùªk¡C ¥t°Ñ¦ÒªÑ²¼¥«»ù¡A¤À§é®vªº¥Ø¼Ð»ù¡A¥«³õ¨ÖÁÊ»ù¡A ȱo¦U¦ì¤j¤j²`¤J¬ã¨s¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/16 ¤U¤È 04:22:37²Ä 5476 ½g¦^À³
|
Large investors have recently bought and sold shares of the company. Waterfront Wealth Inc. acquired a new position in shares of ASLAN Pharmaceuticals in the 4th quarter valued at $302,000. Millennium Management LLC boosted its position in shares of ASLAN Pharmaceuticals by 2.8% in the 2nd quarter. Millennium Management LLC now owns 1,613,113 shares of the company¡¦s stock valued at $804,000 after purchasing an additional 43,949 shares during the period. Renaissance Technologies LLC lifted its stake in ASLAN Pharmaceuticals by 574.1% in the 2nd quarter. Renaissance Technologies LLC now owns 475,896 shares of the company¡¦s stock worth $236,000 after acquiring an additional 405,296 shares in the last quarter. Bank of America Corp DE lifted its stake in ASLAN Pharmaceuticals by 34.4% in the 1st quarter. Bank of America Corp DE now owns 259,722 shares of the company¡¦s stock worth $233,000 after acquiring an additional 66,544 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of ASLAN Pharmaceuticals during the 4th quarter worth about $89,000. Institutional investors own 38.65% of the company¡¦s stock. ¤j«¬§ë¸êªÌ³Ìªñ¶R½æ¤F¸Ó¤½¥qªºªÑ²¼¡C ¤ô©¤°]´I¤½¥q¦b²Ä¥|©u«×¦¬ÁʤF»ùÈ30.2¸U¬ü¤¸ªºªü´µÄõ»sÃĤ½¥qªº·sªÑ²¼¡C ¤dÁHºÞ²z¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĤ½¥qªºªÑ²¼ÀY¤o¼W¥[¤F2.8%¡C Millennium Management LLC²{¦b¾Ö¦³1,613,113ªÑ¸Ó¤½¥qªºªÑ²¼¡A»ùÈ804,000¬ü¤¸¡A¦b¦¹´Á¶¡¤SÁʶR¤F43,949ªÑ¡C ´_¿³¬ì§Þ¦³³d¥ô¤½¥q¦b²Ä¤G©u«×¼W«ù¤F574.1%ªºªü´µÄõ»sÃĪѥ÷¡C ´_¿³¬ì§Þ¦³³d¥ô¤½¥q¦b¤WÓ©u«×¼W«ù¤F405,296ªÑ«á¡A²{¦b¾Ö¦³475,896ªÑ¸Ó¤½¥qªÑ²¼¡A»ùÈ23.6¸U¬ü¤¸¡C ²Ä¤@©u«×¡A¬ü°ê»È¦æ(Bank Of America Corp DE)¼W«ù¤Fªü´µÄõ»sÃĤ½¥q34.4%ªºªÑ¥÷¡C¬ü°ê»È¦æDE¥Ø«e«ù¦³259,722ªÑ¸Ó¤½¥qªÑ²¼¡A»ùÈ23.3¸U¬ü¤¸¡A¦¹«e¸Ó¤½¥q¦b¤W¤@©u«×¼W«ù¤F66,544ªÑ¡C³Ì«á¡AGSA Capital Partners LLP¦b²Ä¥|©u«×ÁʶR¤F»ùȬù8.9¸U¬ü¤¸ªºªü´µÄõ»sÃĤ½¥qªº·sªÑ¥÷¡C¾÷ºc§ë¸êªÌ«ù¦³¸Ó¤½¥q38.65%ªºªÑ¥÷¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/16 ¤U¤È 03:52:38²Ä 5475 ½g¦^À³
|
¥¼¨Óý³Ý¤ÎEOE¡K¡KAD¥H¥~ªºASLAN004¾AÀ³¯gªº±ÂÅv¡C ¥i¥H参¦Ò¥H¤ULebrikizumab 2.2017/08/08 ±qAD¤G´ÁÁ{§É¶}©l°µ°_ (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB. |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/8/16 ¤U¤È 03:30:39²Ä 5474 ½g¦^À³
|
¨ä¹êTang Capital¤w¸g¬O³Ì¤jĹ®a¤F¡C¡C¡C ASLN³Ì¤jªÑªFTang Capital²Ä¤G©u¦A¶R¶i2268¤dªÑADR¡AÁ`«ùªÑ¨Ó¨ì5555¤dªÑADR,«ùªÑ约8%.(¥h¦~9¤ë1b¸Ñª¼«á¶}©l¶R¶i¡A¥§¡¦¨¥»1.36¬ü¤¸/ªÑ¡C °²³]Tang Capital¦A¶R¶i5555¤dªÑADR(ªÑ»ù5¤¸)«ùªÑ¹F¨ì约16% Á`¥§¡¦¨¥»¤]¤~3.18¤¸¡A¦^¨ì¥h¦~9¤ë°_¶^ÂI¦Ó¤w¡C ¦ý«ùªÑ16%¡A¦b¨È·à±d¸gÀç¹Î¶¤¸Ì±¬O§_Á¿¸Ü¥i¥H¤jÁn¤F¡C¡C¡C¡C »¡¤£©w¤§«á¨È·à±dn³Q¨ÖÁÊ¡A±onTang Capital¦P·N¡A¤~ºâ¼Æ¡C¡C¡C¡C¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/16 ¤U¤È 03:17:12²Ä 5473 ½g¦^À³
|
¼Ú°Ï±ÂÅv¤Î¸êª÷ª¬ªp¸Õºâ:¡K¡K×1 ¨Ì¾ÚLebrikizmab ¼Ú°Ï±ÂÅv Almirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C ®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C (1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C (1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C ¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸. ¨Ì¥Ø«eAD±ÂÅv¦æ±¡ASLAN004¥i¯ànLebrikizmab*3¿. ----(2019/02 Dupilumab ³Ì°ª¾P°â¦ô50»õ¬ü¤¸, 2022¦~Dupilumab ³Ì°ª¾P°â¦ô140»õ¬ü¤¸,2022¦~¦ô¥i¹F80»õ¾P°â) AD¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸*3=2.4»õ¬ü¤¸. ¦©°£¤ä¥ICSL 3000¸U¬ü¤¸,¤Î2023¦~¦ô6000¸U¬ü¤¸ªºÁ{§ÉºÞ¾P. 2023¦~ªºASLN µ|«eÀç¾l¦ô¥i¦³1.5»õ¬ü¤¸.¡K¡KC ================================= (2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C (3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C (4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C ¥H¤W1.15»õ¬ü¤¸ *3=3.45»õ¬ü¤¸----ASLN 欧·ùº¦¸°Ó业¤Æ销°âASLAN004 ---¦©°£¤ä¥ICSL 9250¤d¸U ---2.5250»õ¬ü¤¸ ³Ñ¾l.-----A --3´ÁADÁ{§É¶O¥Î¬ù4»õ¬ü¤¸+3¦~ºÞ¾P5000¸U+¨ä¥L¤G´ÁASLN004/ASLNA003¦ô1.5»õ¬ü¤¸.=¦Xp6»õ¬ü¤¸----B B-A-C=2.0»õ¬ü¤¸¯Ê¤f,©ú¦~¸Ñª¼«á¤½¶}¥«³õ¶Ò¸ê©Î¨p¶Ò. ¥H¤W¬°Ó¤H¦ôºâ2024/2025/2026¦~ªºASLN¸êª÷¶i¥X. ±ÂÅvª÷ªº¤j¤p©M¶Ò资³W¼Ò¤j¤p¬ÛÃö¡C ¥H¤W¶È¹ïAD¡A¨ä¥L¾AÀ³¯g¦û¬ùAD¥«³õªº80%¡A¦ý±N¥u¶i¤J¤G´Á ý³Ý¡AEOE¡A³o¤G项¦ôp·|¥ý°µ¡A9¤ë15¤éR&D day ´Nª¾¹D¤F¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/16 ¤W¤È 10:49:02²Ä 5472 ½g¦^À³
|
¼Ú°Ï±ÂÅv¤Î¸êª÷ª¬ªp¸Õºâ: ¨Ì¾ÚLebrikizmab ¼Ú°Ï±ÂÅv Almirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C ®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C (1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C (1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C ¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸. ¨Ì¥Ø«eAD±ÂÅv¦æ±¡ASLAN004¥i¯ànLebrikizmab*3¿. ----(2019/02 Dupilumab ³Ì°ª¾P°â¦ô50»õ¬ü¤¸, 2022¦~Dupilumab ³Ì°ª¾P°â¦ô140»õ¬ü¤¸,2022¦~¦ô¥i¹F80»õ¾P°â) AD¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸*3=2.4»õ¬ü¤¸. ¦©°£¤ä¥ICSL 3000¸U¬ü¤¸,¤Î2023¦~¦ô6000¸U¬ü¤¸ªºÁ{§ÉºÞ¾P. 2023¦~ªºASLN µ|«eÀç¾l¦ô¥i¦³1.5»õ¬ü¤¸. ================================= (2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C (3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C (4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C ¥H¤W1.15»õ¬ü¤¸ *3=3.45»õ¬ü¤¸----ASLN 欧·ùº¦¸°Ó业¤Æ销°âASLAN004 ---¦©°£¤ä¥ICSL 9250¤d¸U ---2.5250»õ¬ü¤¸ ³Ñ¾l.-----A --3´ÁADÁ{§É¶O¥Î¬ù4»õ¬ü¤¸+3¦~ºÞ¾P5000¸U+¨ä¥L¤G´ÁASLN004/ASLNA003¦ô1.5»õ¬ü¤¸.=¦Xp6»õ¬ü¤¸----B B-A=3.5»õ¬ü¤¸¯Ê¤f,©ú¦~¸Ñª¼«á¤½¶}¥«³õ¶Ò¸ê©Î¨p¶Ò. ¥H¤W¬°Ó¤H¦ôºâ2024/2025/2026¦~ªºASLN¸êª÷¶i¥X. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/8/16 ¤W¤È 10:13:03²Ä 5471 ½g¦^À³
|
ÕY¸Ñª¼«á¨ä¹êÅç²Õ3¡A¯à¦³°ª©ó§ù¥²ª¢ªºÀø®Ä¤Î§C°Æ§@¥Î¡A¬Û«H¥«È·|¤ñ10»õ¬ü¤¸°ª¤W¤@¿¤£¤î~~~¥[ªoªü·à Experimental 3: ASLAN004 400 mg every four weeks (q4w) ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/16 ¤W¤È 07:35:35²Ä 5470 ½g¦^À³
|
©ú¦~3/4¤ë¸Ñª¼¦¨¥\¡I Y¼Æ¾Ú¶W¶VDupilumab 3´Á¨C¤G¶g¤@°w¡A40% EASI75 69%(ASLAN004) vs 48%(dupilumab) 69%/48%=142% Y©M¨é°Ó½Í¦nªº¥]¾P»ù6.4¬ü¤¸/ªÑ(¥«»ù8¬ü¤¸) Y§A¬OTang Capital CEO , §A·|¦b¸Ñª¼«e¥«³õ§C»ù¦¬ÁÊ ASLN¡HÁÙ¬O参¥[¨p¶Ò¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/16 ¤W¤È 04:44:00²Ä 5469 ½g¦^À³
|
whalewisdom.com/stock/asln ASLN³Ì¤jªÑªFTang Capital²Ä¤G©u¦A¶R¶i2268¤dªÑADR¡AÁ`«ùªÑ¨Ó¨ì5555¤dªÑADR,«ùªÑ约8%.(¥h¦~9¤ë1b¸Ñª¼«á¶}©l¶R¶i¡A¥§¡¦¨¥»1.36¬ü¤¸/ªÑ¡C ·s¥[©Y²H°¨¿ü«ùªÑ¨S°Ê¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/15 ¤U¤È 07:33:15²Ä 5468 ½g¦^À³
|
www.nejm.org/doi/full/10.1056/nejmoa1610020 Dupilumab ¹Ï¤G¡A¤T´ÁÁ{§É¼Æ¾Ú¡CÁÍ¶Õ¹Ï ¤j¬ù12¶gªvÀø¥i±µªñ100%EASIªº¥§¡Àø®Ä¡C ¤j¬ù8¶gªvÀø¥i¹F90%ªºEASI¤Îpruritus NRS ªº¥§¡Àø®Ä¡C¡]¥iª¾EASI75ªº¥¼¸Ñª¼ªº¤ñ¨Ò¡^ ¤j¬ù4¶gªvÀø¥i¹F70%ªºEASIªº¥§¡Àø®Ä¡A¥§¡¥i°EASI50%¡C 5¤ë7¤é¶}36Ó¡]36/59=61%¡^¤¤¤ß¥[3Ó¤ë¡A¬ù¸g¦Ü¤Ö¤@Ó¤ëªvÀø¡A8¤ë7¤é¤j¬ù¥iª¾¬O§_¹F°EASI50¡AºÙ¦³¤ÏÀ³ªº¥¼¸Ñª¼ªº¤ñ¨Ò¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/15 ¤U¤È 07:09:14²Ä 5467 ½g¦^À³
|
Aslan Pharmaceuticals Price Target Cut to $7.00/Share From $8.00 by HC Wainwright & Co. ªü´µÄõ»sÃĪº¥Ø¼Ð»ù³QHC Wainwright&Co.±q¨CªÑ8.00¬ü¤¸¤U½Õ¦Ü7.00¬ü¤¸¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/15 ¤U¤È 07:01:31²Ä 5466 ½g¦^À³
|
Aslan Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co. HC Wainwright&Co.¹ïªü´µÄõ»sÃĤ½¥qºû«ù¡¨¶R¶i¡¨«Øij. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/15 ¤U¤È 01:42:16²Ä 5465 ½g¦^À³
|
www.nejm.org/doi/full/10.1056/nejmoa1610020 Dupilumab ¹Ï¤G¡A¤T´ÁÁ{§É¼Æ¾Ú¡CÁÍ¶Õ¹Ï ¤j¬ù8¶gªvÀø¥i¹F90%ªºEASI¤Îpruritus NRS ªºÀø®Ä¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/15 ¤U¤È 12:48:18²Ä 5464 ½g¦^À³
|
¼Ú¬w°Ï±ÂÅvµ{§Ç¥i¯à¤xû£°Ê¡A°t¦X9¤ë7-10¤é¦b¼Ú¬w¥Ö½§Âå¾Ç¨ó·|µoªí¤T½g½×¤å¡A¤~¯à¦b¸Ñª¼«á°¨¤Wñ¸p¡C ³o¼Ë1.25»õ¬ü¤¸¡]3000¸U¬ü¤¸¤T´ÁÁ{§É¶}©l¤ä¥I¡A¨ä¥Lùµ{ª÷¡A¨úÃÒ«e¥I¡^¥I CSLªº´N¦³µÛ¸¨¤F¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/8/15 ¤U¤È 12:41:51²Ä 5463 ½g¦^À³
|
100¤H(¦û1/3)¥¼¸Ñª¼ªº¼Æ¾Ú¡K.. ¨ä¹ê¤j·§¤w¸gª¾¹Dµ²ªG¤F¡K¡K¡K ªÑ»ù·|öt¡Aªí¥Ü¼Æ¾Ú¡K¡K¡K¡K |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/15 ¤U¤È 12:35:43²Ä 5462 ½g¦^À³
|
Lebrikizumab 2b ¸Ñª¼¤é¤½¥¬¡G2019¦~2¤ë7¤é ¼Ú¬w±ÂÅv ÀH«á7¤é¤½¥¬¡C2¤ë14¤é A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis Study Design Go to sections Study Type : Interventional (Clinical Trial) Actual Enrollment : 280 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis Actual Study Start Date : January 30, 2018 Actual Primary Completion Date : February 7, 2019 Actual Study Completion Date : May 23, 2019 www.clinicaltrials.gov/ct2/show/NCT03443024 ¤G¡B®Ú¾ÚLebrikiumab³Q±ÂÅvAlmirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C ¡K¡K«eª÷+¶}µoùµ{ª÷1.98»õ¬ü¤¸+12.5»õ¬ü¤¸¡A³Ì°ª¾P°âùµ{ª÷(30»õ¬ü¤¸³Ì°ª¾P°â) +¾P°â¤À¼í10%-20% ±ÂÅvª÷1.98+2.1(5/30*12.5¡K¡K5»õ¬ü¤¸销°â°ò¦)¡A约4»õ¬ü¤¸¡C 4»õ¬ü¤¸/20%(欧¬w区)=20»õ¬ü¤¸¡K¡K¾ãÅéLebrikiumab±ÂÅvª÷AD»ùÈ¡K¡KB Lebrikizumab ¼Ú¬w°Ï±ÂÅv¦X¬ù(2019/02) www.sec.gov/edgar/search/?r=el#/q=Dermira ùµ{ª÷(1)3000+(1.1)5000+(2)3000+(3)4000+(4)4500=19,500(¸U¬ü¤¸) +(5)®ÚÕulebrikizumab¦b欧¬wªº¦~净销°â额达¨ì8600ÉE¬ü¤¸¦Ü30亿¬ü¤¸ªº¬Y¨Ç门槛¡A ¤ä¥I³Ì¦h12.5亿¬ü¤¸ªº´Ú项¡A¨C笔ýͦbªº¨½µ{¸O¦¡¥I´Ú约¥eÓì¥Î净销°â额门槛ªº7%¦Ü15%¡F¥H¤Î ¾P°â¤À¼í(6)°ò¤_欧¬wlebrikizumab¦~净销°â额¬Û应S围ªº层级¦Ê¤À¤ñS围ªº¯S许权¨Ï¥Î费¤ä¥I¡A¨ä¤¤²Ä¤@¦~净销°â额层级ªº¦Ê¤À¤ñ从§C两¦ì数开©l¡A³Ì°ª净销°â额层级ªº¦Ê¤À¤ñ¼W¥[¨ì§C¤G¤Q¦ì数¡C ®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C (1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C (1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C (2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C (3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C (4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C (5)®ÚÕulebrikizumab¦b欧¬wªº¦~净销°â额达¨ì8600ÉE¬ü¤¸¦Ü30亿¬ü¤¸ªº¬Y¨Ç门槛¡A¤ä¥I³Ì¦h12.5亿¬ü¤¸ªº´Ú项¡A¨C笔ýͦbªº¨½µ{¸O¦¡¥I´Ú约¥eÓì¥Î净销°â额门槛ªº7%¦Ü15%¡F¥H¤Î (6)°ò¤_欧¬wlebrikizumab¦~净销°â额¬Û应S围ªº层级¦Ê¤À¤ñS围ªº¯S许权¨Ï¥Î费¤ä¥I¡A¨ä¤¤²Ä¤@¦~净销°â额层级ªº¦Ê¤À¤ñ从§C两¦ì数开©l¡A³Ì°ª净销°â额层级ªº¦Ê¤À¤ñ¼W¦Ü20% |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/8/15 ¤U¤È 12:35:19²Ä 5461 ½g¦^À³
|
¨ä¹ê 4¤ë19¤é¡A¤w¶}20Ó©Û¶Ò¤¤¤ß¡A °²³]¥Î2Ó¤ë¨Ó©Û¶Ò+¿z¿ï¡A ¥Î4Ó¤ëªvÀø¡A «h10¤ë¤¤¡A¤½¥q¤w¦³¬ù100¤H¥¼¸Ñª¼ªº¨C2¶g¼Æ¾Ú¡K.. (¶V¨ì¦~©³,¤º½u¥æ©ö¶V©úÅã) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/15 ¤U¤È 12:22:15²Ä 5460 ½g¦^À³
|
ÁÂÁ¡I¸Ø±i¤j×¥¿¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/8/15 ¤U¤È 12:19:01²Ä 5459 ½g¦^À³
|
¤Þ¥Î¤Ñ©R¤jµoªí ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/7 ¤W¤È 04:51:41 ASLAN004 AD 2b Á{§É:(§ó·s) ¦¬®×¤¤¤ß¼W¥[¡A¬ü°ê¦A¼W16³B¡A¥þ²y²Öp36³B¡C ×¥¿¬° 5¤ë7¤é¡A¤w¶}36Ó©Û¶Ò¤¤¤ß¡A °²³]¥Î2Ó¤ë¨Ó©Û¶Ò+¿z¿ï¡A ¥Î4Ó¤ëªvÀø¡A «h11¤ëªì,16¶gªvÀø§¹¦¨¡C36/59=61%¡C 12¤ëªì¸ê®Æ¦¬¶°§¹¦¨©M¤½§G(12¤ëªì¥H«á¥i¥H´¦ÅS´Á¤¤¼Æ¾Ú)¡A °²³]¼Ú¬w10¤ë©³§¹¦¨©Û¶Ò¡C 59/59,2¤ë©³¡A§¹¦¨16¶g |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/15 ¤W¤È 10:04:12²Ä 5458 ½g¦^À³
|
6¤ë24¤é¡A¤w¶}36Ó©Û¶Ò¤¤¤ß¡A °²³]¥Î2Ó¤ë¨Ó©Û¶Ò+¿z¿ï¡A ¥Î4Ó¤ëªvÀø¡A «h12¤ë©³,16¶gªvÀø§¹¦¨¡C36/59=61%¡C¡C 1¤ë©³ 45/59=77%¡AªvÀø16¶g§¹¦¨¡A °²³]¼Ú¬w10¤ë©³§¹¦¨©Û¶Ò¡C 59/59,2¤ë©³¡A§¹¦¨16¶g |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/14 ¤U¤È 05:32:05²Ä 5457 ½g¦^À³
|
This is a summary of current recommendations for ASLAN Pharmaceuticals and Geron, as provided by MarketBeat.com. ³o¬OMarketBeat.com´£¨Ñªº¹ïAslan PharmPharmticals©MGeron¨â¤äªÑ²¼ªº·í«e«ØijºKn¡C ASLAN Pharmaceuticals currently has a consensus target price of $5.50, indicating a potential upside of 548.58%. Geron has a consensus target price of $4.50, indicating a potential upside of 91.49%. Given ASLAN Pharmaceuticals¡¦ higher possible upside, analysts plainly believe ASLAN Pharmaceuticals is more favorable than Geron. ªü´µÄõ»sÃĥثeªº¦@Ãѥؼлù¬°5.5¬ü¤¸¡Aªí©ú¼ç¦b¤W¦æªÅ¶¡¬°548.58%¡CGeronªº´¶¹M¥Ø¼Ð»ù¬°4.50¬ü¤¸¡A ªí©ú¼ç¦b¤W¦æªÅ¶¡¬°91.49%¡C¦Ò¼{¨ìªü´µÄõ»sÃħ󦳥i¯à¤W¦æ¡A¤ÀªR®vÅãµM»{¬°ªü´µÄõ»sÃĤñGeron§ó¦³§Q¡C ASLAN Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. ªü´µÄõ»sÃĪº¨©¶ð«Y¼Æ¬°1.91¡Aªí©ú¨äªÑ»ùªºªi°Ê©Ê¤ñ¼Ð·Ç´¶º¸500«ü¼Æ°ª¥X91%¡C ¬Û¤ñ¤§¤U¡AGeronªº¨©¶ð«Y¼Æ¬°0.94¡A³oªí©ú¨äªÑ»ùªºªi°Ê©Ê¤ñ¼Ð·Ç´¶º¸500«ü¼Æ§C6%¡C ASLAN Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. ªü´µÄõ»sÃĪº¦¬¤J©M¦¬¯q¤ñGeron§ó°ª¡C Geronªº¥«¬Õ²v§C©óAslan PharmPharmticals¡A ³oªí©ú¥¦¥Ø«e¬O¨â°¦ªÑ²¼¤¤§ót¾á±o°_ªº¤@°¦¡C ASLAN Pharmaceuticals beats Geron on 8 of the 14 factors compared between the two stocks. ªü´µÄõ»sÃĦb¨â°¦ªÑ²¼¤ñ¸ûªº14Ó¦]¯À¤¤¦³8ÓÀ»±Ñ¤FGeron¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/14 ¤U¤È 05:19:01²Ä 5456 ½g¦^À³
|
ì¨Ó¦p¦¹¡AÁÂÁ¸Ѵb¡I Asln¥[ªo¡A§Æ±æ¤j®a³£¯à¦p¤Ñ©R¤jÁ¿ªº¡A¹J¨ì¦¹Ãø±o ªº¾÷¹J¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/14 ¤U¤È 02:51:41²Ä 5455 ½g¦^À³
|
³v®ö«È¤j¡A ¤£¦p¹w´Á¡I Ib´Á¥½EASI75 ¤ñ´Á¤¤³ø§iÀø®Ä°¤Ó¦h¡C ´Á¤¤³ø§i EASI75 ¬O69% vs 0% ´Á¥¼³ø§i EASI75 50% vs 13% |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/14 ¤U¤È 01:32:19²Ä 5454 ½g¦^À³
|
2021¦~9¤ë27¤é¤½¥¬1b ªº8©P¼Æ¾Ú¡A ¬Ý°_¨Ó¤ñdupilumab16¶gªvÀøÁÙn¦n¡A «ç«oµo¥Í´d¼@¡H¹ê¦b¤£¸Ñ¡I ¤£¹L¤£ºÞ©ú¤Ñ¹L«á¦p¦ó¡A §Æ±æªÑ»ù´Â¤Wµo®i⋯ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/14 ¤W¤È 08:22:32²Ä 5453 ½g¦^À³
|
²q测--×1 1.ASLAN 2021¦~3¤ë¤½¥¬ASLAN004 lb ´Á¤¤¼Æ¾Ú EASI75 =69% vs 0% ªÑ»ù³Ì°ª5¬ü¤¸/ªÑ¡A 2021 3-5¤ë¨é°Ó¥Ø¼Ð»ù8-10¬ü¤¸/ªÑ¡C 2.2021¦~9¤ë27¤é¤½¥¬1b ¼Æ¾Ú EASI 75 =50%(¹êÅç组) vs 13%(¹ï·Ó组) ¡K¡KDupilumab 48.5%vs13% (aslan004 8¶gªvÀøITT¤ÀªR/dupilumab16¶gªvÀøÀø®Ä) 1b Àø®Ä´Á¤¤¤Î´Á¥½®t²§¬°©Û¶Ò6¦ì(6/22=27%)ªº«D¶Ç²ÎAD¯f±w¡A¦Ó¥L̪ºEASI75=0% ªÑ»ù³Ì§C 6¤ë¨Ó¨ì0.355¬ü¤¸/ªÑ 3.CEO ©ó2022¦~6¤ë7¤é¨é°Ó³X½Í¤¤´¦ÅS¡A±N¦b2bÁ{§É«e¡Aç°£10%-15%ªº«D¶Ç²ÎAD¯f±w¡C¥u¿ï¶Ç²ÎAD¯f±w¶i¤J¤UÁ{§É¡A±µªñDupilumab ªº¤T´Á¯f±w¤À°t¡C ªÑ»ù2022¦~6¤ë7¤é0.38¬ü¤¸¡AÀH«á°_º¦¡A2Ó¦h¤ë«á¤µ¤Ñ¡Aº¦¦^0.85¬ü¤¸¡A¤jº¦120%¦h¡A ÀH2b©Û¶Ò²Ä¤@¦WÀ³¤w§¹¦¨16¶gªvÀø¡AÁö¥¼¸Ñª¼¡A¦ý¥i²M·¡¤F¸Ñ¨C2¶gªºÀø®Ä¶i®i¡C ²z½×¤W¥»ªiªÑ»ùÀ³©¹5¬ü¤¸¾aªñ¡A«Ý¸Ñª¼«e¤@Ó¤ë约©ú¦~¤¸¤ë©³¡A¦A¯}«e°ª¡C Y2b¸Ñª¼«á¦p1b RITT ¤ÀªR¡A 2bITT ¤ÀªR 16¶gªvÀø«áÀø®Ä¥i¹FEASI75=69%/13%¡AªÑ»ù¤W10¬ü¤¸¥ç¦³¥i¯à¡A 2b¸Ñª¼«áºò±µ¼Ú¬w°Ï±ÂÅv¡A¥Ñ±ø¥ó´N¤j¬ù¥i¬Ý¥XASLAN004ªº¾ãÅ饫³õ»ùÈ¡C¼Ú°Ï¦û¬ù20%ªº¥þ²y¥«³õ»ùÈ¡C ¥H¤WÓ¤H²q´ú¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/14 ¤W¤È 07:47:40²Ä 5452 ½g¦^À³
|
预测 1.ASLAN 2022¦~3¤ë¤½¥¬ASLAN004 lb ´Á¤¤¼Æ¾Ú EASI75 =69% vs 0% ªÑ»ù³Ì°ª5¬ü¤¸/ªÑ¡A ¨é°Ó¥Ø¼Ð»ù8-10¬ü¤¸/ªÑ¡C 2.2022¦~9¤ë27¤é¤½¥¬1b ¼Æ¾Ú EASI 75 =50%(¹êÅç组) vs 13%(¹ï·Ó组) ¡K¡KDupilumab 48.5%vs13% (aslan004 8¶gªvÀøITT¤ÀªR/dupilumab16¶gªvÀøÀø®Ä) 1b Àø®Ä´Á¤¤¤Î´Á¥½®t²§¬°©Û¶Ò6¦ì(6/22=27%)ªº«D¶Ç²ÎAD¯f±w¡A¦Ó¥L̪ºEASI75=0% ªÑ»ù³Ì§C 6¤ë¨Ó¨ì0.355¬ü¤¸/ªÑ 3.CEO ©ó6¤ë7¤é¨é°Ó³X½Í¤¤´¦ÅS¡A±N¦b2bÁ{§É«e¡Aç°£10%-15%ªº«D¶Ç²ÎAD¯f±w¡C¥u¿ï¶Ç²ÎAD¯f±w¶i¤J¤UÁ{§É¡A±µªñDupilumab ªº¤T´Á¯f±w¤À°t¡C ªÑ»ù6¤ë7¤é0.38¬ü¤¸¡AÀH«á°_º¦¡A2Ó¦h¤ë«á¤µ¤Ñ¡Aº¦¦^0.85¬ü¤¸¡A ÀH2b©Û¶Ò²Ä¤@¦WÀ³¤w§¹¦¨16¶gªvÀø¡AÁö¥¼¸Ñª¼¡A¦ý¥i²M·¡¤F¸Ñ¨C2¶gªºÀø®Ä¶i®i¡C ²z½×¤W¥»ªiªÑ»ùÀ³©¹5¬ü¤¸¾aªñ¡A«Ý¸Ñª¼«e¤@Ó¤ë约©ú¦~¤¸¤ë©³¡A¦A¯}«e°ª¡C Y¸Ñª¼«á¦p1b RITT ¤ÀªR¡A 2bITT ¤ÀªR 16¶gªvÀø«áÀø®Ä¥i¹FEASI75=69%/13%¡AªÑ»ù¤W10¬ü¤¸¥ç¦³¥i¯à¡A ºò±µ¼Ú¬w°Ï±ÂÅv¡A¥Ñ±ø¥ó´N¤j¬ù¥i¬Ý¥XASLAN004ªº¾ãÅ饫³õ»ùÈ¡C¼Ú°Ï¦û¬ù20%ªº¥þ²y¥«³õ»ùÈ¡C ¥H¤WÓ¤H²q´ú¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/8/13 ¤W¤È 10:21:32²Ä 5451 ½g¦^À³
|
½L«á¶R³æÁÙ¬O»á¦h ¤U¶gÄ~Äò§V¤O§ð¤W1¤¸ ¤j®a¥[ªo |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/13 ¤W¤È 08:41:00²Ä 5450 ½g¦^À³
|
°ê¥~¤ÀªR®v¥Ø¼Ð»ù8¬ü¤¸/ªÑ¡A ¨Ì¾ÚºD©Ê¡A¥i¯à¦b©ú¦~3¤ë©Î4¤ë 2b¸Ñª¼¤é¨ì¹F¡C «e´£ 004ªº2b Àø®ÄEASI75 69%(¹êÅç²Õ)/13%(¹ï·Ó组) IGA 0.1 54%(¹êÅç²Õ)/8%(¹ï·Ó²Õ) Dupilumab ¤T´Á EASI75. 48.5% vs 13% IGA0.1 36% vs 8% 2b ²Ä¤@¦ì3¤ë¤¤¦¯¶}©lªvÀø¡A¤½¥q¤w¦³¥¼¸Ñª¼ªº¨C2¶g¼Æ¾Ú¡A |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/8/12 ¤U¤È 11:53:38²Ä 5449 ½g¦^À³
|
¶q¯à¤]¾ãÓ¥X¨Ó ·Pı©ú¤ÑºÎ¿ô¤@¬Ý´N¶W¹L1¤¸¤F «e°}¤lÁÙ¦bW´oªÑ»ù«ç¤W1¤¸¡A¦p¤µ¦n¹³»´»´ÃPÃP´Nn¹F¨ì ¯u¬O¥@¨ÆÃø®Æ°Ú |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/8/12 ¤U¤È 11:49:53²Ä 5448 ½g¦^À³
|
1¬ü¤¸¡ã3¬ü¤¸®M¨c¶q¤£¤j¡A£¸©Ô´N¹L¡A«ç»ò¤U¨Ó «ç»ò¤W¥h ´Nºâ©Ô¹L3¬ü¤¸¤]¤£n¶Ã½æ¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/12 ¤U¤È 10:09:42²Ä 5447 ½g¦^À³
|
ASLN.usªÑ»ù«æ³t¤Wº¦5.80%¡CºI¦Üµo½Z¡A¸ÓªÑ³ø0.730¬ü¤¸/ªÑ¡A¦¨¥æ¶q1.3¸UªÑ¡A´«¤â²v0.02%¡A®¶´T2.75%¡C ³Ìªñªº°]³ø¼Æ¾ÚÅã¥Ü¡A¸ÓªÑ¹ê²{Àç·~¦¬¤J0.00¬ü¤¸¡A²b§Q¼í-12.94¦Ê¸U¬ü¤¸¡A¨CªÑ¦¬¯q-0.19¬ü¤¸¡A¤ò§Q0.00¬ü¤¸¡A¥«¬Õ²v-1.33¿¡C ¾÷ºcµû¯Å¤è±¡A¦b©Ò¦³2®a°Ñ»Pµû¯Åªº¾÷ºc¤¤¡A100%ªº¨é°Óµ¹¤©¶R¤J«Øij¡AµL¨é°Óµ¹¤©«ù¦³¡B½æ¥X«Øij¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/8/12 ¤U¤È 09:52:00²Ä 5446 ½g¦^À³
|
¤½¥q¬£¦³¤ßÀ³¸Ó¶X³oªi§âªÑ»ù©Ô¨ì1¤¸¥H¤W ¬Û«H¤]·|Åý¥«³õ«H¤ß¤j¼W |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/12 ¤U¤È 09:48:47²Ä 5445 ½g¦^À³
|
¤WÓ©u«×¡A¸Ó¤½¥q¨CªÑ¦¬¯q¤ñ¹w´Á§C¤F0.01¬ü¤¸¡Aµ²ªG²Ä¤G¤ÑªÑ»ù¤U¶^¤F3.91%¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/12 ¤U¤È 09:44:27²Ä 5444 ½g¦^À³
|
Aslan Pharma¤½§Gªº¨CªÑ¦¬¯q¬°-0.19¬ü¤¸¡A°ª©ó¹w´Áªº-0.2¬ü¤¸¡A¶W¥X¹w´Á5.0%¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/12 ¤U¤È 07:30:15²Ä 5443 ½g¦^À³
|
ASLN ¤½¥¬²Ä¤G©u©u³ø¤Î§ó·s¥¼¨Ó¨½µ{¸O finance.yahoo.com/news/aslan-pharmaceuticals-reports-second-quarter-110000376.html Anticipated upcoming milestones Three abstracts with new data on biomarkers and patient reported outcome measures from the Phase 1b proof-of-concept trial of eblasakimab have been accepted for e-poster presentation at the 31st EADV Annual Congress held in person and virtually, from September 7 to 10, 2022, in Milan, Italy. The Company will host a Research and Development (R&D) Day on September 15, 2022, with a hybrid in-person and virtual format. More information will be announced in the weeks ahead. Topline data from the Phase 2b TREK-AD trial of eblasakimab is expected in the first half of 2023. Second quarter 2022 financial highlights Cash used in operating activities for the second quarter of 2022 was US$9.7 million compared to US$6.9 million in the same period in 2021. Cash, cash equivalents and short-term investments as of June 30, 2022, were US$78.1 million. 预计§Y将¨ì来ªº¨½µ{¸O ¤T¥÷关¤_¥ì¥¬©Ô¦è单§Ü1b´Á·§©À验证试验ªº¥Íª«标§Óª«©M±wªÌ报§i结ªG«ü标ªº·s数ÕuºKn¤w³Q±µ¨ü¡A将¦b2022¦~9¤ë7¤é¦Ü10¤é¦b·N¤j§Q¦Ì兰举¦æªº²Ä31届EADV¦~«×¤j会¤W¥H电¤l®ü报ªº§Î¦¡®i¥Ü¡C ¤½¥q将¤_2022¦~9¤ë15¤é举办¤@个¬ã¨sÉO开发¡]R&D¡^¤é¡Aªö¥Î现场©M虚úQ²V¦Xªº§Î¦¡¡C§ó¦h«H®§将¦b¥¼来¤L©P内¤½¥¬¡C eblasakimabªº2b´ÁTREK-AD试验ªºªì¨B数Õu预计将¦b2023¦~¤W¥b¦~¤½¥¬¡C 2022¦~²Ä¤G©u«×财务ºKn 2022¦~²Ä¤G©u«×¥Î¤_经营¬¡动ªº现ª÷为970ÉE¬ü¤¸¡A¦Ó2021¦~¦P´Á为690ÉE¬ü¤¸¡C ºI¦Ü2022¦~6¤ë30¤é¡A现ª÷¡B现ª÷µ¥É²ª«©Mµu´Á§ë资为7810ÉE¬ü¤¸¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/11 ¤U¤È 11:05:07²Ä 5442 ½g¦^À³
|
ªü·à»°¶i«×¡A¥[ªo¡I🤣🤣🤣 |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2022/8/11 ¤U¤È 07:37:32²Ä 5441 ½g¦^À³
|
¸É¥R¤@¤U¤Ñ©R¤j¸ê®Æ Eblasakimab¬O¤@ºØ¼ç¦bªº°w¹ïIL-13¨üÅ骺¤@¬y³æ§Ü¡A¨ã¦³´£¨Ñ®t²§¤Æªº¦w¥þ©Ê©M¦³®Ä©Ê¥H¤Î¯SÀ³©Ê¥Öª¢±wªÌ§ï¶iªº¾¯¶q¤è®×ªº¼ç¤O¡C2021¦~9¤ë¡Aªü´µÄõ«Å§G¤F1b´Á¦h¾¯¶q»¼¼W¾¯¶q¬ã¨sªº¿n·¥µ²ªG¡A¸Ó¬ã¨s½T¥ß¤FASLAN004ªº·§©ÀÅçÃÒ¡A¨Ã¤ä«ù¨ä§@¬°AD·sÀøªkªº¼ç¤O¡C2022¦~1¤ë¡Aªü´µÄõ±Ò°Ê¤FTrek-AD 2b´Á¸ÕÅç¡A¥Hµû¦ôeblasakimab¦b¤¤««×AD±wªÌ¤¤ªº¦w¥þ©Ê©M¦³®Ä©Ê¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/11 ¤U¤È 07:09:24²Ä 5440 ½g¦^À³
|
MENLO PARK, Calif. and SINGAPORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that three abstracts, showcasing new findings related to eblasakimab, will be displayed as e-posters throughout the 31st European Academy of Dermatology and Venereology (EADV) Congress, to be held in-person and virtually from September 7 to 10, 2022, in Milan, Italy. 31st European Academy of Dermatology and Venereology Congress e-poster details Poster 1: Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study (abstract ID: #2464, poster ID: P0343) Poster 2: Eblasakimab, a monoclonal antibody targeting IL-13Ra1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis (abstract ID: #932, poster ID: P0243) Poster 3: Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study (abstract ID: #2459, poster ID: P0342) ¦{门¬¥©¬§J©M·s¥[©Y¡A2022¦~8¤ë11¤é¡]GLOBE NEWSWIRE¡^--ASLAN Pharmaceuticals¡]纳´µ达§JªÑ²¼¥N码¡GASLN¡^¬O¤@®a处¤_临§É阶¬q¡B¥H§K¬Ì学为«点ªº¥Íª«¨î药¤½¥q¡AP¤O¤_开发§ï变±wªÌ¥Í¬¡ªº创·s疗ªk¡C2022¦~8¤ë11¤é¡]GLOBE NEWSWIRE¡^--ASLAN Pharmaceuticals¡]纳´µ达§JªÑ²¼¥N码¡GASLN¡^¬O¤@®a处¤_临§É阶¬q¡B¥H§K¬Ì学为«点ªº¥Íª«¨î药¤½¥q¡A¥¿¦b开发§ï变±wªÌ¥Í¬¡ªº创·s疗ªk¡A¤µ¤Ñ«Å¥¬¡A¤T¥÷®i¥ÜÉO¥ì¥¬©Ô¦è单§Ü¦³关ªº·s发现ªººKn将§@为电¤l®ü报¦b²Ä31届欧¬w¥Ö肤¯f©M©Ê¯f学会¡]EADV¡^¤j会¤W®i¥Ü¡A该¤j会将¤_2022¦~9¤ë7¤é¦Ü10¤é¦b·N¤j§Q¦Ì兰¥H现场©M虚úQ¤è¦¡举¦æ¡C ²Ä31届欧¬w¥Ö肤¯f学©M©Ê¯f学学会¤j会电¤l®ü报详±¡ ®ü报1¡G¦b¤@项随Éó¡B双ª¼¡B¦w¼¢剂对·Óªº1´Á¬ã¨s¤¤¡AEblasakimab§ïµ½¤F¤¤««×¯S应©Ê¥Öª¢¦¨¦~±wªÌªº¦hÏú¯e¯f«ü标 (Abstract ID: #2464, poster ID: P0343) ®ü报2¡GEblasakimab¡A¤@Ïú¹v¦VIL-13Ra1ªº单§J¶©§ÜÊ^¡A¥iú£¤Ö¤¤««×¯S应©Ê¥Öª¢±wªÌªº¦å²M¥Íª«标§Óª«¡A这¨Ç标§Óª«ÉO¯S应©Ê¦³关¡A¦}ÉO¯e¯f严«µ{«×¬Û关¡C (Abstract ID: #932, poster ID: P0243) ®ü报3¡G¦b¤@项随Éó¡B双ª¼¡B¦w¼¢剂对·Óªº1´Á¬ã¨s¤¤¡AEblasakimab§ïµ½¤F¤¤«×¦Ü««×¯S应©Ê¥Öª¢¦¨¦~±wªÌªºæ±Ö}©MºÎ¯v¤£¨¬问题 (Abstract ID: #2459, poster ID: P0342) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/11 ¤U¤È 04:14:57²Ä 5439 ½g¦^À³
|
Tralokinumab ¥h¦~©³®³¨ìFDA¬ü°êÃįg¡AEASI75ªº¤T´ÁÁ{§ÉÀø®Ä¬ù25%¥u¦³Dupilumabªº¤@¥b¡C ¦ý¦h¹ï·Ó²Õ¤@¿¡]100%¡^¡C Dupilumab ¤T´Á¦h¹ï·Ó²Õ2.73¿(273%)¡X¡X48.5% vs13% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/11 ¤U¤È 04:00:38²Ä 5438 ½g¦^À³
|
¬õ¹Ð¤j¡A ¤T´ÁÁ{§É¥²¶·°µ¡C ¥Ø«e§ä¤£¨ìÃÄÃÒ¤£¹Lªº²z¥Ñ¡I ¦pªGEASI75ªºÀø®ÄASLAN004Àu©ó¤éDupilumab40%¡]69%/48¡D5¢H¡^¨º¥[004ªºÃÄÃÒ»ùÈ´N«D±`¡B«D±`°ª¡C ¤W¥«¾P°â5¦~¤º¥i±æ¶W¶VDupilumab¡C ¥un©M |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2022/8/11 ¤U¤È 02:23:54²Ä 5437 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j ·sªºMOA¤@¦ý½T»{¡A¥i¥H½T©wÃÄÃÒ¥²¹L¶Ü¡H ¥i¥H½T»{·|¦³¨º¨Ç§Q¦h |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/8/11 ¤W¤È 10:46:53²Ä 5436 ½g¦^À³
|
CNTB¤£¥Î¤½¥¬¦Û¤vªºMOA¶Ü??? ¨Ì³W©w¬O¤£¥Î¤½¥¬ ÁÙ¬O¤£´±¤½¥¬ ©È¤@¤½¥¬MOA,µ²ªG¸òDupilumab¤@¼Ë. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/11 ¤W¤È 09:04:33²Ä 5435 ½g¦^À³
|
´Á«Ý¥Î·sM0A¨Ó¸ÑÄÀ¡Bµý©ú¡AÀø®ÄÀu©óDupilumab. ¦Ü¤ÖÀu42%ªº¥i¯à¡C 69% vs 48.5%=142% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/11 ¤W¤È 08:55:30²Ä 5434 ½g¦^À³
|
³¯¤j¡Aµ¥9¤ë15¤é¡A¥Ñ¤½¥qªºÂàÄÀÂå¾Ç¹êÅçµ²ªG¨Ó§i¶D§ÚÌ¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/8/11 ¤W¤È 08:03:11²Ä 5433 ½g¦^À³
|
Ãø©Ç³Ìªñ·à¤l¦³¨Ç°Ê¤F ·à¤l¥[ªo¡A¤£n¿éµ¹CNTB |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/8/11 ¤W¤È 07:30:58²Ä 5432 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j 004 MOA ¤£¬O¤w½T»{¤F ¬°¦óÁÙ¦³·sªºMOA |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2022/8/10 ¤U¤È 01:58:20²Ä 5431 ½g¦^À³
|
²×©ó¨Ó¤F |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/10 ¤U¤È 12:02:25²Ä 5430 ½g¦^À³
|
stocktwits.com/symbol/ASLN ASLN ±N©ó9¤ë15¤é 10:00~13:00 ¦b¯Ã¬ù Á|¿ìR&D Day. 1.µoªíASLAN004 1b , PRO DATA, 2.µoªíASLAN004 ·sMOA 3.¥¼¨ÓASLAN004ªºÁ{§É |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/7 ¤W¤È 10:48:55²Ä 5429 ½g¦^À³
|
sec.report/Document/0001193125-22-176648/ CNTB p¹º¤½¶}¥«³õÄw资3»õ¬ü¤¸¡C ¥Ø«e¥«È7¤d2¸U¬ü¤¸¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/6 ¤U¤È 05:33:39²Ä 5428 ½g¦^À³
|
CNTB ¤W¶g±q0.81º¦¨ì1.32¬ü¤¸/ªÑ.¤wº¦50% 7¤ë12¤é«Å¥¬ ,CBP-201 ¤¤°êAD 2B,255¤HÁ{§É,¦~©³¸Ñª¼. finance.yahoo.com/quote/CNTB?p=CNTB CNTB ¶·±q¥«³õ¤j¶Ò¸êª÷°µAD 3´Á. --------------------------------------- |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/8/4 ¤W¤È 10:11:33²Ä 5427 ½g¦^À³
|
¥Dn¬O50%¤H¼Æ¡A¦ý¤]n°t¦X¦¬®×¤¤¤ß¤@¦¸¦¬®×¤¤Hªº¦¬¶°¼Æ¾Úªº§¹¾ã©Ê¡A¬G59/2=29.5¬Û·í©ó30Ó¦¬®×¤¤¤ß¡A¬G30*5¤H=150¤H¬O¤ñ¸û¥¿±`ªºª¬ªp~ |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2022/8/3 ¤U¤È 05:31:36²Ä 5426 ½g¦^À³
|
½Ð°Ý¤j¤j ´Á¤¤¼Æ¾Úªº¤½§G³Ì§Cµ{«×¶È»Ýn50%¦¬®×¤H¼Æ§¹¦¨16¶gªº¸ÕÅç¡A ¬O«ü¤w§¹¦¨©Û¶Ò45³B¤§50%¦¬®×¤H¼Æ ÁÙ¬O«üìpµe©Û¶Ò59³B¤§50%¦¬®×¤H¼Æ ¤H¼Æ»Ý¹F59*5=295¡A295*50%=148¤H§¹¦¨16¶gªº¸ÕÅç¡A |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/8/3 ¤W¤È 08:02:02²Ä 5425 ½g¦^À³
|
¤w§¹¦¨©Û¶Ò¤¤¤ßªº¶}³]µ{«×~ 45/59*100%=76.2% ¦Ó´Á¤¤¼Æ¾Úªº¤½§G³Ì§Cµ{«×¶È»Ýn50%¦¬®×¤H¼Æ§¹¦¨16¶gªº¸ÕÅç¡A¥[¤W3-4¶gªº¼Æ¾Ú¾ã²z¡A«Ü¦³¾÷·|¦b¦~©³«e¤½¥¬¥¿¦V´Á¤¤¼Æ¾Ú...¥[ªoªü·à |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/8/2 ¤W¤È 06:39:25²Ä 5424 ½g¦^À³
|
www.clinicaltrials.gov/ct2/show/NCT05158023 004 2bÁ{§É¡C©Û¶Ò¤¤¤ß¼W¥[¦Ü45³B¡C |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2022/7/27 ¤U¤È 09:08:40²Ä 5423 ½g¦^À³
|
¤U¥b¦~...003¡Bprodata¡B2b´Á¤¤... |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/7/27 ¤U¤È 05:23:36²Ä 5422 ½g¦^À³
|
³o¬O¤@Ó»P®É¶¡Áɶ]ªº°Ó·~Ävª§¼Ò¦¡¡G 1.110¦~3¤ë¶Ò¸êªº¿ú¥u¯à¥Î¨ì112¦~©³¡C 2.ªÑ»ùÀ³©ó112¦~3¤ë«e°ª©ó1¬ü¤¸³sÄò10¤Ñ¡C ¤Wz¨âÂI¬O½T©wªº¡C ------------------------------------------------------¨È·à±d§@ªk----------------------------------------------------- 1.112¦~2¤ë«e´¦ÅS004¤G´ÁÁ{§É´Á¤¤³ø§i©Ô°ªªÑ»ù¡C 2.112¦~¤W¥b¦~004¤G´ÁÁ{§É¸Ñª¼«á¶Ò¸ê¡C 3.¶Ò¸ê·í¤U±N¬O¥þ²y«e¤¤jÃļt¤ñ½Öªº¤f³U²`ªº®ÉÔ¤F¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2022/7/21 ¤W¤È 08:15:38²Ä 5421 ½g¦^À³
|
¦~©³Y¨S¦³´Á¤¤³ø§i¡AªÑ»ùn¤W1¤¸¥O¤H¾á¤ß ·Pı¤½¥qÀ³¸Ó¥X¨Óµ¹Ó§ó©ú½Tªº¹wp´Áµ{ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/7/20 ¤W¤È 10:51:30²Ä 5420 ½g¦^À³
|
2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q. Out-License and Other Agreements Almirall Agreement 2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O --------------------------------------------------- 3.2019/05/31 , CSL»P¨È·à2014¦~°_¦@¦P¶}µo,§Q¼í¦U¥b. 1a °µ§¹ CSL ¨È·à¦@¦P±ÂÅvASLAN004 ¥þ²yµo®i/¥Í²£/°Ó·~¤Æµ¹ ¨È·à±d, (±ÂÅvª÷=(«eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)*2=7.8*2»õ¬üª÷)+ (¥[¾P°â¤À¼í5%~<= 10%.)*2 ¦U±o¤@¥b. ASLAN004 ¶i¤J¤T´Á«e¶·¤ä¥ICSL 3000¸U¬ü¤¸, ¨úÃĵý¤ä¥I9250¸U¬ü¤¸. ¤½¥q¥²¶·¥Hªø¤[¸gÀç¥h¦Ò¶q¸êª÷, §¨Ó¨ÖÁÊDermira (Lebrikizumab)¤½¥qµû¦ô¦bAD¤G´Á¸Ñª¼«á¤~¶}©l.(¨ì«Å§G¨ÖÁʬù11Ó¤ë) 1B 8¶gªvÀø¥u¦¨¥\ÅçÃÒMOA 2B 16¶gªvÀø©MDupilumab ¤T´Á16¶gÀø®Ä¤ñ, ¯à¤ñ¸û¤½¥µû¦ôaslan004»ùÈ. ¨Ì·Ó§¨Ó¨ÖÁÊDermira (Lebrikizumab)¤½¥qµû¦ô, ASLN ¤½¥q2023¦~©³³Q¨ÖÁʬO¸û¦X²z¹w¦ô. |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/7/20 ¤W¤È 10:30:26²Ä 5419 ½g¦^À³
|
§ÚÁ`ı±o¡¨¼Ú¬w°Ï±ÂÅv¡¨¬OºØ°g«ä¡C ¥þ²y«e¤¤jÃļt³£¤w¸gª¾¹DÁÉ¿Õµá§ùÁת¢ªº¾P°âÃB¤F¡A¬°¦óÁÙn¨Ó¸ò¨ä¥LÃļtÄvª§¨È·à±d004ªº¼Ú¬w°Ï±ÂÅv¡H¡H ¤¤jÃļt¤@©w¬O¤ñ½Öªº¤f³U²`¡Aª½±µ§â¨È·à±d¨Ö¤F¡C¤T´Á¯dµ¹¨ÖÁʤ½¥q¦Û¤v§@¡C ¬yµ{¦p¤U¡G 1.´Á¤¤³ø§i¤½¥¬(ªÑ»ù«e¤@Ó¤ë¶}©l°Ê) 2.´Á¤¤³ø§i¤½¥¬«á¡A¥þ²y«e¤¤jÃļt¶}©l»P¨È·à±d±K¤Á±µÄ²½Í¨ÖÁÊ¡C 3.¦¹®É¨ÖÁÊ»ù³Ì«K©y¡A¤£nµ¥¨ì2bÁ{§É¸Ñª¼¡C 4.µ¥¨ì2bÁ{§É¸Ñª¼(¦P®É¶}©ñ¼Ú¬w°Ï±ÂÅv)¡A¦A¨Ó½Í¨ÖÁÊ¡A¨ÖÁÊ»ù´N¶Q¤F¡C (³o¬O§ÚªºÅÞ¿è¡A«e´£¬O004ÃĮĤñ§ùÁת¢¦n(ÃĮİÝÃD¤Ñ©R¤j¤j¬O±M®a)) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/7/20 ¤W¤È 09:38:58²Ä 5418 ½g¦^À³
|
¤U¥b¦~¦ôp§¹¦¨¨½µ{ 1.2b 295 ¤HÁ{§É¡A¦¬®×§¹¦¨(9-10¤ë) 2.¤½§G1b ¥Íª««ü¼ÐªºÀø®Ä 3.¤½§G004ªºAD¿W¯SMoA |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/7/20 ¤W¤È 09:29:46²Ä 5417 ½g¦^À³
|
004 ªº2b¸Ñª¼¤Î欧¬w°Ïªº±ÂÅv ¥²¶·¬°Äw资5-6»õ¬ü¤¸¡C ´Á¤¤³ø§i«á¡A¦p¯àªÑ»ù©Ô¤W8¬ü¤¸/ªÑ¡A ¥H6.4¬ü¤¸/ªÑ¶Ò资¡A¤~ȱo¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2022/7/20 ¤W¤È 09:22:08²Ä 5416 ½g¦^À³
|
ÅÞ¿è«ä¦Ò¡G 3¤ë©³¦]ªÑ»ù§C©ó1¬ü¤¸¡A³Qĵ§i©µ«á6Ó¤ë§ïµ½(§Y9¤ë©³«eªÑ»ùn°ª©ó1¬ü¤¸³sÄò10¤Ñ)¡A ¦Ó9¤ë©³©¡º¡¤]¥u¯à¦A©µ6Ó¤ë¡A§Y112¦~3¤ë©³YªÑ»ù¤´§C©ó1¬ü¤¸¡A«h±N³Qn¨D¤U¥«¡C ¨È·à±dY¦Ò¼{±N¼Ú¬w±wªÌ¦C¤JªvÀø¡AµM«á¨Óµ¥©ú¦~3¤ëªº¸Ñª¼¡C³o¼Ë®É¶¡¤Ó»°¡B·ÀI¤Ó¤j(¸ê®Æ¾ã²z¤£¤Î)¡C ¤@©w·|¦³´Á¤¤³ø§i¡A®É¶¡¸¨©ó111¦~12¤ë¦Ü112¦~2¤ë¤½¥¬´Á¤¤³ø§iªº¾÷·|«Ü¤j(²Å¦XÅÞ¿è)¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/7/19 ¤U¤È 06:03:30²Ä 5415 ½g¦^À³
|
Ó¤H¦ôp ¦~©³¯à§¹¦¨16¶gªvÀøªº43*5=215¤H(+215/295=73%)¦³¾÷·|. (Y¦³»Ýn¦~©³¥i´Á¤¤³ø§i) ¨ä¥L¼Ú¬w±wªÌ¥i¯à9¤ë¤¤¤U¦¯¶}©lªvÀø,©ú¦~¤¸¤ë~2¤ë©³¦³¾÷·|§¹¦¨295¤H 16¶gªvÀø. ©ú¦~3¤ë¸Ñª¼«Ü¤j¥i¯à. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/7/19 ¤W¤È 11:14:56²Ä 5414 ½g¦^À³
|
¥J²Ó¹LÂo¦¬®×ªº«~½è(¿z¿ï¶Ç²ÎAD±wªÌ),ÁÙ¬O«Ü¦³¾÷·|¦b¦~©³«e¤½¥¬¥¿¦Vªº´Á¤¤¼Æ¾Ú~~~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/7/15 ¤U¤È 10:49:36²Ä 5413 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3 ASLAN004 AD 2b Á{§É ¼W¥[¦L«×¤@Ó¦¬®×¤¤¤ß¡A²Öp¥þ²y43Ó¦¬®×¤¤¤ß¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/7/14 ¤U¤È 04:05:24²Ä 5412 ½g¦^À³
|
Lebrikizumab ý³Ý¤ÎCOPD ¤T´Á¥¢±Ñ,ªvÀø AD¨Öµo¯gªº¥\¯à¤£¤ÎDupilumab ¦b¤@½uÃÄÄvª§¤O®t,¬G¸Õ§ä¤G½uÃÄ¥«³õ. ¦ý¦]MOA ©MDupilumab ¦P¬°«¬¤Gª¢¯g¸ô®|¤§¤@. ¥»¦¸·sAD¤G½u¤T´Á¯à§_¦¨¥\???¥¼ª¾ À³¥u¦³¦b¥Îdupilumab ¦³AE/µ²½¤ª¢°Æ§@¥ÎªÌ¨¤W¤~¦³¤ñ¸û¨ÎªºÀø®Ä§a!(Öt¹ê¬ã¨s¬ùdupilumap 25%~35%µ²½¤ª¢) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/7/14 ¤U¤È 03:01:42²Ä 5411 ½g¦^À³
|
¥Íª«¦Û§ä¥Í¸ô ¥ÎDupilumabµL¤ÏÀ³ªÌ¦b¤T´ÁÁ{§É¬ù35%,¹FEASI75ªÌ¬ù48.5%. §¨Ó¶}Lebrikizumab (LY3650150) ¶}-««×AD ¤G½u¥ÎÃÄ(¥ÎDupilumab µL¤ÏÀ³©ÎAE¦ÓµLªk¨Ï¥ÎªÌ) ¤T´ÁÁ{§É 120¤H. Study Design Go to sections Study Type : Interventional (Clinical Trial) Estimated Enrollment : 120 participants Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab Estimated Study Start Date : August 18, 2022 Estimated Primary Completion Date : August 2, 2023 Estimated Study Completion Date : December 6, 2023 clinicaltrials.gov/ct2/show/NCT05369403?term=Lebrikizumab&draw=2&rank=3 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab 纳¤J标ã¡C ©Ò¦³参ÉOªÌ¤§«e¥²须±µ¨ü过²Å¦X¥H¤U条¥ó¤§¤@ªº§ù¤Ç鲁(dupilumab)单§Üªv疗¡C ¦]ÆÓ¤Ï应¡B³¡¤À¤Ï应¡B¥¢¥h疗®Ä¦Ó°±¤î§ù¤Ç鲁单(dupilumab)§Üªv疗ªº参ÉOªÌ¥²须¤§«e±µ¨ü过§ù¤Ç鲁单§Ü¡]标ª`剂¶q¤ô¥¡^ªv疗¦Ü¤Ö4个¤ë¡C ¦]对药ª«¤£@¨ü©Î发¥Í¤£¨}¨Æ¥ó¡]AEs¡^¦Ó°±¤î§ù¤Ç鲁单§Üªv疗ªº参ÉOªÌ¥i¥H进¤J¬ã¨s¡A¦Ó¤£n¨D¤§«e§ù¤Ç鲁单§Üªv疗ªº时间¡C ¦]费¥Î问题©ÎÆÓªk获±o§ù¤ñ卢单§Ü¡]¦p«O险¡^¦Ó°±¤î§ù¤ñ卢单§Üªv疗ªº参ÉOªÌ¡A¥i¥H¦b没¦³n¨D¤§«e§ù¤ñ卢单§Üªv疗时间ªº±¡úG¤U进¤J¬ã¨s¡C Inclusion Criteria: All participants must have prior treatment with dupilumab meeting one of the following conditions: Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab (at labeled dose level) for at least 4 months. Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment. Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab (for example, insurance coverage) may enter the study with no required prior length of dupilumab treatment. |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2022/7/13 ¤U¤È 08:03:41²Ä 5410 ½g¦^À³
|
±bºÞ¶OÀ³¸Ó¨C¶¡°Æ©e°U¦¬ªº®É¶¡³£¤£¤@¼Ë À³¸Ó¥i¥H½ÐÀç·~ûÀ°§Aª`·Nn¦¬¶O®É³qª¾ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/7/13 ¤U¤È 07:52:15²Ä 5409 ½g¦^À³
|
Adr«OºÞ¶O ¤£¬O¤¤ë¤U¦¯¤w¸g¦¬¤F ? La Jolla Pharmaceutical «Ü·|½æ¤½¥q Innoviva ¥H¨CªÑ 6.23 ¬ü¤¸ªº²{ª÷©ÎÁô§tªº¥ø·~»ùȦ¬ÁÊ La Jolla ªº©Ò¦³¬y³qªÑ¬ù 1.49 »õ¬ü¤¸¦¬ÁÊ La Jolla »sÃĤ½¥q La Jolla ªº¥D¾É²£«~ GIAPREZA ®¡]¦åºÞºò±i¯À II¡^©ó 2017 ¦~ 12 ¤ëÀò±o¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½ (FDA) ªº§åã¡A¥Î©ó¼W¥[·P¬V©Ê©Î¨ä¥L¤À§G©Ê¥ð§J¦¨¤Hªº¦åÀ£ ¤À§G©Ê¥ð§J ±Ñ¦å©Ê¥ð§J¡]Septic Shock¡^ ¹L±Ó©Ê¥ð§J(©ÎºÙµL¨¾¿m©Ê¥ð§J¡Aanaphylactic Shock) ¯«¸g©Ê¥ð§J¡]Neurogenic Shock¡^ La Jolla ²Ä¤G¶µ²£«~ XERAVA ®¡]®J©Ô¥ËÀô¯À¡^©ó 2018 ¦~ 8 ¤ëÀò±o FDA §åã¡A¥Î©óªvÀø 18 ·³¤Î¥H¤W±wªÌªº½ÆÂø¸¡µÄ¤º·P¬V¡] cIAI ¡^ GIAPREZA :ºI¦Ü2021 ¦~ 9 ¤ë 30 ¤éªº¤EÓ¤ë¡AGIAPREZA ¬ü°ê²£«~²b¾P°âÃB¬° 2430 ¸U¬ü¤¸¡A¸û 2020 ¦~¦P´Á¼Wªø 18%¡C XERAVA ºI¦Ü 2021 ¦~ 9 ¤ë 30 ¤é¤î¤TÓ¤ë¡AXERAVA ¬ü°ê²b²£«~¾P°âÃB¬° 290 ¸U¬ü¤¸ GIAPREZA+XERAVA ¨â¶µ²£«~¤@¦~¾P°âÃB¤£¨ì5000¸U¬ü¤¸ Innoviva ¥H¨CªÑ 6.23 ¬ü¤¸ªº²{ª÷©ÎÁô§tªº¥ø·~»ùȦ¬ÁÊ La Jolla , La Jolla Pharmaceutical Company «Ü·|½æ¤½¥q |
|
|
|